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Current research has suggested that monocyte/macrophages can coexist as different phenotypes 
which display an array of disparate properties. Monocyte/macrophage subsets may also divergently 
harbour the ability to acquire characteristics of other vascular cell types, such as vascular smooth 
muscle cells (VSMC) and endothelial cells. These findings imply that monocytes yield progenitor 
potential which could be potentially exploited for therapeutic purposes. The aim of this study is to 
robustly assess the progenitor potential of different in vitro monocyte/macrophage subsets into 
other vascular cells, namely, VSMCs and endothelial cells. Cultured human primary monocytes with 
subsequent polarisation with macrophage-colony stimulating factor (M-CSF) and termed M-Mac, or 
granulocyte-macrophage colony stimulating factor (GM-CSF) and termed GM-Mac, can appear like 
VSMCs based on the expression of genes/proteins considered specific to VSMCs (namely a-SMactin, 
caldesmon, calmodulin, myosin heavy chain-11, smoothelin, and vimentin). GM-Macs display a 
greater VSMC-like gene expression pattern compared to their M-Mac counterparts, through up-
regulation of α-SMactin, caldesmon, calmodulin, myosin heavy chain-11, smoothelin, and vimentin. 
Interestingly, gene and protein expression of the endothelial cell (EC)-specific markers PECAM-1 
(CD31) and VE-cadherin (CDH5) are also expressed by cultured macrophages. Mirroring the VSMC-
like cell experiments, GM-Macs display greater expression of EC markers than M-Macs. These 
findings infer that pro-inflammatory GM-Macs already harbour the ability to express VSMC-like and 
EC-like genes/proteins, whereas their anti-inflammatory M-Mac counterparts do not. Accordingly, 
we propose that GM-Macs may foster the ability to mimic vascular cells (VSMCs and/or ECs) in 
response to injury or under angiogenic conditions, to provide temporary barrier function for 
example. Interestingly, the growth factors FGF2 and VEGF-A were shown to upregulate PECAM-1 
and VE-cadherin expression in M-Mac but not GM-Mac. We also observed an inverse relation 
between expression of VE-cadherin mRNA and protein expression in M-Mac after stimulation with 
FGF2, suggesting the involvement of a post-transcriptional regulatory mechanism. Indeed, M-Mac 
VE-cadherin protein expression was identified to be dependent upon microRNA (miR)-27a-3p. 
Moreover, miR-27a-3p levels appear to be regulated through a FGF-receptor type-1 and signal 
transducer and activator of transcription-3 (Stat3) signalling pathway. Finally, GM-Macs and FGF2-
stimulated M-Macs harboured the ability to form angiogenic sprouts, supporting their transition 
towards an endothelial cell-like phenotype. In conclusion, the novel findings within this thesis 
demonstrate the divergent progenitor capacity of macrophage subsets, which may be utilised for 
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Coronary artery disease (CAD) due to atherosclerosis is listed as the most common cause of death 
not only within western countries, but more recently also in less-developed parts of the world 
(World Health Organisation, 2014). CAD can be defined as a spectrum of clinical manifestations due 
to underlying atherosclerosis that causes occlusion of an affected coronary artery and associated 
ischaemia of the related myocardial tissue. Depending on the severity of the arterial occlusion and 
degree of myocardial ischaemia (Figure 1.1.1), CAD can be categorised based on the clinical 
manifestations/presentation into stable angina and acute coronary syndrome (ACS) (Sanchis-Gomar 
et al., 2016). Stable angina is associated with significant occlusion of one or more coronary arteries, 
and can be triggered by physical exertion or emotional stress that places further oxygen demand 
from the arterial supply to the myocardial tissue, with symptoms (such as chest pain) typically 
resolving after administration of glyceryl trinitrate (National Clinical Guidelines Centre, 2011). On the 
other hand, acute coronary syndrome (ACS) is associated with thrombus formation overlying an 
unstable atherosclerotic plaque and can be further stratified as unstable angina or myocardial 
infarction (MI) (Libby and Theroux, 2005). Unstable angina is associated with chest pain at rest 
(without a triggering factor) and pathologically characterised by ischaemia of the myocardial tissues 
without necrotic changes. However, if left untreated, MI can ensue. 
The diagnosis of ACS requires careful interpretation of clinical signs and symptoms (most commonly 
chest pain with other non-constitutional signs/symptoms, such as tachycardia, perfuse sweating, and 
hypertension) together with raised circulating cardiac proteins (for example troponin and creatinine 
kinase) as well as changes in electrocardiogram (ECG) (Barstow et al., 2017). Elevated levels of 
cardiac enzymes require at least 3-4 hours before their detection in the serum, thus are not 
considered as a sensitive early detection tool compared to ECG (Kumar and Cannon, 2009). 




Nevertheless, no changes in ECG does not rule out MI, as in the case of non-ST segment elevation 
myocardial infarction (NSTEMI) (Barstow et al., 2017). Therefore, through the ECG findings upon 
presentation of high-risk patient to emergency, MI can be classified as either STEMI (ST segment 
elevation myocardial infarction) or NSTEMI.  
These two spectrums of CAD require different therapeutic interventions (Jneid et al., 2017) even 
though the underlying pathogenesis of both are relatively similar. Previously, MI used to be classified 
based on the extent of non-viable (necrotic) myocardial tissue (heart wall), however, this no longer 














Figure 1.1.1 Spectrum of clinical conditions due to atherosclerosis 
Based on clinical presentation, coronary artery disease is classified into stable angina and acute 
coronary syndrome (ACS). Stable disease is associated with chest pain commonly associated with 
physical exertion or emotional stress. Significant blockage or stenosis of the arterial lumen by 
atherosclerotic plaque is the underlying pathology. Chest pain can occur without any triggering 
factor during rest and is classified as unstable angina and may be relieved upon administration of 
glyceryl trinitrate (GTN), a vasodilator agent. It is associated with sudden blockage of the coronary 
artery due to thrombus formation overlying an atherosclerotic plaque, this blockage does not 
however cause complete obstruction. Persistent chest pain not relieved by vasodilator agents 
warrants prompt intervention as it indicates MI with almost total to complete lumen occlusion by 
thrombus formation over an atherosclerotic plaque. Based on ST segment evaluation from an 
electrocardiogram, MI can be classified into ST-elevation or non-ST elevation MI. STEMI is associated 
with significant cardiac muscle (myocardium) death (necrosis) compared to less extensive damage to 
the myocardium in NSTEMI.  
Adapted from original source https://www.thrombosisadviser.com/coronary-and-peripheral-artery-
disease. 
 
Atherosclerosis is a focal, chronic inflammatory, fibro-proliferative response to injury, which despite 
the presence of systemic risk factors, occurs at localised susceptible sites within main arteries such 
as the coronary and carotid arteries.  
It is believed that endothelial dysfunction plays a significant role in initiating atherosclerosis before 
any visible structural changes within the vessel wall (Gimbrone and García-Cardeña, 2016; Stary, 
2000). In addition to atherogenesis, endothelial dysfunction persistently contributes to subsequent 
plaque progression and associated complications such as plaque rupture and thrombus formation 
(Bonetti et al., 2003). Systemic risk factors continually expose the endothelium to hypertension, 
excess lipid (hyperlipidaemia), hyperglycaemia as well as tobacco toxins (as in chronic smoking), 
collectively identified as traditional risk factors of atherosclerosis, and can all induce and contribute 





Jialal, 2006). Oxidative stress reduces the bioavailability of nitric oxide (NO), one of the most 
important substances released by intact functional endothelium for normal vascular homeostasis. 
Reduced bioavailability of NO is associated with vasospasms, thrombosis, vascular inflammation, and 
the migration and proliferation of medial vascular smooth muscle cells (VSMCs) into the intima, all 
actions which collectively promote atherogenesis (Förstermann, 2010; Singh and Jialal, 2006).  
As mentioned above, atherosclerosis occurs at selective sites such as the branching points (for 
example bifurcations) or curvatures within major arteries. At these locations, the pattern of blood 
flow is disturbed, resulting in haemodynamically-characterised oscillatory low shear stress, that 
predisposes to endothelial dysfunction (Chiu and Chien, 2011). In the straight segments of artery, 
where blood flow is unidirectional with haemodynamically normal laminar shear stress, the 
endothelium is protected from becoming dysfunctional through the maintained expression of 
Krüppel-Like Factor 2 (KLF2) and nuclear factor (erythroid-derived 2)-like 2 (NRF2) transcription 
factors (Fledderus et al., 2008). NRF2 regulates expression of downstream genes associated with 
antioxidant molecules such as catalase, superoxide dismutase (SOD), and glutathione, which 
collectively protect from oxidative stress (Gupte et al., 2013). Whereas KLF2 is involved with variety 
of biochemical process that are critical to the regulation of endothelial homeostasis, such as 
inducers of endothelial nitric oxide synthase (eNOS) and thrombomodulin (TM), enzymes 
responsible for sustained NO production and anti-coagulant release at the luminal surface of 
endothelial cells, respectively (SenBanerjee et al., 2004).  
Reportedly, KLF2 can also inhibit the activity of the nuclear factor-kappa B (NFκB)- and activating 
transcription factor-2 (ATF2)-signalling pathways, both key regulators of pro-inflammatory responses 
(Nayak et al., 2011). KLF2 binds to p300, a critical NFκB co-activator, and hence inhibits the 
expression of NFκB-mediated down-stream pro-inflammatory genes such as intercellular adhesion 
molecule 1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), E-selectin, platelet-derived 




monocyte chemotactic protein-1 (MCP-1) and the vasoconstrictor gene endothelin-1 (ET-1) (Jha and 
Das, 2017; Nigro et al., 2011). Whereas by preventing nuclear localisation of phosphorylated ATF2, 
KLF2 supresses activator protein-1 (AP-1) down-stream gene expression, a prominent pro-
inflammatory transcription factor (Fledderus et al., 2007).  
On the contrary, disturbed and oscillatory low shear stress areas are associated with reduced KLF2 
and NRF2 expression, and concomitant upregulation of the AP-1 and NFkB pro-inflammatory 
signalling pathways (Nagel et al., 1999). Thus, endothelial cells exposed to disturbed-flow are pre-
conditioned with high oxidative stress and pro-inflammatory states and hence predisposed to 
initiate atherogenesis (Nigro et al., 2011). Besides differential gene expression, the arterial 
endothelium at disturbed flow regions also undergo rapid and constant turnover, which is associated 
with increased vascular permeability, favouring lipid insudation within the arterial wall (Chien, 2003; 
Chiu et al., 1998).  
In addition, alterations in blood flow and shear stress also affects the behaviour of medial VSMCs. 
Reportedly, disturbed oscillatory shear stress is associated with reduced VSMC apoptosis via an 
(endothelial-derived) NO dependant signalling pathway (Bennett, 1999; Fitzgerald et al., 2008), 
enhanced VSMC migration via increased matrix metalloproteinase (MMP) expression (such as MMP-
2) (Garanich et al., 2005), and heightened VSMC proliferation via PDGF-BB and TGFβ-signalling 
pathways (Palumbo et al., 2002; Ueba et al., 1997). Collectively, these findings demonstrate that 
VSMC at athero-prone sites acquire specific characteristics, which are associated with features of a 
synthetic VSMC phenotype (refer to section 3.1.1 Phenotypic modulation of vascular smooth muscle 
cells).  
Within the normal artery (Figure 1.1.2), VSMCs are not usually present within the tunica intima but 
are the main cellular component of the underlying tunica media. Nevertheless, in some areas of 
arterial segments (such as branch points/bifurcations and curvatures), VSMCs accumulate within the 




diffuse intimal thickenings (Nakashima et al., 2002; Nakashima et al., 2007). However, these intimal 
thickenings can progress later in life to involve lipid accumulation and various degrees of monocyte 
infiltration and subsequent macrophage accumulation (Nakashima et al., 2002). Therefore, there are 




Figure 1.1.2 Schematic diagram of a medium sized artery  
The arterial wall of a healthy artery is comprised of a monolayer of endothelial cells resting upon 
basement membrane. Beneath the endothelial layer is a potential subendothelial space comprised of 
extracellular matrix proteins such as collagen and proteoglycans. The intima is thin layer (size is 
exaggerated in this diagram) separated by an internal elastic lamina from the underlying tunica 
media, which consists of vascular smooth muscle cells and extracellular matrix components. However, 
in some regions vascular smooth muscle cells may be present within the tunica intima without any 
lipid deposition, termed as adaptive intimal thickening. Image adapted from original source (Lusis, 
2000) and made using elements retrieved from https://smart.servier.com. 
 
Essentially, the transformation of adaptive intimal thickenings into early atherosclerotic lesions 
involves the perpetual accumulation and retention of lipid within the wall at these sites (Figure 
1.1.3). Interestingly, lipid accumulation within the arterial wall has been documented not only in the 
diseased arterial wall but also within the healthy artery (Rapp, 1989; Smith and Staples, 1982). This 
suggests that normal lipid metabolism involves its entry into and efflux from the arterial wall. 








Figure 1.1.3 Low-density lipoprotein (LDL) retention within the arterial wall  
In the atheroprone region of an artery, an insult to the integrity of endothelium can be triggered by 
disturbed/oscillatory low shear stress through elevated oxidative stress and reduced bioavailability of 
NO. This is associated with conditions that favours atherogenesis such as upregulation of adhesion 
molecules (i.e. E-selectin and VCAM-1), platelet activation, VSMC migration and proliferation, and 
heightened permeability associated with lipoprotein insudation and infiltration of inflammatory cells 
(monocytes). Lipoprotein accumulation within the intimal thickening can interact with proteoglycans 
and undergo modification (oxidation) that allows internalisation by macrophage and their 
subsequent transformation into foam cells. This stage is thought to be reversible or can progress into 
the earliest form of atherosclerotic plaque, a pathological intimal thickening (Kolodgie et al., 2007; 
Nakashima et al., 2007). There are little or no fibrotic changes at this stage. Such early lesions are 
often referred to as fatty streaks or intimal xanthomas and are visible en face as a flat or slightly 
raised yellowish discolouration on the luminal aspect of an artery. Image adapted from original 






Lipids such as cholesterol are insoluble in water and must be transported throughout the circulating 
blood by lipoproteins, which exist and are classified dependent on their different particle density 
(Figure 1.1.4). However not all lipoproteins cause atherosclerosis, with the commonly described low 
density lipoprotein (LDL) considered the major causal lipoprotein in atherosclerosis, in part due to its 
abundancy within the circulating blood, especially during fasting states (Linton, 2019). Traditionally, 
measuring LDL-cholesterol levels have been common practice in assessing cardiovascular risk 
(Arsenault et al., 2011). However, patients with coronary artery disease may have normal plasma 
LDL-cholesterol levels (Genest et al., 1992; Lamarche et al., 1997). Possibly, measurement of LDL 
cholesterol underestimates smaller (dense) LDL particles which are more atherogenic (Mudd et al., 
2007). Indeed, small LDL particles are more atherogenic than larger size LDL particles due to its 
reduced affinity to bind to LDL receptor, therefore less clearance/uptake by peripheral tissues which 
allows them to be more available in the blood stream (Ivanova et al., 2017). 
Recent evidence demonstrates that not only LDL, but other apolipoprotein-B-containing lipoproteins 
with a diameter of less than 70 nm, such as chylomicron remnants, VLDL, IDL and Lp (a) are capable 
of promoting atherosclerosis (Borén and Williams, 2016; Williams and Wu, 2016). Apolipoproteins 
are an integral part of the structure that envelopes the hydrophobic lipid (of lipoprotein structure) 
(Figure 1.1.5). Several classes of apolipoprotein have been described with apolipoprotein-B 
commonly associated with atherosclerosis (Shapiro and Fazio, 2017). Compelling evidence has 
emerged that measurement of plasma levels of apolipoprotein-B may provide better picture of 





Figure 1.1.4 Different classes of lipoproteins  
Based on their size and density, lipoproteins carry lipid (in the forms of triglycerides and cholesterol 
ester) within the circulatory system and can be classified into chylomicrons, VLDL, IDL, LDL and HDL. 
Chylomicrons are the largest lipoprotein and function to transport digested triglycerides from the 
small intestine to peripheral tissues. In the peripheral tissues (such as muscle, adipose and cardiac 
tissue) chylomicrons are metabolised by the lipoprotein lipase enzyme and then transported to the 
liver for subsequent metabolism to produce low density lipoproteins (VLDL, IDL and LDL) before 
distribution back into circulation. On the other hand, HDL transports lipid away from peripheral 
tissues (including the vessel wall) to the liver. Reportedly, HDL is associated with antioxidant and 
anti-inflammatory properties, and is therefore considered an anti-atherogenic lipoprotein (Rye et al., 
2009). LDL, IDL and VLDL are classed as pro-atherogenic lipoproteins or famously described as ‘bad 
cholesterol’. Chylomicrons, however, are controversial whether they can be considered pro-
atherogenic due to their larger size and therefore inability to cross the endothelium. However, a few 
studies documented evidence that chylomicrons (of size less than 70 nm) may possibly contribute to 
atherosclerosis (Nakano et al., 2008; Pal et al., 2003).  (VLDL = very low density-lipoprotein, IDL = 
intermediate density lipoprotein, LDL = low density lipoprotein, Lp (a) = lipoprotein a is part of LDL 
particle, HDL = high density lipoprotein (HDL2 and HDL3 are different density of HDL)). Image adapted 





Figure 1.1.5 Lipoprotein structure 
Lipoprotein molecules are comprised of an internal hydrophobic core (consists of triglyceride and 
cholesterol ester) surrounded by a monolayer of phospholipids, free cholesterol, and apolipoprotein. 
Apolipoproteins serve as a scaffold that secures the entire lipoprotein structure in place and serves as 
a ligand for lipoprotein receptors (i.e LDL-receptor) expressed by endothelial cells, vascular smooth 
muscles cells and monocyte/macrophages. Apolipoprotein-B is associated with VLDL remnants, IDL, 
LDL and Lp (a), whereas apolipoprotein-A is associated with HDL. Reportedly, apolipoprotein-E is 
associated with reduced atherosclerosis plaque progression (Greenow et al., 2005; Raffai et al., 
2005). Image adapted from original source (Feingold and Grunfeld, 2018) and made using elements 
retrieved from https://smart.servier.com. 
 
Intriguingly, low-density lipoprotein cholesterol (LDL-C) recruitment into the arterial wall of a healthy 
artery occurs at the same rate between athero-prone and athero-protected areas (Schwenke and 
Carew, 1989). Therefore, atherosclerosis occurs not merely due to higher lipid influx but most 
importantly, LDL-C retention within the adaptive intimal thickening. Indeed, an in vivo study has 
shown that through genetic manipulation of perlecan heparan sulphate proteoglycans (a major 
component of adaptive intimal thickenings) in a mouse model of atherosclerosis, lower 
subendothelial lipoprotein retention is detected and results in decreased aortic atherosclerotic 
plaque formation, despite heightened endothelial permeability to LDL-C (Tran-Lundmark et al., 
2008).  
A study has suggested the possible pathway for circulating LDL uptake by endothelial cells in 
atherosclerosis is transcytosis mediated through scavenger receptor-B1 (SR-B1), activin receptor-like 




is then transported across endothelium to the basolateral compartment and subsequent release into 
the subendothelial space. 
Reportedly, the ionic binding between positively charged amino acids in apolipoprotein-B100 and 
negatively charged sulphate and carboxylic acids-glycosaminoglycan (-GAG) chains of proteoglycans 
leads to structural changes in apolipoprotein-B, hence causing lipid modification and retention 
within the subendothelial space (Khalil et al., 2004). Modification and oxidation of LDL-C results in 
the formation of oxidised-LDL (oxLDL), an immunogenic LDL which serves as a potent inducer of 
circulating monocytes (and other inflammatory cells) towards sites of LDL retention. This is achieved 
through the enhanced endothelial cell expression of adhesion molecules (i.e ICAM-1, VCAM-1 and 
specific integrins) (Yamada et al., 2008) alongside release of select chemokines (i.e monocyte 
chemoattractant protein-1 (MCP-1), RANTES (regulated upon activation, normal T cell expressed and 
secreted also known as (C-C) motif ligand 5; CCL5), and fractalkine (CX3CL1)) (Hansson, 2009).  
Modification and oxidation of LDL is a complex biochemical process which is crucial to the 
development of atherosclerotic plaques. While native LDL is not taken up by macrophages, several 
studies have shown a contributory role for LDL oxidation to atherogenesis. An in vivo study 
demonstrated the importance of the lipid oxidation hypothesis by using probucol, an antioxidant 
that prevents LDL oxidation, which results in the reduction of atherosclerotic plaque formation in 
hypercholesterolaemic mice (Kita et al., 1987). Another in vivo study showed that overexpression of 
15-lipoxygenase, an enzyme involved in LDL oxidation within the vascular endothelium, resulted in 
the enhanced development of atherosclerotic plaques within LDL-receptor deficient mice (Harats et 
al., 2000). Similarly, deficiency of 12/15-lipoxygenase (a macrophage-derived LDL oxidising enzyme) 
resulted in reduced atherosclerosis in Apoe deficient mice (Huo et al., 2004). 
The increased expression of adhesion molecules by endothelial cells facilitates the rolling and 
adhesion of circulating monocytes on the endothelium and their ensuing trans-endothelial migration 




cell secretion of chemokines (MCP-1/CCL2 and CX3CL1) and concomitant monocyte expression of 
the associated cognate  receptors (CCR2 and CX3CR1, respectively), which act as signalling cues to 
direct monocytes (and other inflammatory cells) towards sites  of oxLDL retention within intimal 
thickenings (Zernecke and Weber, 2014).  
Besides its putative role as a chemotactic agent for monocyte/macrophages towards focal sites 
within intimal thickenings, oxLDL also plays significant role in enhanced expression and release  of 
growth factors by macrophage and endothelial cells, such as platelet derived growth factor (PDGF) 
and fibroblast growth factor-2 (FGF2), which can induce VSMC migration and proliferation (Lindner 
et al., 1991; Stiko-Rahm et al., 1992). An additional recent report suggests that oxLDL promotes 
VSMC migration and proliferation via osteopontin, a chemotactic cytokine-like protein (Liu et al., 
2014). Reportedly, oxLDL also enhanced collagen production by VSMCs in vitro and in vivo (Jimi et 
al., 1994; Jimi et al., 1995), suggesting oxLDL can also contribute to establishment of the fibrous cap 
within atherosclerotic lesions (Maiolino et al., 2013). On the contrary, oxLDL also modulates 
expression, secretion, and activation of matrix metalloproteinase-9 (MMP-9), an enzyme proposed 
to be associated with degradation of the fibrous cap and therefore predisposing atherosclerotic 
plaques to rupture (Sanda et al., 2017). It has long been suggested that despite its immunogenic 
nature, oxLDL is also cytotoxic to vascular cells and may cause cell death (Cathcart et al., 1985; Hsieh 
et al., 2001), thus supporting a role for oxLDL to the development of the necrotic core within 
atherosclerotic plaques. In addition, oxLDL is also associated with reduced prostacyclin secretion, a 
known inhibitor of platelet activation, thus oxLDL may also indirectly promote platelet adhesion 
(Thorin et al., 1994), and therefore predispose to thrombus formation during atherosclerotic plaque 
disruption. Indeed, a recent study showed that oxLDL can induce platelet activation via tyrosine 
kinase and Rho kinase signalling pathways (Wraith et al., 2013).   
After their transmigration into intimal thickenings, monocytes interact with the local environment 




macrophages. Maturation into macrophages is associated with up-regulation of scavenger receptors 
(such as cluster of differentiation 36 (CD36) (Park, 2014) and lectin-like oxidised LDL receptor-1 (LOX-
1) (Xu et al., 2013)), which permits the macrophages to engulf oxLDL, a process which transforms 
them into foam cell macrophages, the presence of which is a hallmark of atherosclerosis. At this 
stage, the lesion in humans is termed a pathological intimal thickening (Kolodgie et al., 2007; 
Nakashima et al., 2007), but also referred to as a fatty streak or intimal xanthoma (particularly in 
animal models) and is grossly visible en face. Such lesions may progress further or can regress.  
The progression of a pathological intimal thickening into an advanced atherosclerotic plaque (Figure 
1.1.6) involves marked foam-cell macrophage apoptosis, ineffective clearance of dying foam cells, 
and the consequential formation of a lipid-rich, necrotic core (Kolodgie et al., 2007). The process is 
somewhat different in mouse models of atherosclerosis, where intimal xanthomas consist mainly of 
foam-cell macrophages, with proliferation and migration of medial VSMC into the intima alongside 
collagenous matrix deposition to form the fibrous cap overlying the developing necrotic core. In 
human and mouse developing plaques, the recruitment and activation of other inflammatory cells is 
observed including T-cells (Hansson, 2009). Collagenous matrix deposition mainly by VSMC leads to 
formation and maintenance of the fibrous cap overlying the lesion. Overtime, the plaque may reach 
its optimal growth, and further progression is thought to involve the repeated rupture and healing of 
advanced plaques, alongside compensatory adaptation of the arterial wall itself, a process termed 
outward arterial remodelling. Reportedly, outward (or compensatory) arterial remodelling is an 
important process that accompanies atherosclerotic plaque development in order to maintain lumen 
size and therefore preserve normal blood flow (Schoenhagen et al., 2001). This process involves a 








Figure 1.1.6 Schematic diagram of a stable atherosclerotic plaque 
Schematic diagram representative of a stable atherosclerotic plaque with a necrotic core and intact 
thick fibrous cap overlain by endothelial cells. The lesion may result in luminal encroachment, and 
therefore cause varying degrees of lumen stenosis. Stable plaques are commonly clinically 
asymptomatic. In the same section of the artery, the wall opposite to the site of the atherosclerotic 
lesion displays a normal intima. Image adapted from original source (Insull, 2009).  
 
During their progression, atherosclerotic plaques undergo continuous remodelling involving a 
balance between matrix deposition and degradation. Heightened degradation through the action of 
proteases such as matrix metalloproteinases (MMP) can weaken the fibrous cap and predispose it to 
rupture (Johnson, 2017). The formation of intraplaque blood vessels from the adventitial vasa 
vasorum (termed neovascularisation) are also associated with plaque instability (Kolodgie et al., 
2003; Michel et al., 2011), which alongside increased matrix degradation and VSMC death within the 
fibrous cap, predispose to rupture and subsequent thrombosis formation. Reportedly, some plaques 
rupture and heal without any clinical manifestation (Arbab-Zadeh and Fuster, 2015; Burke et al., 
2001; Mann and Davies, 1999), while ruptured plaques with marked thrombosis can cause sudden 
luminal blockage and therefore disrupt arterial supply to the affected myocardial tissue (ischaemia), 




In the majority of MI cases, the blockage is due to atherosclerotic plaque rupture and ensuing 
thrombosis formation. However, about one third of MI cases are not associated with plaque rupture, 
and instead attributed to endothelial erosion, a mechanism involving loss of endothelial cells 
overlying an otherwise intact plaque (but highly stenotic), triggering thrombosis formation (White et 
al., 2016).  
Most of the therapeutic strategies for clinically-relevant atherosclerosis focus on the management of 
circulating lipid levels through the administration of lipid-lowering agents (such as statins), or the 
complications of plaque rupture (thrombosis or marked stenosis) which involves delivery of an anti-
coagulant drug (such as Prasugrel), or interventions including reperfusion therapy, stenting, or 
coronary artery bypass grafting, depending on disease extent. However, in opposition to lipid 
management, the focus on plaque inflammation as an interventional target has only recently 
become an area of active research.  
Reportedly, AGI-1067 (also known as succinobucol), is a phenolic antioxidant and a derivative of the 
lipid-lowering agent probucol, and has been shown to inhibit tumour necrosis factor alpha (TNFα) 
induced VCAM-1, MCP-1 and E-selectin expression in human aortic endothelial cells, alongside 
reducing LDL levels and preventing the development of atherosclerotic plaques in both Apoe-
deficient and Ldlr-knockout mice, without exerting a lipid-lowering effect (Sundell et al., 2003). 
However, clinical trial of succinobucol did not support its therapeutic use for atherosclerosis (Tardif 
et al., 2008a; Tardif et al., 2008b). Some in vivo studies have proposed an athero-protective role for 
interleukin-6 (IL-6) (Madan et al., 2008; Schieffer et al., 2004). However, IL-6 has been shown to have 
a causal association with coronary artery disease based on genetic and biomarker data (Sarwar et 
al., 2012; Swerdlow et al., 2012). 
Interleukin-1β (IL-1β) is a prominent inflammatory cytokine proven to be associated with human 
atherosclerotic plaque progression (Dewberry et al., 2000). Reportedly, an in vivo study showed 




domain-like [NOD-like] receptor protein 3 (NLRP3) inflammasome, promoted atherosclerosis 
(Duewell et al., 2010). Canakinumab is an antibody targeting IL-1β and clinically licensed for 
treatment of rheumatologic autoimmune diseases such as cryopyrin-associated periodic syndrome 
and systemic juvenile idiopathic arthritis (Lachmann et al., 2009; Ruperto et al., 2012). Recently, a 
clinical trial assessing the effectiveness of canakinumab treatment in cardiovascular disease patients 
with high circulating levels of C-reactive protein (CRP), demonstrated dose-specific IL-1β inhibition 
proved beneficial through the reduction of cardiovascular events (including nonfatal myocardial 
infarction, nonfatal stroke, or cardiovascular death) over a five-year follow-up period, in the absence 
of lowering plasma LDL levels (Ridker et al., 2017). However, canakinumab treatment was associated 
with a significant increased death rate related to infection (i.e sepsis), associated with low white cell 
count as canakinumab systemically blocked IL-1β and not specifically within atherosclerotic plaques. 
These recent clinical findings strongly support a causal role for plaque inflammation in 
atherosclerosis and associated major adverse cardiovascular event.  
Therefore, research on inflammatory cells (especially monocyte/macrophages) and their related 
signalling pathways offers promising novel therapeutic targets, while also considering the potential 
adverse effects connected with systemic anti-inflammatory treatments. Indeed, 
monocyte/macrophages can exist as divergent phenotypes with pro- and anti-inflammatory 
properties, necessitating the need to fully characterise their behaviour and function before the 
application of anti-inflammatory treatments for atherosclerosis prevention.  
1.2 Monocyte subsets  
In humans, monocytes account for 1% - 9% of total leukocyte numbers within the peripheral 
circulation (Lynch et al., 2018). Monocytes are primarily generated within the bone-marrow (from 
haematopoietic cells) but can also be released into the circulation from the spleen. Monocytes 
circulate within the blood before they leave the blood stream to be recruited to tissues to transform 




Human monocytes co-exist as different subpopulations which are classified (in humans) based upon 
their expression of specific cell-surface receptors, mainly cluster of differentiation 14 (CD14) and 
CD16. CD14 serves as a co-receptor along with Toll Like Receptor-4 (TLR4) and lymphocyte antigen 
96 (also known as Myeloid Differentiation factor 2, MD2), for the detection and uptake of bacterial 
lipopolysaccharide (LPS). On the other hand, CD16 (also known as Fc Fragment of immunoglobulin-
gamma (IgG) Receptor IIIa, FCGR3A) participates in antigen-antibody complex clearance from the 
circulation, alongside additional antibody-dependent responses. Both are therefore surface 
receptors which play key roles during the early stages of immune responses (Yang et al., 2014). 
Therefore, monocyte subpopulations are stratified upon their CD14 and CD16 cell-surface 
expression as classical, intermediate and nonclassical monocyte subsets (Table 1.2.1). 
The dominant monocyte subpopulation is the classical type which are considered to display high 
phagocytosis function. Accordingly, this subset expresses genes associated with phagocytosis, and 
those related to anti-microbial proteins, angiogenesis, wound healing, and coagulation (Idzkowska et 
al., 2015; Wong et al., 2011). Classical monocytes also highly co-express other cell-surface receptors 
such as (C-C) motif chemokine receptor type 2 (CCR2) the receptor for monocyte chemoattractant 
protein-1 (MCP-1), which plays a key role in monocyte chemotaxis at sites of inflammation including 
atherosclerotic plaques. CD62 or leukocyte-selectin (L-selectin) is a cell adhesion molecule involved 
in monocyte adherence and retainment at sites of inflammation and is also highly expressed by 
CD14++CD16- classical monocytes.  
Opposingly, non-classical monocytes (CD14+16++) exhibit low cell-surface expression of CCR2 and 
CD62 but express abundant cell-surface C-X3-C motif chemokine receptor 1 (CX3CR1), which is also 
known as the fractalkine receptor, and is involved in regulating chemotaxis of this subpopulation 
(Ancuta et al., 2003). Based upon the spatial and temporal expression of fractalkine, CD14+CD16++ 




As their name suggests, intermediate monocytes (CD14+CD16+) have been proposed as a transition 
state between the classical to non-classical monocytes, as monocytes are thought to arise from a 
single common precursor (Idzkowska et al., 2015). Moreover, following induction with macrophage 
colony-stimulating factors (M-CSF), there is an expansion of intermediate monocytes before 
progression into the non-classical type (Weiner et al., 1994). As expected, intermediate monocytes 
display characteristics of the other two subtypes, for example, they express CCR2 (a feature of 
classical monocytes) and CX3CR1 (a marker of nonclassical monocytes). Nevertheless, intermediate 
monocytes are now recognised as not just a mere transition state between the two subtypes, but 
separately associated with antigen presentation and T-cell activation, and therefore proposed to be 
actively involved in inflammatory mediated processes (Stansfield and Ingram, 2015).   
In mice, monocytes are classified based upon the density of lymphocyte antigen 6 complex (Ly6C) 
surface receptor into high, middle, or low (Table 1.2.1). Ly6Chigh and Ly6Cmiddle are considered 
analogous to human classical monocytes, displaying abundant expression of CCR2 and highly 
inflammatory function, whereas the Ly6Clow sub-population exhibit low CCR2 expression and serve as 




Table 1.2.1 Classification of human monocytes based upon CD14 and CD16 cell-surface receptor expression, and characterisation of mouse 
monocytes based on Ly6C cell-surface levels 
(CD = a cluster of differentiation; CCR = (C-C) motif chemokine receptor; CX3CR1 = (C-X3-C) motif chemokine receptor 1; Ly6C = lymphocyte antigen 6 
complex; MNC = Mononuclear cells). Adapted from (Yang et al., 2014) 
 
Species Subsets Surface markers % in MNC Chemokine receptors Function(s) 
Human 
Classical CD14++CD16- 80-95 CCR2highCX3CR1low Phagocytosis 
Intermediate CD14+CD16+ 2-11 CCR2midCX3CR1highCCR5+ Highly inflammatory 
Non-classical CD14+CD16++ 2-8 CCR2lowCX3CR1high Patrolling 
Mouse 
Ly6Chigh (Ly6C+) CD11b+CD115+Ly6Chigh 40-45 CCR2highCX3CR1low Phagocytosis & Pro-inflammatory 
Ly6Cmiddle (Ly6C+) CD11b+CD115+Ly6Cmiddle 5-32 CCR2highCX3CR1low Highly inflammatory 






1.3 Macrophage classification 
Similar to monocytes, the diversity of macrophages (Table 1.3.1) can be appreciated based on their 
cell-surface receptor expression, alongside their production of key cytokines and growth factors 
(Colin et al., 2014). The two most commonly described macrophage subsets are the classically 
activated (M1) and alternatively activated (M2) macrophages.  
Table 1.3.1 In vitro macrophage phenotypes 
Overview of macrophage subsets, principal inducers, and their characteristics. (IFN!: interferon ! ; 
LPS: lipopolysaccharide; TNF": tumour necrosis factor alpha; IL: interleukin; CXCL: C-X-C motif 
chemokine ligand; MHC: major histocompatibility complex; CD: cluster of differentiation; MARCO: 
macrophage receptor with collagenous structure; iNOS: inducible nitric oxide synthase; STAT: signal 
transducer and activator of transcription; NF-#B p: Nuclear factor-kappa B-cell p heterodimer; IRF5: 
interferon regulatory factor 5; MR: mannose receptor; TGFβ : transforming growth factor beta: IL-Ra: 
interleukin-1 receptor antagonist; CCL: (C-C) motif chemokine ligand; IRF4: interferon regulatory 
factor 4; PPAR!: peroxisome proliferator-activated receptor gamma; IC: immune complexes; TLR: toll 
like receptor; IL-IR: interleukin-1 receptor; A2R: adenosine A2A receptor agonist; VEGF: vascular 
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Classically activated macrophages (M1) are induced by T-helper 1 (Th-1) cytokines (produced by Th-1 
lymphocytes) such as  IFNg, alongside inflammatory cytokines including TNFα and microbial 
products, for example lipopolysaccharides (LPS) (Mosser and Edwards, 2008). M1 macrophages are 
considered to promote inflammatory responses via secretion of pro-inflammatory cytokines 
including interleukin-6 (IL-6), IL-1b, TNFa, IL-2, and IL-23 (Colin et al., 2014). They also produce toxic 
agents such as nitric oxide and reactive oxygen species (ROS) to curb infection (Mosser, 2003). 
Several chemokines are also expressed and released by M1 macrophages, for instance CXCL9, 
CXCL10, and CXCL5, which act to promote further recruitment of Th1 lymphocytes and natural killer 
(NK) cells, and therefore linked with sustained inflammation (Colin et al., 2014). These functions are 
beneficial during acute infection responses for the resolution of infection, but may impair wound 
healing if their presence and action is prolonged, resulting in chronic sterile inflammation (Colin et 
al., 2014). Induced by T-helper 2 (Th-2) lymphocyte cytokines, alternatively activated macrophages 
(M2) are considered to be principally involved in tissue repair and resolution processes (Mosser, 
2003). Accordingly, they display phagocytic, pro-angiogenic and pro-fibrotic properties (Colin et al., 
2014). More recently, alternatively activated macrophages (M2) have been further subclassified into 
M2a, M2b, M2c and M2d subsets, with specific inducers identified alongside particular secretory 
products (as shown in Table 1.3.1). Functionally, M2a macrophages are involved in wound healing, 
M2b and M2c macrophages are classified to have immunoregulatory roles (Mosser and Edwards, 
2008), whereas M2d macrophages are involved in tumour growth (Haskó and Pacher, 2012; Zhou et 
al., 2020). The M2 macrophage subsets exhibit high levels of mannose receptor (CD206) expression 
except for M2d macrophages (Colin et al., 2014). Collectively, M2 macrophages have been shown to 
have anti-inflammatory properties except for M2b macrophages, which secrete pro-inflammatory 
factors similar to M1 macrophages alongside high levels of the anti-inflammatory molecule IL-10, but 




1.4 The role of monocytes and macrophages in atherosclerosis  
As cells of innate immune system, monocytes and macrophages have been demonstrated to play a 
key role in the development of atherosclerosis, as depletion of monocytes from the circulation was 
associated with reduced atherosclerotic plaque formation in a rabbit model (Ylitalo et al., 1994). 
Additionally, increased monocyte number within the blood, termed as monocytosis, strongly 
correlates with atherosclerotic plaque progression and incidence of MI (Raffort et al., 2017).  
Figure 1.4.1 illustrates how classical and non-classical monocyte subsets participate in 
atherosclerosis (Johnson and Newby, 2009). Modified LDL (chiefly oxLDL) induces vessel wall 
expression of the CCL2 (MCP-1) chemokine which interacts with its cognate receptor CCR2 on 
monocytes in order to attract circulating classical monocytes into the developing lesion. 
Differentiation of monocytes into macrophages ensues with subsequent oxLDL internalisation. 
Scavenger receptor-mediated oxLDL uptake by macrophages and ongoing oxLDL accumulation 
results in the formation of lipid-laden macrophages, more commonly termed as foam cells 
(Kunjathoor et al., 2002). Ingested oxLDL can undergo degradation, or after processing be released 
(efflux) from the cell via the reverse cholesterol transport mechanism via HDL, which has been 
associated with plaque regression (Tall et al., 2008).  
During this innate immune response, non-classical monocytes can be recruited to the lesion. 
Reportedly, this process is mediated by the chemokine receptors for CX3CL1 and CCL5 (Johnson  and 
Newby, 2009; Tacke et al., 2007). Macrophages (and other immune cells such as dendritic cells) 
present antigen on their cell surface to T-lymphocytes. As a result, various cytokines are produced to 
promote plaque growth such as IFNg and TNFa. Both cytokines are known to be pro-inflammatory 
and widely researched as potential therapeutic targets for the treatment of atherosclerosis (Brånén 
et al., 2004; Gotsman and Lichtman, 2007). On the contrary, some of the cytokines produced are 




(Han and Boisvert, 2015). Another molecule released from macrophages considered to be athero-
protective is transforming growth factor-beta (TGFb) (Toma and McCaffrey, 2012).  
Supporting key roles for the monocyte populations to the development of atherosclerosis, genetic 
deletion of CCL2 and CX3CL1 chemokine or their receptors (CCR2 and CX3CR1 respectively) was 
associated with reduced atherosclerotic plaque size in murine models through blunting 
monocyte/macrophage accumulation (Saederup et al., 2008). The differentiation of monocytes into 
distinct macrophage phenotypes requires different cytokines as depicted in Figure 1.4.1. However, 
there is scant evidence that specific monocyte subsets give rise to select macrophage 






Figure 1.4.1 Monocytes and macrophages in atherosclerosis 
Innate immune responses involve mainly CCL2 mediated monocyte (CD14+CD16- or classical 
monocytes) chemotaxis whereas further immunoinflammatory responses entail the CX3CL1 mediated 
pathway (CD16+ non-classical monocyte population). Subsequently, macrophage interaction with 
local cues determines their roles in atherosclerosis progression. For example, pro-inflammatory 
growth factors/cytokines (LPS, TNF"	 and IFNg) are associated with expansion of atherosclerotic 
plaque (such as necrotic core formation) and weakening of the fibrous cap (causing plaque rupture) 
which suggests characteristics of M1 macrophages. On the other hand, interaction of intimal 
macrophages with anti-inflammatory growth factors/cytokines (such as IL-4 and IL-13) is associated 
with fibrous cap formation, plaque calcification and neovascularisation, characteristics attributed to 
the diverse alternatively activated macrophage (M2) population. Other M2 macrophage roles in 
atherosclerosis are described in section 1.5 (Macrophage subpopulations in atherosclerosis) (CCL2 = 
chemokine (C-C motif) ligand 2, oxLDL = oxidised low-density lipoprotein, CX3CL1 = chemokine (C-X3-
C motif) ligand 1, LPS = lipopolysaccharide, TNFa = tumour necrosis factor alpha, IFNg = interferon 






1.5 Macrophage subpopulations in atherosclerosis 
Macrophages are essential in the initiation and progression of atherosclerosis (Johnson and Newby, 
2009). During atherosclerosis, macrophages accumulate within developing lesions in part due to 
reduced emigration (Ludewig and Laman, 2004). There is a specific distribution of macrophage 
subpopulations within atherosclerotic plaques. At plaque shoulders, where it is prone to rupture, M1 
macrophages appear to be the dominant population. Within the fibrous cap, M1 and M2 
macrophage distribution is similar, while in the adventitial region of atherosclerotic plaques, M2 
macrophages predominate (Stöger et al., 2012). Overall, M1 macrophages predominantly populate 
in unstable plaques in comparison to stable lesions (Cho et al., 2013; Lee et al., 2013). Figure 1.5.1 
summarises the diverse macrophage subpopulations within atherosclerotic plaques, their proposed 
mediators, and cell-surface receptors (Colin et al., 2014). 
Classically activated macrophages (M1) which can be induced by IFN!, LPS, oxLDL, and cholesterol 
crystals, exert pro-inflammatory properties associated with increased expression of TNF", CD86 and 
MHCII, which are associated with atherosclerotic plaque progression. M(hb) is 
haemoglobin/haptoglobin-stimulated macrophage subset which is located and dominates within 
sites of intraplaque haemorrhage. This subset is proposed to clear free haemoglobin from within 
intra—plaque bleeds through the CD163 receptor (Araujo et al., 2012). M(hb) macrophages are also 
associated with elevated expression of IL-10, an anti-inflammatory cytokine. The release heme by 
M(hb) may primes macrophage into M(heme) with expression of activating transcription factor 
(ATF)-1 and heme oxygenase-1 (HMOX1), both prevents formation of foam cells and are therefore 
anti-atherogenic. Thus, both CD163 M(Hb) and M(heme) can be considered as atheroprotective 
macrophage subset. However, recent finding suggests that CD163 high M(hb) macrophage assists in 
plaque angiogenesis, heightened vascular permeability, and exerts a pro-inflammatory role via 
hypoxia inducible factor-1 α (HIF1α)/ vascular endothelial cell growth factor A (VEGF-A) dependant 






Figure 1.5.1 Specific macrophage subpopulations found within atherosclerosis plaques 
Various macrophage subpopulations have been detected within atherosclerotic plaques and specific 
roles proposed in both human (H) and mouse (M) lesions. M4, M(hem), M(Hb) and M2 macrophage 
subsets are considered less likely to transform into foam cells. Inducers and associated cell-surface 
receptors are indicated by arrows and at cell periphery, respectively. Currently, the Mox subset had 
not been reported in human atherosclerotic lesions. (M1 = classically activated macrophage, M4 = 
PF4 (CXCL4) activated macrophage, Mhem = heme activated macrophage, M(Hb) = 
hemoglobin/haptoglobin (Hb/Hp) activated macrophage, M2 = IL-4 activated macrophage, Mox = 
oxPL (oxidised phospholipid) activated macrophage, IFN! = interferon !, LPS = lipopolysaccharide, 
chol = cholesterol crystal, TNF" = tumour necrosis factor ", CD = cluster of differentiation, MHCII = 
major histocompatibility complex II, PF4 = platelet factor 4, CXCL4 = (C-X-C motif) chemokine ligand 
4, MR = mannose receptor, MMP7 = matrix metalloproteinase 7, S100A8 = S100 calcium binding 
proteins, HMOX1 = heme oxygenase-1, Srx1 = sulforedoxin-1,  Txnrd1 = thioredoxin reductase 1). 
Image adapted from original source (Colin et al., 2014). 
 
The M4 macrophage subset is considered alternatively activated by platelet factor 4 (PF4) which is 
also known as (C-X-C motif) chemokine ligand 4 (CXCL4), which does not readily take up lipid owing 
to reduced expression of scavenger receptors (including CD36 and SCARB1). Reportedly, the M4 
subset is associated with reduced expression of CD163 and HMOX1 enzyme, and is associated with 
high expression of pro-inflammatory cytokines such as IL-6 and TNF", hence rendering them to be 
classed as pro-atherogenic (Domschke and Gleissner, 2019). M4 macrophages are found within the 
intima and adventitia of unstable plaques. The mannose receptor CD206, matrix metalloproteinase 7 
(MMP-7) and S100A8 are considered markers for the M4 macrophage subset (Domschke and 




IL-4 activated macrophages (M2a macrophage subset) is associated with anti-inflammatory 
production of growth factors/cytokines such as fibronectin, insulin-like growth factor (IGF), and 
transforming growth factor beta (TGF&). Similar to M4 macrophages, the M2a subset also express 
high levels of CD206, a carbohydrate receptor with high phagocytosis function for the clearance of 
dying/dead cells, but not to readily ingest lipids. These lines of evidence suggest the role of M2a 
macrophages is to stabilise atherosclerotic plaques, supported by their prevalence within the fibrotic 
cap and lowly detected within the lipid core (Chinetti-Gbaguidi et al., 2011). However, it has been 
shown that when IL-4 activated M2a macrophages interact with oxLDL, they produce pro-
inflammatory cytokines such as IL-8 (Hirose et al., 2011). Relatedly, M-CSF has also been deemed an 
activator for M2 macrophage polarisation, and induces an increase in IL-6 and MCP-1 expression, 
both of which are pro-inflammatory mediators (van Tits et al., 2011).  
In vivo studies have also postulated a macrophage sub-population that is induced by oxidised 
phospholipids (oxPL) termed as Mox, and is associated with lower phagocytosis activity and higher 
antioxidant properties linked to their elevated levels of enzymes such as HMOX-1, thioredoxin 
reductase 1 (Txnrd1) and sulforedoxin-1 (Srx1) (Kadl et al., 2010). However, more recent in vivo 
findings proposed that the Mox subset served as a pro-inflammatory and pro-atherogenic 
macrophage population (Que et al., 2018).  
Besides their primary role in mediating inflammatory responses during atherosclerosis, monocytes 
and macrophages can also mediate VSMC responses. Macrophages can facilitate medial VSMC 
migration through the secretion of proteases (such as MMPs) that degrade the extracellular matrix 
to permit VSMC motility (Newby, 2005), and additionally by expression of chemokines or growth 
factors such as macrophage migratory inhibitory factor (MIF) (Schrans-Stassen et al., 2005) and 
extracellular vesicle release (Niu et al., 2016). MIF is a pro-inflammatory cytokine secreted by 
macrophages, VSMCs, and endothelial cells (van der Vorst et al., 2015), and is reportedly able to 




therefore proposed to contribute to atherosclerotic plaque development (Chen et al., 2015). In a 
recent report, extracellular vesicles released by foam cell macrophages were taken up by VSMC, and 
able to modulate the actin cytoskeleton and focal adhesions through the extracellular-regulated 
kinase (ERK) and protein kinase B (Akt) signalling pathways, promoting VSMC adhesion and 
migration (Niu et al., 2016). 
Within advanced atherosclerotic plaques, macrophages secrete proteases with the ability to degrade 
collagen and also induce VSMC apoptosis (through loss of cell-to-matrix and cell-to-cell junctions), 
both actions which can weaken the integrity of the fibrous cap and render it prone to rupture 
(Newby, 2007; Skjøt-Arkil et al., 2010). The production of reactive oxygen species by macrophages is 
also thought to cause VSMC death (Li et al., 1997). Furthermore, apoptosis of foam cell macrophages 
and VSMCs contribute to central necrosis of the atherosclerotic plaque and subsequent expansion of 
the necrotic/lipid core. Macrophages also secrete pro-angiogenic factors and can therefore promote 
neovascularisation within atherosclerotic plaques, possibly via a CD163/HIF1α/VEGF-A pathway, 
with the formation of neovascularisation considered to predispose to intraplaque haemorrhage, 







1.6 Colony stimulating factors as regulators of macrophage phenotypes 
Haematopoietic cytokines are a family of glycoprotein molecules which act on haematopoietic 
progenitor cells and their progeny to stimulate cell proliferation and differentiation into specific 
blood cell types (Metcalf, 2008). As depicted in Figure 1.6.1, numerous cytokines have been 
identified to take part in the production of blood cells, including immune cells. Blood cells are 
constantly produced from common progenitor cells to maintain steady state levels in healthy 
individuals to replace the matured cells which have a limited life span. Some cytokines show limited 
lineage specificity such as erythropoietin (EPO), thrombopoietin (TPO), IL-2 and IL-7, while others 
display a broad range of activity including colony stimulating factors (CSF).  
Of interest, there are four colony stimulating factors (CSF) which have been classified based on the 
cells they primarily stimulate, namely macrophage-colony stimulating factor (M-CSF), 
granulocyte/macrophage -colony stimulating factor (GM-CSF), granulocyte-colony stimulating factor 
(G-CSF), and multi-potential colony stimulating factor (multi-CSF) which is more commonly referred 
to as interleukin-3 (IL-3). CSFs are  secreted by various cell types, including immune cells themselves, 
endothelial cells and VSMCs (Barreda et al., 2004). CSFs stimulate cell proliferation and colony 
formation by promoting clonal cell growth and supressing apoptosis. Their secretion is tightly 
regulated by positive and negative feedback mechanisms, and increased under certain stimuli such 
as infection and stress (Barreda et al., 2004).  
Through the action of CSFs, two distinct macrophage subsets (Figure 1.6.2) have been identified in 
vitro, namely M-Mac and GM-Mac, based on differentiation with M-CSF or GM-CSF, respectively 
(Waldo et al., 2008). When compared to M-Mac, GM-Mac are characterised as highly invasive, have 
an increased susceptibility to apoptosis, are more proliferative, and accumulate modified LDL more 
rapidly. They are also associated with increased expression of MMP-12, MMP-14 and the microRNA 




targets MMP-14), and galectin-3 (Gal-3) (Di Gregoli et al., 2014; Di Gregoli et al., 2017; Di Gregoli et 
al., 2020; Johnson et al., 2014).  
Therefore, GM-Mac are considered a pro-inflammatory macrophage subset and associated with the 
progression of atherosclerotic lesions towards an unstable plaque phenotype. Conversely, M-CSF 
polarised macrophages (M-Mac) can be regarded as anti-inflammatory and associated with a stable 
plaque phenotype (Di Gregoli et al., 2017; Di Gregoli et al., 2020; Johnson et al., 2014; Johnson et al., 
2008).  
 
Figure 1.6.1 Haematopoietic cytokines involved in the differentiation of blood cells and 
immune cells 
Haematopoietic stem cells (HSC) give rise to cells of myeloid and lymphoid origin. Myeloid lineage 
cells eventually give rise to red blood cells, platelets, granulocytes (basophil, eosinophil and 
neutrophil) and monocyte/macrophages (including dendritic cells, Langerhans cells, and Kupffer 
cells). Lymphoid lineage cells included all lymphocytes and natural killer cells. (IL = interleukin, M-CSF 
= macrophage colony stimulating factor, GM-CSF = granulocyte-macrophage colony stimulating 
factor, G-CSF = granulocyte colony stimulating factor, TPO = thrombopoietin, SCF = stem cell factor, 








Figure 1.6.2 Colony stimulating factors (CSF) as regulators of macrophage phenotype  
M-CSF polarised macrophages (M-Mac) display heightened expression of TIMP-3 (red cells), which 
has been implicated in the resolution of inflammation and therefore the anti-inflammatory actions of 
M-Macs (Casagrande et al., 2012). Conversely, GM-CSF polarised macrophages (GM-Mac) have 
marked MMP-14 levels (green cells), which affords these macrophages with augmented destructive 
activity and therefore propagate atherosclerotic plaque instability. (TIMP-3 = Tissue inhibitor of 
metalloproteinases-3, MMP-14 = Matrix metalloproteinases-14) (Di Gregoli et al., 2014; Johnson et 
al., 2008). Image on the left-hand side made using elements retrieved from 














1.7 Progenitor potential of monocytes and macrophages  
Together with dendritic cells, monocytes and macrophages form the mononuclear phagocyte 
system. They exhibit phagocytic capacity and antigen presenting function (Gordon and Plüddemann, 
2019). However, recent evidence has suggested that monocytes harbour the ability to differentiate 
into cell types with non-phagocytic properties.  
Indeed, recent studies have suggested that under in vitro conditions, human monocytes have the 
capacity to differentiate into non-phagocytic pluripotent stem-like cells with a variety of different 
names including; pluripotent stem cells (PSCs) (Zhao et al., 2003); monocyte-derived multipotential 
cells (MOMC) (Kuwana et al., 2003; Seta and Kuwana, 2010); a CD14+CD43lowKDR+ subset (KDR 
stands for kinase insert domain receptor, which is also known as VEGFR2) (Romagnani et al., 2005); 
and programmable cells of monocyte origin (PCMO) (Ruhnke et al., 2005a; Ruhnke et al., 2005b; 
Ungefroren and Fändrich, 2010). A study by Romagnani and colleagues have shown that 
CD14+CD34low cells are the major source of circulating endothelial progenitors (Romagnani et al., 
2005). While Harraz et al, reported CD14+ monocytes have the potential to be incorporated into the 
endothelium of blood vessels in ischaemic mouse limbs and transdifferentiate into endothelial cells 
(Harraz et al., 2001). 
Additionally, it has been reported in the literature that CD14+ monocytes co-express endothelial 
lineage markers and form cord-like structures in vitro in response to pro-angiogenic factors 
(Fernandez Pujol et al., 2000; Schmeisser et al., 2001). In addition, peripheral blood mononuclear 
cells (PBMC) cultured with macrophage-colony stimulating growth factor (M-CSF) for 5 days exhibit 
fibroblast like morphology with expression of CD14 and CD45, alongside the haematopoietic stem 
cell (HSC) surface receptor CD34 (Zhao et al., 2003). These cells were also induced towards other cell 
types including macrophages, T-lymphocytes, epithelial cells, neuronal cells, endothelial cells and 
liver cells, through stimulation with different growth factors, and were therefore considered to 




of differentiation towards a specific cell type was determined through the evaluation of a single cell-
type specific marker, for example von Willebrand Factor (vWF) to confirm differentiation into an 
endothelial cell. Moreover, only approximately 10% of PBMCs are monocytes and it is plausible that 
a circulating progenitor cell type which can respond to M-CSF, is present within the circulation (and 
therefore PBMC preparations) and accounts for the pluripotent cell type observed in some of the 
above studies. 
In another study, human PBMCs cultured upon fibronectin produced mesenchymal progenitor cells 
which expressed CD14, CD45 and CD34 with a mixed morphology and phenotypic features of 
phagocytes, endothelial cells, and mesenchymal cells (Kuwana et al., 2003). These cells were termed 
as monocyte-derived multipotential cells (MOMC) or monocyte derived mesenchymal progenitor 
cells (MOMP) and exhibited decreasing proliferation rates with subsequent passage and stopped 
growing after the fifth passage (Kuwana et al., 2003; Kuwana et al., 2006; Seta and Kuwana, 2007). 
Co-culture of MOMC with embryonic rat cardiomyocytes produced cells with electrophysiological 
characteristics of cardiac muscle tissues after three weeks with the ability to beat spontaneously and 
produce action potentials (Kodama et al., 2005). Similarly, co-culture of MOMC with neuronal cells 
resulted in neuronal lineage cells (Kodama et al., 2006). Additionally, MOMC treated with pro-
angiogenic growth factors led to cells with endothelial cell characteristics (Kuwana et al., 2006). 
However, the efficiency of MOMC differentiation towards an endothelial cell-like phenotype is 
higher than that towards cardiomyocytes and neuronal cells (Kodama et al., 2005; Kodama et al., 
2006; Kuwana et al., 2003; Kuwana et al., 2006).  
In a different study, human PBMCs were shown to differentiate into a phenotype which acquired a 
state of plasticity or programmability, with surface expression of CD14, CD90 (thymocyte 
differentiation antigen 1; Thy-1) and CD115 (also known as colony stimulating factor 1 receptor; 
CSF1R and macrophage colony-stimulating factor receptor; M-CSFR) following 6-day treatment with 




2010). These cells were termed as programmable cells of monocyte origin (PCMO) and shown to 
resume cell division in a CD115-dependent manner (Pufe et al., 2008; Ruhnke et al., 2005b; 
Ungefroren et al., 2010). Incubation of PCMOs with hepatocyte condition medium and islet-cell 
condition medium resulted in their transformation into liver cells and pancreatic cells, respectively, 
with associated secretory function observed in vitro and in vivo (Ruhnke et al., 2005b). In another 
study, collagen-producing chondrocytes were successfully yielded from PCMOs upon stimulation 
with various related growth factors (Pufe et al., 2008).   
Collectively, these findings provide insight that under specific conditions and within specific 
microenvironments, PBMCs and by inference, monocyte/macrophages can be modified to exit from 
their original state and associated properties and transform towards new cell types, mimicking 
characteristics under which they are newly ‘programmed’. Indeed, human blood monocytes have 
been extensively studied within regenerative medicine research (such as tissue engineering), as a 
potential alternative to embryonic stem cells as they can be readily retrieved from venepuncture 
and are simpler to maintain under tissue culture conditions (King and Perrin, 2014; Ungefroren et al., 
2010). 
In regard to cardiovascular diseases such as atherosclerosis, a similar approach could be studied, and 
potentially exploited, in a therapeutic preventative aspect. It would therefore be pertinent to study 
the capacity of differing macrophage subsets to transform towards vascular cell phenotypes, 
particularly macrophage subsets associated with cardiovascular diseases, and investigate the 
mechanisms involved in order to potentially promote or retard phenotypic differentiation for 






Select phenotypes of macrophage harbour the potential to differentiate towards vascular cell types.  
1.9 Project Aims and Objectives  
I. Evaluate the potential of differing human macrophage subsets to transform towards a 
VSMC-like phenotype, using growth factors shown to modulate the differentiation of 
VSMCs, and through assessing the expression of markers purported to be VSMC-specific.  
II. Evaluate the potential of differing human macrophage subsets to transform towards an 
endothelial cell-like phenotype, using growth factors shown to stimulate endothelial cell 
growth, and through assessing the expression of markers purported to be endothelial 
cell-specific.  
III. Assess the contributory role of microRNA in regulating macrophage subset 







2 Materials and Methods 
2.1 Macrophage culture and polarisation 
2.1.1 Isolation of Human Peripheral Blood Monocytes 
Materials: Ethylenediaminetetraacetic acid (EDTA) tubes, Falcon tubes, Ficoll-PaqueTM PLUS (GE 
Healthcare), SepMateTM tubes (Stem Cell technologies), Dulbecco’s Phosphate Buffered Saline 
(DPBS; 1X; Gibco by Life TechnologiesTM), Hank’s Balanced Salt Solution (HBSS; PAA The cell culture 
company) and RPMI/FCS media (see RPMI/FCS media below).  
2.1.2 Isolation of PBMCs from whole blood by density gradient 
centrifugation 
Human blood samples (between 20-25ml) were collected from random healthy subjects, according 
to ethical governance and guidelines (South West 4 Research Ethics Committee reference 
09/H0107/22). The blood was collected in EDTA tubes and processed within two hours of collection. 
EDTA-treated (anti-coagulant) blood was diluted (1:1) with sterile DPBS and layered carefully over 
Ficoll-Paque PLUS media (GE Healthcare Life Sciences) at ~45o tilted Falcon tube to avoid 
intermixing. The tubes were then subjected to centrifugation at 400 g (room temperature with the 
brake off) for 25 minutes to produce cell layers (Figure 2.1.1).  
 
Figure 2.1.1 Isolation of PBMCs 
DPBS-diluted blood layered on top of Ficoll-Paque (in 1:1). Differential migration during 
centrifugation results in the formation of layers containing different cell types: aggregated 
underneath a clear Ficoll-paque layer are erythrocytes, while mononuclear cells and other sediment 
particles appear as a cloudy white ring at the interface of plasma (topmost layer) and Ficoll-Paque 




The cloudy layer containing the PBMCs was collected and washed with sterile HBSS before 
centrifugation at 400 g (for 15 minutes). After centrifugation, the supernatant was removed to 
recover the pellet (at the bottom of the tube). New sterile HBSS was added, and the cell pellet 
resuspended by drawing in and out of pipette gently. The sample was submitted to centrifugation 
for 10-minutes, and the wash step repeated twice more.  
During this PhD, the group changed to using SepMateTM tubes as they save hands-on-time and are 
more reproducible, giving consistent yields with minimal carry over of toxic Ficoll-Paque. For the 
isolation of PBMCs using SepMateTM tubes, firstly Ficoll-Paque was added through the central hole 
inside the tubes. DPBS diluted blood was then added into the tube by pipetting it down the side of 
the tubes (in a vertical position). The blood is kept separated from the Ficoll-Paque by an insert 
within the SepMateTM tubes. Subsequently, the sample was subjected to centrifugation for 10 
minutes at 1200 g at room temperature with the brake on (Figure 2.1.2). The top liquid layer was 
collected which contains enriched mononuclear cells and plasma by pouring it off into a Falcon tube 
swiftly and avoiding placement of the SepMateTM tube in an inverted position for more than two 
seconds. The collected cells (and plasma) were washed with HBSS by centrifugation at 300 g for 10 
minutes. The wash step was repeated for a further two times.  
 
 
Figure 2.1.2 Isolation of PBMCs using SepMateTM tubes 
Isolation of PBMCs using SepMateTM tubes reduces the centrifugation time into 10 minutes as 









2.1.3 Isolation of monocytes by adhesion 
After a final wash with HBSS, the cell pellet was re-suspended in RPMI/FCS media (see section 2.2 
RPMI/FCS media). Cells were suspended at a concentration of 2.5 X 106 per ml and were transferred 
to a plastic 12-well tissue culture plate and incubated for 2 hours at 37oC (5% CO2). The cells were 
then washed with sterile DPBS for three times to remove non-adherent cells before being cultured in 
RPMI/FCS media supplemented with colony stimulating factors (CSF).  
2.2 RPMI/FCS media 
Materials: DPBS (Dulbecco’s Phosphate Buffered Saline; 1X; Gibco by Life TechnologiesTM), RPMI 
1640 media (Gibco by Life TechnologiesTM), L-Glutamine (PAA), Penicillin (Invitrogen), Streptomycin 
(Invitrogen), Gentamicin (PAA), and 10% Foetal Calf Serum (FCS; Life Technologies). The full media 
used to support differentiation of PBMCs to macrophage and referred to as RPMI/FCS media, 
consisted of RPMI 1640 (Sigma-Aldrich) supplemented with 1% Penicillin/Streptomycin (100 U/ml 
Penicillin; 100 µg/ml streptomycin) (Invitrogen), 10% Foetal Calf Serum (Gibco), 200 mM L-
Glutamine and 10 mg/ml Gentamicin (PAA). All supplements were filtered through a 0.20 µm sterile 
filter, and the media stored at 4oC when not in use, and pre-warmed before adding to cells.  
2.3 Macrophage culture  
Macrophage-colony stimulating factor (M-CSF) which is also known as colony stimulating factor-1 
(CSF-1) and granulocyte/macrophage-colony stimulating factor (GM-CSF) which is also known as CSF-
2, are important haematopoietic growth factors and potent cytokines for cell survival, proliferation, 
differentiation, and activation (Fleetwood et al., 2009). Blood monocytes will not survive if cultured 
in medium alone without CSFs (Akagawa, 2002). Accordingly, blood monocytes were cultured in 
RPMI/FCS media supplemented with M-CSF (40 ng/ml) or a combination of M-CSF + GM-CSF (20 
ng/ml each) for six days to produce fully differentiated macrophages, polarised towards M-Mac or 
GM-Mac respectively. The media was changed to fresh RPMI/FCS plus the respective CSFs at day 3 




Table 2.3.1 Growth factors for macrophages used in this study. 
(M-CSF = macrophage-colony stimulating factor, GM-CSF = granulocyte/macrophage-colony 
stimulating factor, both are recombinant human proteins) 




factor Supplier Catalogue No. 
 
M-CSF 100 µg/ml 40 ng/ml 1:2500 R&D 130-096-492  
GM-CSF 100 µg/ml 20 ng/ml 1:1250 R&D 130-093-865  
 
2.4 Cell collection for RNA analysis 
Qiazol lysate  
Total RNA, including microRNA, was extracted using Qiazol (miRNeasy mini-kit, Qiagen, cat. No. 
217084). Upon the end of planned culture experiments, cells were washed with sterile PBS before 
350 µl Qiazol lysis buffer was added. Cell lysates were then scraped using a blue pipette tip to aid 
lysis, before transferal into a sterile RNase/DNase-free Eppendorf tube and stored at -80oC until the 
RNA extraction and purification procedure. 
Cell lysate in RLT buffer  
RLT lysate buffer (RNeasy plus mini-kit, Qiagen, cat. No. 74134) was used to collect mRNA only. b-
mercaptoethanol was added to RLT lysis buffer at 1:100 v/v as per manufacturer’s instructions. Cells 
were washed with sterile PBS twice before 350 µl RLT lysis buffer was directly added onto the cells. 
The lysates were then scraped using a 1ml syringe barrel and the cell lysate transferred into a sterile 
RNase/DNase-free Eppendorf tube and stored at -80oC until the RNA extraction and purification 
procedure.  
2.5 RNA extraction and purification 
Materials used as follows: 1) miRNeasy mini-kit, Qiagen cat. No. 217004 (contains RNeasy mini spin 
columns, collection tubes (1.5 ml and 2 ml), Qiazol lysis reagent, RNase free buffers (RWT and RPE) 
and RNase-free water); or 2) RNeasy plus mini-kit, Qiagen, cat. No. 74134 (contains: gDNA eliminator 




Protocol for RNA extraction and purification: miRNeasy minikit 
The cell lysate (in Qiazol) was thawed and briefly centrifuged before the addition of 140 µl 
chloroform. The mixture was vortexed for 15 seconds and then left at room temperature for 3 
minutes before centrifugation at 12000 g speed at 4oC for 15 minutes. The centrifugation results in 
the generation of a two-layer phase; an upper aqueous clear layer above a bottom pink layer. The 
top aqueous phase (containing the RNA) was collected and transferred to a RNAse free Eppendorf 
tube (Ambion) while the pink solution was discarded. Next, 525 µl absolute ethanol was added to 
the collected clear aqueous phase and mixed thoroughly by pipetting up and down. The mixed 
solution ~ 700 µl in volume was then transferred to a column tube and centrifuged at 8000 g for 15 
seconds at room temperature. The flow-through was discarded and 700 µl RWT buffer added to the 
column before centrifugation at 8000 g for 15 seconds at room temperature. The flow-through was 
once again discarded and 500 µl RPE buffer added before centrifugation at 8000 g for 15 seconds at 
room temperature. This step was repeated with RPE buffer with a 2-minute centrifugation. Again, 
the flow-through was discarded, and the collection tube changed before centrifugation at 16000 g 
for 1 minute at room temperature. The column was then placed in a new Eppendorf RNAse free 
tube. Then, 30 µl RNAse free H2O was added directly on top of the membrane inside the column 
before centrifugation at 8000 g for 1 minute to elute the RNA.  
Protocol for RNA extraction and purification: RNeasy plus mini kit 
The cell lysate (in RLT buffer) was thawed and briefly centrifuged. The sample was then transferred 
to a genomic (g) DNA eliminator spin (purple) column (RNeasy plus mini kit, Qiagen) and centrifuged 
for 30 seconds at 8000 g. The flow through was collected and the column discarded. Then, 350 µl 
70% alcohol was added to the sample (flow through) and mixed well by pipetting up and down. The 
mixture was then transferred to a RNeasy spin (pink) column (RNeasy plus mini kit, Qiagen) and 
centrifuged for 15 seconds at 8000 g. The flow through was discarded and the column kept. Next, 




through was discarded and the column kept before addition of 500 µl RPE buffer to the column and 
centrifuged (for 15 seconds at 8000 g). This step was repeated with 500 µl RPE buffer and 
centrifuged for 2 minutes at 8000 g. The flow through was discarded and the column placed in a new 
collection tube for a 1-minute centrifugation. The collection tube was then changed with a new 
Eppendorf RNAse free tube (Qiagen), and 30 µl RNAse free H2O (Qiagen) added directly on top of the 
column membrane. The column was centrifuged for 1 minute at 8000 g to elute the RNA. The 
column was discarded, and RNA sample kept at -20oC or -80oC before the RNA quantification 
procedure.  
2.6 RNA Quantification 
Initial RNA concentrations were determined using a NanoDropTM 1000 Spectrophotometer (Thermo 
Scientific). The absorbance rate at 260/280 was used to assess the purity of RNA. Initial RNA 
concentrations (ng/µl) were recorded for calculation of mRNA volume for the subsequent RT-PCR 
reaction. This facilitated the use of the same RNA concentration to generate equal amounts of cDNA. 
Samples with a 260/280 ratio <1.8 (contamination with ethanol or phenol) or a 260/230 ratio >2.2 





2.7 cDNA synthesis (Reverse Transcription Polymerase Chain Reaction, RT-
PCR) 
Materials used: miScript II RT kit (cat. no. 218161), QuantiTect Reverse Transcription Kit (cat. no. 
205313), and Thermal Cycler C1000 TouchTM (Bio-Rad). 
All reactions were set up on ice to minimise the risk of RNA degradation.  
RT-PCR using QuantiTect RT kit (for RLT lysate) 
The QuantiTect Reverse Transcription Kit contains: 1) 7x gDNA Wipeout Buffer, 2) RNase-free water, 
3) Quantiscript Reverse Transcriptase, 4) 5x Quantiscript RT Buffer and 5) RT Primer Mix.  
Firstly, the purified RNA sample (+ RNase-free water) was incubated with 2µl/reaction gDNA wipeout 
buffer (total volume reaction = 14 µl), at 42oC for 2 minutes to remove contaminating genomic DNA. 
Following the gDNA elimination process, reverse transcription reaction was performed by adding RT 
primer mix (volume: 1x), RT Quantiscript buffer (4x) and Quantiscript reverse transcriptase (1x). 
Total reaction volume was 20µl (Table 2.7.1), and was placed within a Thermal Cycler C1000 TouchTM 
(Bio-Rad) and incubated at 42oC for 30 minutes followed by 95oC for 3 minutes. The cDNA was stored 
at -20oC until required for the QPCR reaction procedure.  
Table 2.7.1 Reverse-transcription reaction components 
RT master mix consisted of Quantiscript Reverse Transcriptase, RT Buffer and RT Primer Mix. 
RT Primer Mix and RT buffer were premixed (1:4) for routine RT reaction and stored at -20oC.  
Component Volume/reaction (µl) 
Quantiscript Reverse Transcriptase 1 
Quantiscript RT Buffer, 5x 4 
RT Primer Mix 1 
gDNA elimination reaction components  
(H2O + Vol.RNA + gDNA) 
14 






RT-PCR using miScript II RT kit for total RNA (Qiazol lysate)  
The miScript II RT kit contains: 1) miScript Reverse Transcriptase mix, 5x miScript HiFlex buffer, 10x 
Nucleics mix and RNase-free water. 
Reverse transcription PCR of purified RNA was performed with miScript II RT kit using the reaction 
components shown in Table 2.7.2. Firstly, the reaction mix was prepared by adding miScript Reverse 
Transcriptase mix, Nucleics mix and 5x miScript HiFlex buffer to an RNase/DNase-free Eppendorf 
tube. The reaction mixes were vortexed briefly before addition of the purified RNA (+ RNase free 
water) for a total reaction volume of 20 µl for each sample.  
The reaction was carried out in a Thermal Cycler C1000 TouchTM (Bio-Rad) at 37oC for 60 minutes 
followed by 95oC for 5 minutes.  
Table 2.7.2 Reverse Transcription reaction components (miScript) 
Components Volume/ reaction (µl) 
miScript Reverse Transcriptase 
mix 2 
5x miScript HiFlex buffer 4 
10x Nucleics mix 2 





2.8 96-well Quantitative-Polymerase Chain Reaction (Q-PCR) 
96-well Quantitative-PCR (Q-PCR) (or real-time PCR) was performed using LightCycler® 480 SYBR 
Green I Master (Roche, Germany, cat. No. 04707516001). The primers used for human genes are 
described in Table 2.8.1 (designed and purchased from Qiagen) or Table 2.8.2 (home designed 
primers, purchased from Sigma-Aldrich). Qiagen primers were reconstituted in 1.1 ml Tris 
ethylenediaminetetraacetic acid EDTA (TE) buffer, pH 8.0 and aliquoted in DNAse free tubes. Home 
designed primers comprised of separate forward and reverse primers which were reconstituted in 
TE at a volume instructed on the manufacturers sheet and used in 1:2 for each.  
Table 2.8.1 QuantiTect primer assay used for QPCR  
QuantiTect primers contain a mix of lyophilised forward and reverse primers for a specific 
target. Each assay is derived from gene sequences contained within the NCBI Reference 
Sequence database (https://www.ncbi.nlm.nih.gov/refseq/).  
Gene name Gene symbol Cat. No.  Refseq transcripts 
a-SM-actin ACTA2 QT02407307 NM_001141945, NM_001613 
b-actin ACTB QT00095431 NM_001101, XM_006715764 
Calmodulin-1 CALM1 QT00997906 NM_001166106, NM_006888 
Calponin-1 CNN1 QT00067718 NM_001299, XM_005259741 
Desmin DES QT00071778 NM_001927 
Smoothelin SMTN QT00026677 NM_001207017, NM_001207018 
Transgelin (SM22-alpha) TAGLN QT00072247 NM_001001522, NM_003186 
Vimentin VIM QT00095795 NM_003380, XM_006717500 




Table 2.8.2 Home designed primers used in the study 
Primers were designed using the primer blast programme on the Sigma-Aldrich website.  
Gene name Forward/Reverse Primer Sequence (5’ – 3’) 
CDH5 (VE-cadherin) Forward    CGCAATAGACAAGGACATAAC 
 
Reverse  TATCGTGATTATCCGTGAGG 
Caldesmon  Forward    AAACGCCAGAAGATGCCAGA  
  Reverse  ACACCACTGCTTTTCTGCAC  
FGFR1 Forward    AGGAACTTTTCAAGCTGC 
 
Reverse  CATCATGTACAGCTCGTTG 
FGFR2 Forward    ATGGAGATATGGAAGAGGAC 
  Reverse  CATCTTCTGGCTCTAATGTG 
FGFR3 Forward    GAAGATGCTGAAAGACGATG 
 
Reverse  GCAGGTTGATGATGTTTTTG 
FGFR4 Forward    CTGAGGACAATGTGATGAAG 
  Reverse  CCGTTGCTGGTTTTCTTATAG 
FLT1 Forward    ATGTGAAACCCCAGATTTAC 
 
Reverse  TGATTGTAGGTTGAGGGATAC 
KDR Forward    GTACATAGTTGTCGTTGTAGG 
  Reverse  TCAATCCCCACATTTAGTTC 
KLF4 Forward    TCTTGAGGAAGTGCTGAG 
 
Reverse  ATGAGCTCTTGGTAATGGAG 
MYH1 Forward    CCGGGAAAACCGAAAACACC  
  Reverse  CCAGCTCTCCGTAGGCAAAA  
NANOG Forward    CCAGAACCAGAGAATGAAATC 
 
Reverse  TGGTGGTAGGAAGAGTAAAG 
PECAM-1 Forward    AGATACTCTAGAACGGAAGG 
  Reverse  CAGAGGTCTTGAAATACAGG 
SOX2 Forward    ATAATAACAATCATCGGCGG 
 
Reverse  AAAAAGAGAGAGGCAAACTG 
VWF Forward    TGTATCTAGAAACTGAGGCTG 
  Reverse  CCTTCTTGGGTCATAAAGTC 
36B4 Forward    GCCAGCGAAGCCACGCTGCTGAAC 
 




Table 2.8.3 Master reaction mixture including LightCycler® 480 SYBR Green I Master reaction 
mix 
It is essential the SYBR Green I Master reaction mix is protected from light. *For the PCR 
primers 1 µl for the QuantiTect primers were used, whereas 0.5 µl for each of the forward and 
reverse home-designed primers were used. 
Reagent/components Volume (µl) 
Water, PCR grade 3 
*PCR Primer(s) 1 
SYBR Green I Master 5 
Total volume/reaction 9 
 
The reaction mix shown in Table 2.8.3 was mixed thoroughly by pipetting up and down several times 
(without vortexing). The master reaction mixture was loaded into the respective wells of a 96-well 
plate followed by 1µl of sample/well (cDNA, at same concentration for each reaction). Total volume 
for each reaction was 10µl. Each cDNA sample was analysed in duplicate. As negative controls, a 
blank RT reaction sample was used for each primer. Once mixture loading was completed, the plate 
was sealed with sticky sealing plastic (Greiner Bio-one, cat. no. 676040). The plate was then 
centrifuged for 30 seconds at 500 g on an MPS-1000 mini-plate spinner (Labnet) before being loaded 
into a Roche LightCycler® 480. The PCR programme ‘SYBR Green I 96-II’ was run with the protocol 
summarised in Table 2.8.4.  
Table 2.8.4 QPCR reaction protocol used in the study 
Step Temperature (oC) Duration Number of cycles 
Pre-incubation 95oC 5 minutes 1 
Amplification 
Denaturation: 95oC 10 seconds 
45 Annealing: 60oC 10 seconds 
Extension: 72oC 10 seconds 
Melting curve 
95oC 5 seconds 
1 65oC 60 seconds 
97oC Continuous 




2.9 Q-PCR data analysis 
The expression of a specific gene for each experimental condition was expressed as Cycles to 
Threshold (CT), which were obtained from the LightCycler® 480 software after each reaction had 
completed. This value corresponds to the number of cycles an amplified cDNA template takes to 
reach a linear threshold of fluorescence detection (otherwise known as amplicon concentration) and 
was used for calculating fold changes in mRNA expression. As cDNA samples were analysed in 
duplicate, two CT values were derived per sample and were therefore averaged to give a mean CT 
value for each sample. The 2˄- ΔΔCT were calculated for each sample and averaged for the group to 
reflect average fold change in expression against a control group for each experiment.  With regards 
to mRNA normalisation, the expression of two housekeeping genes was assessed, 36B4 and b-actin.  
2.10 Western Blotting 
2.10.1 Cell collection for protein analysis 
Cells were washed twice with sterile PBS, before 120μl of 5% SDS lysis buffer (50 mM Tris-HCL pH 
6.8, 10% Glycerol, 5% SDS) were added. The cells were scraped with the insert of a 1ml syringe and 
lysates were collected in Eppendorf tubes (0.5ml). Cell lysates were stored at -20°C until use for 
protein assay and electrophoresis procedure. 
2.10.2 Protein assay (Protein quantification) 
Materials used as follows: Micro Bicinchoninic Acid (BCA) Protein Assay Kit (Thermo Scientific, 
cat.no. 23235) contains Micro BCA Reagent A (MA), Micro BCA Reagent B (MB), Micro BCA Reagent 
C (MC) and Bovine Serum Albumin (BSA) 2 mg/ml; high-performance liquid chromatography (HPLC) 






Protocol for protein assay using Micro BCA Protein Assay Kit 
First, 140μl of HPLC water were added into the respective wells of a 96-well plate (flat bottom) 
followed by 5μl of sample (in SDS lysate buffer) in duplicate. A set of protein standards was prepared 
using BSA at the following concentrations; 0, 0.1, 0.25, 0.5, 1.0, 2.5, 5.0, 10 mg/ml. Next, 150μl of 
the BCA reaction mix which comprises of Reagent A, Reagent B and Reagent C (in 25:24:1 volume), 
were added to each well. The reactions were then incubated for 1 hour at 37°C before analysis at 
560 nm on ELISA plate reader (Thermo Scientific Multiskan EX). The protein concentration for each 
sample was obtained using the BSA standard curve. 
2.10.3 Polyacrylamide Gel Electrophoresis (PAGE) 
Gel electrophoresis to separate different protein sizes was performed using a Bio-Rad system. Cell 
lysates (in SDS) were diluted in HPLC water (amount determined from the protein assay) in order to 
obtain equal protein concentrations within a total 20μl volume. Subsequently, 5μl of bromoethanol 
blue (as electrophoretic colour marker) and 1.5μl of β-mercaptoethanol (a reducing agent to allow 
protein molecules to undergo electrophoresis consummately by molecular weight) were added to 
each sample. The mixture was incubated at 95°C for 10 minutes. Then, the mixture was briefly 
centrifuged before loading into Mini-PROTEAN® TGX Stain Free Gels (Bio-Rad, cat. no. 456-8024 for 
7.5% polyacrylamide gels; or cat. no. 456-8084 for 4-15% polyacrylamide gels) and subjected to 
electrophoresis in a Mini-PROTEAN® Tetra Cell (Bio-Rad, 165-8004) filled with 10% running buffer 
(Bio-Rad cat. no. 161-0732) for 30 minutes at 200V. A Protein marker (Geneflow Limited, cat. no. 
S60024) was used as a molecular weight marker.  
2.10.4 Stain free gels 
Once electrophoresis is completed, the gels are then exposed to ultraviolet (UV) light using a 
ChemiDocTM MP System (Bio-Rad, cat. no. 170-8280), to activate a covalent reaction between 
tryptophan residues in the (protein) samples with the trihalo-compounds in Mini-PROTEAN® TGX 




ChemiDocTM software and subsequently used to evaluate equal protein loading and as a control 
when calculating relative expression of a target protein. 
2.10.5 Blotting & Immunodetection 
Materials used for blotting: Trans-Blot® TurboTM Transfer Instrument and Cassettes (Bio-Rad, cat. no. 
170-4155), Midi/Mini Nitrocellulose Transfer (ready to use) pack with two buffer-saturated ion 
reservoir stacks and pre-wetted nitrocellulose 0.2 µm membrane (Bio-Rad, cat. no. 170-4158) and 
membrane roller (Bio-Rad, cat. no. 1651279).  
The electrophoretically separated protein gel was subsequently transferred to a 0.2μm pore 
nitrocellulose membrane between two reservoir stacks (Figure 2.10.1) inside a trans-blot cassette. 
Any bubbles trapped between the two stacks were removed through use of a membrane roller 
before the top cassette was put in place. The cassettes were then loaded into a trans-blot 
instrument and transfer carried out for 7 minutes at 40 volts.  
 
Figure 2.10.1 Schematic diagram layering of an assembled transfer pack (Bio-Rad) 
The gel is sandwiched between two buffered-saturated stacks and directly above a blotting 
membrane, to ensure efficient transfer of proteins from the gel to the membrane. (Image adapted 




Following the trans-blotting, the nitrocellulose membrane was then incubated with 5% milk solution 
in Tris-Buffered Saline-Tween (TBS-T; 200mM Tris, 2% Tween 20, pH 7.6), for 30 minutes on a roller 
to block any non-specific antibody binding.  
Materials used for immunoblotting:  SignalBoostTM Immunoreaction Enhancer Kit (Merck Millipore, 
cat. no. 407207) contains: Solution 1 for primary antibodies (KP31812) and Solution 2 for secondary 
antibodies (KP31855). 
The membrane was washed with TBS-T buffer and incubated overnight at 4°C with the relevant 
primary antibody (Table 2.10.1 and Table 2.10.2) diluted to the desired concentration in SignalBoost 
Solution 1. 
Table 2.10.1 Primary antibodies used for immunodetection of VSMC-markers by Western 
blotting 
(CALM1 = calmodulin-1, Myh11 = myosin heavy chain-11, SMTN = smoothelin, CST = Cell Signalling 
Technology). 
Antibody Species Molecular Weight (kDa) Concentration Supplier Cat. No. 
Caldesmon-1 Rabbit 
70-80 (non-muscle) 
1/1000 CST #12503 
120-150 (smooth muscle) 




Rabbit 227 - 250 1/1000 Abcam Ab 82541 
Smoothelin Mouse 
110 (long isoform) 
1/250 Santa Cruz biotech 
Sc-
376902 59 (short isoform) 






Table 2.10.2 Primary antibodies used for immunodetection of EC-markers by Western 
blotting 
All antibodies are from Cell Signalling Technology (CST). 
Antibody Species Molecular Weight (kDa) Concentration Cat. No. 
FGF Receptor 1 Rabbit 90, 120, 145 1/500 D8E4 XP (#9740) 
PECAM-1 (CD31) (89C2) Mouse 130 1/1000 #3528S 
Phospho-Stat3 (Tyr 705) Rabbit 79, 86 1/1000 D3A7 XP (9145) 
Phospho-Stat5 (Tyr694) Rabbit 90 1/500 (#9351) 
Stat3 (total Stat3) Rabbit 79, 86 1/500 D1B2J #30835 
Stat5a (4HI) (total Stat5) Mouse 90 1/500 #4807 
VE-cadherin (D87F2) Rabbit 130-140 1/1000 #2500S 
 
After overnight incubation with the relevant primary antibody, the membrane was washed in TBS-T 
twice and incubated in 5% milk (in TBS-T) for 30 minutes at room temperature.  
Subsequently, the membrane was incubated with the relevant secondary IgG antibodies (Table 
2.10.3) directed against the appropriate species (all Dako) diluted 1:1000 in SignalBoost Solution 2 
for 1 hour at room temperature.  
 
Table 2.10.3 Secondary antibodies used for immunodetection by Western blotting 
(IgG = Immunoglobulin, HRP = Horseradish Peroxidase. All antibodies are from Dako) 
 
Secondary Antibodies Cat. No. 
Polyclonal Goat Anti-Rabbit IgG/ HRP P0448 
Polyclonal Goat Anti-Mouse IgG/ HRP P0447 






After the incubation, the membrane was washed in three changes of TBS-T, followed by a 30 minute 
wash and three further 5 minute washes. 
Materials used for immunodetection: LuminataTM Forte Western chemiluminescent HRP substrate 
(Merck Millipore, cat. no.12634645) and ChemiDocTM MP Imaging System (Bio-Rad).  
To detect the HRP-labelled proteins, an Enhanced Chemi-Luminescence (ECL) Luminata Forte 
Western HRP Substrate detection solution was used. The membrane was incubated for 3 minutes 
with ECL and luminescence was then detected by ultraviolet light using the ChemiDocTM MP Imaging 
System. The relative density of the detected bands was determined using Image LabTM software 
version 5.1 (Bio-Rad) by optical densities (mm2) and normalised to stain-free gels. 
2.11 Immunocytochemistry 
Fluorescence immunocytochemistry (ICC) was deployed to detect VSMC and EC markers as listed in 
Table 2.11.1 and Table 2.11.2. Firstly, cells (5 X 105 cells in 200 µl) were seeded in 8-well Millicell EZ 
glass slides (Merck Millipore, cat. no. PEZGS0816) and subjected to the relevant experimental 
conditions until ready for fixation. Consequently, cells were washed twice with DPBS and fixed in 3% 
(w/v) paraformaldehyde/PBS for 10 minutes at room temperature. After washing three times with 
PBS, the cells were permeabilised with 0.2% (v/v) Triton X-100/PBS. The cells were then briefly 
washed with PBS, and non-specific antibody binding was blocked by Image-iT FX signal enhancer 
(Invitrogen, cat. no. 136933) for 30 minutes at room temperature. The cells were then incubated 
with the relevant primary antibodies (Table 2.11.1 and Table 2.11.2) overnight at 4°C. The following 
day, cells were washed three times with PBS and incubated with a relevant fluorescently-conjugated 
secondary antibody (either anti-mouse, anti-goat, or anti-rabbit IgG according to the species of the 
respective primary antibody) diluted 1:100 in PBS for 1 hour at room temperature in the dark 
(wrapped with aluminium foil). Finally, cells were washed twice with PBS, and the slides mounted 




cat. no. P36931) as a nuclear counterstain. The cells were then imaged, and representative fields 
acquired using an Olympus BX41 microscope and Q-capture pro 6.0 software. Nuclei appeared blue 
and positive protein expression was green.  
 
Table 2.11.1 Primary antibodies used for immunofluorescence labelling of VSMC-markers 
(a-SM-actin = a- smooth muscle actin, Myh11 = myosin heavy chain-11) 
Antibody Dilution Cat. No. Supplier Species Secondary antibody 
a-SM-actin 1/200 A-2547 Sigma Mouse Goat anti-mouse  
Caldesmon 1/400 Ab45689 Abcam Rabbit Goat anti-rabbit 
Mac-2 (Galectin-3) 1/200 CL8942AP Cedar Lane Goat Rabbit anti-goat 
 
Table 2.11.2 Primary antibodies used for immunofluorescence labelling of EC-markers 
(CD31 = cluster of differentiation 31. All antibodies are from Cell Signalling Technology). 
Antibody Dilution  Cat. No. Species Secondary antibody 
PECAM-1 (CD31) 1/1600 #3528S Mouse Goat anti-mouse 






2.12 Statistical analysis 
Statistical analysis was performed using GraphPad InStat statistical software. For experiments 
comparing means of more than two groups, a repeated measures analysis of variance (ANOVA) test 
was used with a Tukey-Kramer Multiple Comparisons post-test. If matching of samples was not 
effective, a Friedman (non-parametric repeated measures ANOVA) test was used with a Dunn post-
test. All data is presented as mean ± standard error of the mean (±SEM). When data were presented 
as a fold change and compared to 1 or 100, a paired two-tailed t-test was used for normally 
distributed data. If data failed the normal distribution test and assumed to have different standard 
deviations, the alternate (Welch) t test was used. If samples still failed to display Gaussian 
distribution, a Mann-Whitney (non-parametric) test was used. An output of P<0.05 was accepted as 





3 In vitro human macrophages display divergent 
polarisation towards vascular smooth muscle cell-like 
phenotypes 
 
3.1 Introduction  
3.1.1 Phenotypic modulation of vascular smooth muscle cells 
Vascular smooth muscle cells (VSMCs) populate the medial compartment of the vessel wall, within 
which they regulate physiological blood flow by dynamically controlling vessel luminal diameter, 
through contraction and relaxation. During vasculogenesis, VSMCs exhibit a highly proliferative and 
migratory phenotype associated with heightened extracellular matrix synthesis, while at the same 
time acquiring contractile capabilities before their differentiation towards a contractile phenotype 
(Owens et al., 2004). Within healthy arteries, VSMCs proliferate at very low rates in order to retain 
their contractile function, hence the contractile phenotype nomenclature (although they are also 
sometimes termed quiescent). Contractile VSMCs are characterised by marked expression of 
contractile proteins such as a-smooth muscle actin (a-SM-actin), caldesmon, and smooth-muscle 
myosin heavy chain-11 (Myh11) (Dobnikar et al., 2018). VSMCs can also exist as a synthetic 
phenotype which are present during both developmental processes such as neovascularisation in 
the embryo (Ball et al., 2010) and vessel formation (Owens et al., 2004), and also during 
cardiovascular disease states including adverse vascular remodelling and atherosclerosis (Chistiakov 
et al., 2015). The shift between the two phenotypes can be modulated by various factors such as 
inflammation, signalling factors including platelet derived growth factor-BB (PDGF-BB) and 
transforming growth factor-b1 (TGFb1), mechanical stimulation, extracellular matrix proteins (i.e 
fibronectin and laminin) and their degradation, and endothelial cells (Figure 3.1.1). Phenotypic 
modulation of VSMCs from a contractile form to a synthetic proliferative phenotype has been 
proposed to play a significant role during the pathogenesis of vascular diseases including 





Figure 3.1.1 Phenotypic switching of vascular smooth muscle cell phenotype. 
A simplified diagram summarising the triggers and characteristics of vascular smooth muscle cell 
phenotypic modulation. Example of soluble signalling factors are PDGF-BB, TGFb1, basic fibroblast 
growth factor, insulin like growth factor, and endothelin-1. (RER: rough endoplasmic reticulum; ECM: 
extracellular matrix). Image adapted from original source (Beamish et al., 2010) and made using 
elements retrieved from https://smart.servier.com.  
 
3.1.2 Signalling factors supporting phenotypic modulation of vascular 
smooth muscle cells. 
Reportedly, PDGF-BB and TGFb1 act as signalling cues for the proliferation and phenotypic switching 
of VSMCs from a contractile state towards a synthetic phenotype. PDGF-BB is a known mitogen and 
chemoattractant for VSMC in vitro (Hwang et al., 2020; Pukac et al., 1998; Zhao et al., 2011), and has 
been documented to promote VSMC migration and proliferation in vivo (Ferns et al., 1991; 
Rutherford et al., 1997), and subsequent intimal thickening in vivo (Jawien et al., 1992). Therefore, 
PDGF-BB promotes phenotypic switching of VSMCs into synthetic cells. PDGF-BB binds to the PDGF-
beta receptor (PDGFR-b) and activates downstream signalling pathways including ERK, p38 mitogen-
activated protein kinase (p38 MAPK) pathways and phosphatidylinositol 3-kinase-Akt (PI3K-Akt) to 
enhance VSMC phenotypic switching (Yamaguchi et al., 2001). PDGF can be found within 




1974). Since its discovery, purportedly many cell types have been shown to produce PDGF, including 
vascular endothelial cells, macrophages, VSMCs and fibroblasts (Bowen-Pope and Raines, 2011).  
Phenotypic switching of VSMCs from a contractile to a synthetic state is associated with a reduced 
synthesis of α-SM-actin, the protein responsible for the contractile function of VSMCs. The 
phenomenon of the phenotypic switching VSMCs indicates that VSMCs are not terminally 
differentiated cells, but  retain remarkable plasticity and exist as a continuum of the two phenotypes 
(Casscells, 1991). In addition to effects on VSMCs, PDGF-BB also influences the chemotactic activity 
of macrophages (Inaba et al., 1993), and therefore proposed to be involved in attracting 
inflammatory cells (such as monocyte/macrophages and neutrophils) to the sites of platelet release 
(vascular injury) (Deuel et al., 1982), and as such considered a major growth factor for macrophages 
and VSMCs in atherosclerosis (Kozaki et al., 2002; Tang et al., 2005; Wågsäter et al., 2009). 
TGFb1 is a polypeptide member of the TGF superfamily of cytokines and is secreted by many cell 
types. Its functions include control of cell growth, proliferation, and differentiation, apoptosis, 
inflammation, tissue repair, and the related expression of extracellular matrix proteins during 
vascular remodelling (Blobe et al., 2000; Guo and Chen, 2012). TGFb1 and its downstream signalling 
factors such as Smad proteins (similar to mothers against decapentaplegic, Sma gene in 
Caenorhabditis elegans and mothers against decapentaplegic gene in Drosophila) (Derynck et al., 
1996) are important regulators of VSMC phenotypic switching (Tang et al., 2011). TGFb1 contributes 
to the development of SMCs from embryonic stem cells and phenotypic switching during disease 
states (Sinha et al., 2004). Reportedly, an in vivo study demonstrated TGFβ1-deficient mice display 
defective haematopoiesis and vasculogenesis, resulting in inadequate capillary tube formation and 
unstable vessels with reduced cellular adhesiveness (Dickson et al., 1995). TGFb1 has also been 
shown to play a major role in promoting alternative activation of macrophages (Gong et al., 2012). 
Co-operative actions of PDGF-BB and TGFb1 have been proposed to promote wound healing, 




In addition, a number of other modulators have been shown to direct VSMC phenotypic modulation, 
including FGF2, insulin-like growth factors (IGFs), epidermal growth factor (EGF), α-thrombin, factor 
Xa, angiotensin II (Ang II), endothelin-1, and unsaturated lysophosphatidic acids (Beamish et al., 
2010). However, in order to successfully induce VSMC-like cells from progenitor cell populations, 
researchers have previously cultured human embryonic stem cells (Gerecht-Nir et al., 2003; Vo et al., 
2010) and human pluripotent stem cells (Wanjare et al., 2013) with a combination of PDGF-BB and 
TGFb1. Therefore, in this study both growth factors were used in combination to determine if 
primary macrophage subpopulations harboured the progenitor potential to differentiate towards a 
VSMC-like phenotype.  
3.1.3 Gene and protein markers commonly associated with a vascular 
smooth muscle cell phenotype 
The diverse function of VSMCs is in part attributable to the variety of gene and protein products they 
express. However, no single marker (at the gene or protein level) has been shown to be exclusive to 
VSMCs (Owens et al., 2004). However, due to their abundance a few selected VSMC-associated 
markers are commonly used to define a VSMC phenotype, including vimentin, calmodulin, 
smoothelin, caldesmon, smooth muscle myosin heavy chain-11, and a-SM-actin (Owens et al., 
2004). 
Vimentin is an intermediate filament, a major cytoskeletal structure that supports organelles within 
the cytoplasm and thus is important for cellular mechanical integrity (Katsumoto et al., 1990). 
Vimentin is found in almost all eukaryotic cells, including fibroblasts, endothelial cells, and 
commonly used as a marker for epithelial-mesenchymal transition (EMT) (Satelli and Li, 2011) and 
endothelial to mesenchymal transition (EndMT) (Hong et al., 2018). However, vimentin is highly 
expressed by VSMCs within large-sized arteries such as the aorta and carotid arteries (van Engeland 
et al., 2019). It is involved in regulating force transmission and contraction in VSMCs (Wang et al., 




which is increased upon their differentiation towards a macrophage-like phenotype (Beneš et al., 
2006).  
Calmodulin is a calcium binding protein, found in many cells including VSMCs and monocytes. It 
mediates the effect of calcium as part of calcium signal transduction pathway and activates many 
enzymes related to cell metabolism, inflammation, apoptosis, immune response, and smooth muscle 
contraction. For smooth muscle cell contraction, activation of calmodulin-dependent myosin light-
chain kinase (MLCK) by calcium catalyses myosin phosphorylation which then triggers cross-bridging 
and the development of force contraction of VSMCs (Walsh, 1994). In macrophages, calmodulin-
inducible nitric oxide synthase (iNOS)-complexes are responsible for coordinating pathways involving 
inflammatory cytokines such as TNFα, and in response to bacterial infection (Smallwood et al., 2006; 
Weber et al., 2006).  
Smoothelin is a specific marker for contractile VSMCs (van der Loop et al., 1997; van der Loop et al., 
1996). There are two smoothelin isoforms, A and B with molecular weights of 59 kDa and 110 kDa 
respectively. Smoothelin A is expressed by visceral smooth muscle cells while smoothelin-B is 
expressed by VSMCs. It has been demonstrated that smoothelin is encoded by a single gene on 
chromosome 22 but is transcribed by two different promoters to generate the two isoforms (Krämer 
et al., 2001; van Eys et al., 2007). Little is known about smoothelin function. However interruption of 
the smoothelin gene in mice resulted in reduced contraction force of peristalsis that leads to 
starvation (Niessen et al., 2005) and reduced arterial contractility (Rensen et al., 2008), therefore 
smoothelin is an integral part of the contractile machinery within smooth muscle cells. 
Caldesmon is widely expressed not only in VSMCs but also in various non-muscle cells. Two isoforms 
of caldesmon delineate its distribution, the high molecular weight form is found in smooth muscle 
cells whereas, the low molecular weight isoform is expressed by non-smooth muscle cells. 
Caldesmon and tropomyosin are described as regulatory actomyosin-binding proteins that create 




Myosin is a major contractile protein described as an actin-associated motor protein which 
generates forces via hydrolysis of adenosine triphosphate (ATP). Up to 35 classes of myosin have 
been described (Odronitz and Kollmar, 2007) with various functions demonstrated which not only 
affect contractility but involve processes such as cell migration, cell division, phagocytosis, 
cytokinesis and cell polarity, particularly in non-muscle cells (Leal et al., 2003). Smooth muscle 
myosin heavy chain-11 (SMMHC11), which also known as myosin-11 (Myh11), can give rise to a 
number of isoforms including SM1, SM2 and SMemb (non-muscle isoform) in smooth muscle cells 
(Aikawa et al., 1993). Myh11 is considered  a robust marker that demarcates contractile VSMCs from 
their synthetic counterparts (Beamish et al., 2010).  
Lastly, a-SM-actin is a ~43 kDa protein expressed by contractile VSMCs and commonly used as a 
marker of smooth muscle lineage. Its expression is reduced upon arterial injury (Hao et al., 2003), 
and its expression is therefore associated with reduced VSMC proliferation and migration (Chen et 
al., 2016),  and subsequently utilised as a marker of the contractile VSMC phenotype. The main 
function of a-SM-actin is force generation (Kim et al., 2008) and thus related with regulation of 
arterial contractility and blood pressure homeostasis (Schildmeyer et al., 2000). Reportedly, a-SM-
actin  is also expressed by myofibroblasts (Gan et al., 2007), endothelial cells treated with TGFb1 
(Arciniegas et al., 1992) and monocyte/macrophages under certain conditions in vitro (Ludin et al., 
2012).  
3.2 Aim of this chapter 
The aim of this chapter was to evaluate the expression of genes and proteins commonly associated 
with VSMCs, in distinct human in vitro macrophage subsets, namely M-CSF directed, and GM-CSF 
directed macrophages. Subsequently, the effects of PDGF-BB and TGFb1 on VSMC-linked mRNA and 
protein expression was determined during in vitro culture of human macrophage subsets. 
In addition, the expression of various VSMC specific markers in other differing macrophage 




expression patterns of in vitro primary macrophages with primary VSMCs was conducted alongside 
assessing the expression of a macrophage marker (Mac-2).  
Table 3.2.1 Polarisation of macrophages into various phenotypes in vitro 
(M1 = classically activated macrophage; IFNg = interferon !; LPS = lipopolysaccharide; M2a = 
interleukin-4 (IL-4) activated macrophage; M2c = interleukin-10 (IL-10) activated macrophage; M4 = 
platelet factor 4 (PF4) activated macrophage; Mox = oxidised 1-palmitoyl-2-arachidonoyl-sn-glycero-
3-phosphorylcholine (oxPAPC) activated macrophage; foam cell = oxLDL activated macrophage; 
CXCL4 = (C-X-C motif) chemokine ligand 4); oxLDL = oxidised low-density lipoprotein)  
Macrophage phenotype Cytokines/factors Key Reference(s) 
M1 IFNg and LPS (Martinez et al., 2006), 
M2a IL-4 (Stein et al., 1992), 
M2c IL-10 (Lang et al., 2002), 
M4 PF4 (CXCL4)  (Gleissner et al., 2010), 
Mox  oxPAPC (Kadl et al., 2010) and 






3.3 Materials and Methods 
3.3.1 Macrophage culture  
Human monocyte-derived macrophages were isolated and generated as outlined in the methods 
sections 2.1 and 2.2. 
3.3.2 Stimulation of human macrophages with vascular smooth muscle cell 
(VSMC)-associated growth factors 
Following 7 days differentiation and maturation in culture, human macrophages were co-stimulated 
with 10 ng/ml PDGF-BB and 1 ng/ml TGFb1 for three days to assess their capacity to differentiate 
towards VSMC-like cells. The details of the growth factors are detailed in Table 3.3.1. The media and 
growth factors were changed one day before cell collection.  
Table 3.3.1 Vascular smooth muscle cell-associated growth factors used for macrophage 
stimulation  












100 µg/ml 1/1000 100 ng/ml Miltenyi Biotec 130-108-164 
Human TGFb1 20 µg/ml 1/2000 10 ng/ml R&D Systems 240-B 
 
Human recombinant PDGF-BB (received at a concentration of 25 µg) was reconstituted in sterile PBS 
at a concentration of 100 µg/ml and aliquoted. The recombinant human TGFb1 (received at a 
concentration of 20 µg) was reconstituted in 900 µl 4 mM HCl and 100 µl 10 mg/ml bovine serum 





3.3.3 Polarisation of mature human macrophages (M-Mac) to different 
phenotypes 
Mature M-CSF directed human macrophages (which we term M-Mac) were polarised with the 
designated inducers to generate different macrophage phenotypes as summarised in Table 3.3.2. 
The polarisation factors were added to RPMI/FCS + M-CSF. The macrophages were cultured for two 
days to induce polarisation before stimulation with the VSMC-associated growth factors PDGF-BB 
and TGFb1 for three days (with a media and growth factor change after day two).  
Table 3.3.2 Factors used for the polarisation of distinct macrophage phenotypes 
(LPS = Lipopolysaccharide; IFNg = Interferon g; IL-4 = Interleukin-4; IL-10 = Interleukin-10; PF4 = 
platelet factor 4; CXCL4 = (C-X-C motif) chemokine ligand 4; oxPAPC = oxidised 1-palmitoyl-2-
































100 µg/ml 20 ng/ml 1/5000 
M4 PF4/ CXCL4 
R&D 
Systems 
795-P4 250 µg/ml 10 ng/ml 1/25000 
Mox  oxPAPC 
Hycult 
Biotech 
HC4035 25 µg/ml 25 µg/ml 1/1 
Foam cells oxLDL 
Alfa 
Aesar 





3.3.4 Culture of human vascular smooth muscle cells (VSMCs)  
Primary VSMCs isolated from human coronary artery (purchased from PromoCell; cat. no. C-12511) 
were used as a positive control for this study. VSMCs were maintained under culture conditions 
within Dulbecco’s modified Eagle's Medium (DMEM) (Sigma; PAA, E15-005) supplemented with 
Penicillin/Streptomycin (100 U/ml Penicillin; 100 µg/ml streptomycin) (Invitrogen), 10% Foetal Calf 
Serum (Gibco), 200 mM L-Glutamine and 10 mg/ml Gentamicin (PAA). All supplements were added 
using a syringe filter to prevent infection, mixed well, and stored at 4°C. VSMCs were cultured for 
three days (with a media and growth factor change after day two) in 100 ng/ml PDGF-BB and 10 






3.4.1 In vitro cultured human macrophages exhibit mixed morphology 
Under phase contrast microscopy, human blood-derived monocytes differentiated in the presence 
of M-CSF (M-Mac) for seven days displayed an elongated morphology interspersed with occasional 
circular macrophages, whereas GM-CSF directed macrophages (GM-Mac) exhibited a spherical 
appearance (Figure 3.4.1 a and b respectively). This is in line with the findings of Waldo et al (2008) 
which also described monocyte-derived macrophages showing a rounded morphology when 
differentiated in the presence of GM-CSF, while under M-CSF maturation, the majority of 
macrophages are elongated with the presence of many vacuoles (Waldo et al., 2008). Stimulation for 
three days with PDGF-BB and TGFβ1 had no effects on cell morphology in either macrophage 
phenotype, when observed by phase contrast microscopy.  
 
(a)  (b)  
Figure 3.4.1 Effect of M-CSF and GM-CSF maturation on the morphology of human 
macrophages 
Representative phase contrast microscopy images of (a) seven-day M-CSF (40 ng/ml) directed human 
macrophages (M-Mac), and (b) seven-day GM-CSF (20 ng/ml) directed macrophages (GM-Mac). 
Scale bars represent 200 µm. 
 
In order to determine if the morphology of M-CSF-matured human macrophages (M-Mac) is affected 
by polarisation towards classically (M1) or alternatively (M2) activated phenotypes, M-Macs were 
stimulated for two days with polarising factors then observed under phase contrast microscopy. M1 





(Figure 3.4.2 b). Opposingly, M2a macrophage polarisation with IL-4 resulted in no marked 
difference in morphology when compared to control non-polarised M-CSF-matured macrophages 
(Figure 3.4.2 c). However, M2c polarisation with IL-10 appeared to increase the proportion of 
elongated macrophages relative to the rounded cells, in comparison to non-polarised M-Macs 
(Figure 3.4.2 d).  
Exposure of M-Macs to oxLDL and subsequent intracellular accumulation (also referred to as foam 
cell formation and analogous to lipid-laden macrophages within atherosclerotic plaques) induced 
cells to acquire a more rounded morphology alongside the formation of occasional colonies/clumps 
(Figure 3.4.3 a). Oil red O staining to detect neutral lipids, demonstrated macrophage foam cell 
formation as observed by intracellular lipid accumulation (Figure 3.4.3 b). 
For comparison, cultured primary human coronary artery VSMCs displayed an elongated appearance 
(Figure 3.4.4) not too dissimilar to the elongated morphology observed within a population of the M-














Figure 3.4.2 Effect of M1 and M2 polarisation on the morphology of M-CSF matured human 
macrophages  
Representative phase contrast microscopy images of seven-day M-CSF (40ng/ml) matured human 
macrophages (M-Mac) (a) without polarisation, or polarisation with either (b) LPS (100 ng/ml) and 
IFNg (20ng/ml) to generate M1 macrophages, (c) IL-4 (20ng/ml) to generate M2a macrophages, or 











Figure 3.4.3 Photomicrograph of foam cells in culture. 
(a) Phase contrast microscopy of oxLDL-activated M-CSF macrophages (foam cells). Scale bar 
represents 200 µm. (b) Oil red O staining of foam cells. Lipid stained red/orange while nucleus-










Figure 3.4.4 Photomicrograph of primary arterial vascular smooth muscle culture in DMEM 
full media. 
Scale bar represent 400 µm.  
  
 





3.4.2 GM-CSF-directed macrophage maturation is associated with increased 
expression of VSMC-associated markers in comparison to M-CSF 
matured macrophages  
Considering the marked differences in morphology observed between M-CSF and GM-CSF matured 
human macrophages, the expression profile of a selection of VSMC-associated markers were 
analysed after seven-days maturation between the two phenotypes. Intriguingly, both M-CSF and 
GM-CSF seven-day differentiated macrophages expressed all the VSMC-related markers examined, 
at both the mRNA and protein level (Figure 3.4.5 - Figure 3.4.10). Interestingly, when compared to 
M-CSF matured macrophages (M-Mac), the protein expression of a-SM-actin, caldesmon, 
calmodulin, myosin heavy chain-11, smoothelin and vimentin were all significantly up-regulated in 
GM-CSF differentiated human monocyte-derived macrophages (Figure 3.4.5 - Figure 3.4.10). 
Although, at the mRNA level, reciprocal changes in caldesmon (Figure 3.4.6) and myosin heavy 
chain-11 (Figure 3.4.8) were not observed. Notably, other VSMC-specific markers assessed, including 
calponin, desmin and transgelin were not expressed (at the level of detection) within either M-CSF 






























Figure 3.4.5 GM-CSF maturation increases human macrophage a-SM-actin protein 
expression compared to M-CSF matured macrophages. 
Representative images and quantification of immunofluorescent labelling for "-SM-actin expression 
in seven-day M-CSF or GM-CSF differentiated human macrophages. Green colour indicates a-SM-
actin immunopositivity, and blue indicates nuclei (DAPI counterstain). Scale bars represent 100 µM. 
Data are expressed as percentage of a-SM-actin immuno-positive cells against M-CSF matured 
control macrophages, (mean ±SEM; n=6; ***P < 0.001 denotes significant difference compared to M-





























Figure 3.4.6 Caldesmon mRNA and protein expression in macrophage baseline cultures. 
(a) Caldesmon mRNA levels in GM-CSF macrophages relative to M-CSF directed control macrophages, 
(mean±SEM; n=6; paired t-test).  
(b) Quantification and representative western blots for caldesmon protein expression in GM-CSF 
macrophage relative to M-CSF directed control macrophages. Stain free gel is shown as loading 
control. Data are expressed as fold change against M-CSF-directed control macrophages, 
(mean±SEM; n=6; ***P < 0.001 denotes significant difference compared to M-CSF macrophages; 
paired t-test).  

















































Figure 3.4.7 GM-CSF maturation increases human macrophage calmodulin mRNA and 
protein expression compared to M-CSF matured macrophages. 
(a) Calmodulin mRNA levels in GM-CSF macrophages relative to M-CSF directed control 
macrophages, (mean±SEM; n=6; ***P < 0.001 denotes significant difference compared to M-CSF 
directed control macrophages; paired t-test). 
(b) Quantification and representative western blots for calmodulin protein expression in GM-CSF 
macrophages relative to M-CSF directed control macrophages. Stain free gel is shown as loading 
control. Data are expressed as fold change against M-CSF-directed control macrophages, 
(mean±SEM; n=6; **P < 0.01 denotes significant difference compared to M-CSF macrophages; paired 
t-test).  












































































Figure 3.4.8 Myh11 mRNA and protein expression in macrophage baseline cultures. 
(a) Myh11 mRNA levels in GM-CSF macrophages relative to M-CSF directed control macrophages, 
(mean±SEM; n=6; paired t-test).  
(b) Quantification and representative western blots for Myh11 protein expression in GM-CSF 
macrophages relative to M-CSF directed control macrophage. Stain free gel is shown as loading 
control. Data are expressed as fold change against M-CSF-directed control macrophages, 
(mean±SEM; n=6; ***P < 0.001 denotes significant difference compared to M-CSF macrophages; 
paired t-test).  
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Figure 3.4.9 GM-CSF maturation increases human macrophage smoothelin mRNA and 
protein expression compared to M-CSF matured macrophages. 
(a) Smoothelin mRNA levels in GM-CSF macrophages relative to M-CSF directed control 
macrophages, (mean±SEM; n=6; **P < 0.01 denotes significant difference compared to M-CSF 
directed control macrophages; paired t-test). 
(b) Quantification and representative western blots for smoothelin protein expression in GM-CSF 
macrophages relative to M-CSF directed control macrophages. Stain free gel is shown as loading 
control. Data are expressed as fold change against M-CSF-directed control macrophages, 
(mean±SEM; n=6; *P < 0.05 denotes significant difference compared to M-CSF macrophages; paired 
t-test).  










































































Figure 3.4.10 GM-CSF maturation increases human macrophage vimentin mRNA and protein 
expression compared to M-CSF matured macrophages. 
(a) Vimentin mRNA levels in GM-CSF macrophages relative to M-CSF directed control macrophages, 
(mean±SEM; n=6; *P < 0.05 denotes significant difference compared to M-CSF directed control 
macrophages; paired t-test). 
(b) Quantification and representative western blots for vimentin protein expression in GM-CSF 
macrophages relative to M-CSF directed control macrophages. Stain free gel is shown as loading 
control. Data are expressed as fold change against M-CSF-directed control macrophages, 
(mean±SEM; n=6; *P < 0.05 denotes significant difference compared to M-CSF macrophages; paired 
t-test).  
Refer to appendix A; (8.1.10) CT values and (8.1.11) for full blot image.  
  























































3.4.3 PDGF-BB and TGFb1 co-stimulation divergently affects VSMC-
associated marker expression between M-CSF and GM-CSF-matured 
macrophages  
Previous evidence has shown a combination of PDGF-BB and TGFb1 can differentiate human stem 
cells towards a VSMC-like lineage (Gerecht-Nir et al., 2003; Vo et al., 2010; Wanjare et al., 2013), 
while both growth factors are well characterised modulators of VSMC behaviour, including 
phenotypic modulation. Accordingly, the effects of PDGF-BB and TGFb1 co-stimulation (for 3 days) 
on VSMC-associated marker expression was evaluated in seven-day M-CSF or GM-CSF matured 
human macrophages. The results are organised into two sections, reporting the effects of PDGF-BB 
and TGFb1 co-incubation on M-CSF directed macrophages and GM-CSF directed macrophages within 
sections 3.4.3.1  and 3.4.3.2, respectively.  
Surprisingly, PDGF-BB/TGFb1 co-stimulation significantly upregulated protein expression of  
calmodulin (2.6-fold change; P<0.05; n=6; Figure 3.4.11 b), Myh11 (1.6-fold change; P<0.05; n=6; 
Figure 3.4.12 b) smoothelin (1.8-fold change; P<0.05; n=6; Figure 3.4.13 b) and vimentin (1.7-fold 
change; P<0.05; n=6; Figure 3.4.14 b). However, only a reciprocal increase in vimentin mRNA 
expression was detected (1.8-fold change; P<0.05 n=6; Figure 3.4.14  a), with no change in 
calmodulin, Myh11, or smoothelin mRNA expression identified (Figure 3.4.11 - Figure 3.4.13). No 
effect of PDGF-BB/TGFb1 co-stimulation on caldesmon or α-SM-actin mRNA and protein levels were 
observed (data not shown).  
With regard to GM-CSF matured macrophages, an opposing pattern was observed. PDGF-BB/TGFb1 
co-stimulation significantly decreased protein expression of caldesmon (39%; P<0.01; n=6; Figure 
3.4.15 b), calmodulin (30% change; P<0.05; n=6; Figure 3.4.16 b), and vimentin (33%; P<0.05; n=6; 
Figure 3.4.17 b), although no corresponding differences in mRNA levels were seen (Figure 3.4.15 a - 
Figure 3.4.17 a). No effect of PDGF-BB/TGFb1 co-stimulation on smoothelin, Myh11, or α-SM-actin 
mRNA and protein levels were observed (data not shown). Of note, high molecular weight 












3.4.3.1 PDGF-BB and TGFb1 co-stimulation increases the expression of 
specific VSMC-associated markers in M-CSF matured human 
macrophages  
 























Figure 3.4.11 The effects of PDGF-BB and TGFb1 co-stimulation on calmodulin mRNA and 
protein expression in M-CSF polarised macrophages. 
(a) Calmodulin mRNA levels in PDGF-BB and TGFb1 treated M-CSF macrophages relative to untreated 
M-CSF directed control macrophages, (mean±SEM; n=6; paired t-test).  
(b) Quantification and representative western blots for calmodulin protein expression in PDGF-BB 
and TGFb1 treated M-CSF macrophages relative to untreated M-CSF directed control macrophages. 
Stain free gel is shown as loading control. Data are expressed as fold change against untreated M-
CSF-directed control macrophages, (mean±SEM; n=6; *P < 0.05 denotes significant difference 
compared to M-CSF macrophages; paired t-test).  
Refer to appendix A; (8.1.4) CT values and (8.1.5) for full blot image.  
 






















































































Figure 3.4.12 The effects of PDGF-BB and TGFb1 co-stimulation on Myh11 mRNA and protein 
expression in M-CSF polarised macrophages. 
(a) Myh11 mRNA levels in PDGF-BB and TGFb1 treated M-CSF macrophages relative to untreated M-
CSF directed control macrophages, (mean±SEM; n=6; paired t-test).  
(b) Quantification and representative western blots for Myh11 protein expression in PDGF-BB and 
TGFb1 treated M-CSF macrophages relative to untreated M-CSF directed control macrophages. Stain 
free gel is shown as loading control. Data are expressed as fold change against untreated M-CSF-
directed control macrophages, (mean±SEM; n=6; **P < 0.01 denotes significant difference compared 
to M-CSF macrophages; paired t-test).  
Refer to appendix A; (8.1.6) CT values and (8.1.7) full blot image. 
 





















































































Figure 3.4.13 The effects of PDGF-BB and TGFb1 co-stimulation on smoothelin mRNA and 
protein expression in M-CSF polarised macrophages. 
(a) Smoothelin mRNA levels in PDGF-BB and TGFb1 treated M-CSF macrophages relative to untreated 
M-CSF directed control macrophages, (mean±SEM; n=6; paired t-test).  
(b) Quantification and representative western blots for smoothelin protein expression in PDGF-BB 
and TGFb1 treated M-CSF macrophages relative to untreated M-CSF directed control macrophages. 
Stain free gel is shown as loading control. Data are expressed as fold change against untreated M-
CSF-directed control macrophages, (mean±SEM; n=6; **P < 0.01 denotes significant difference 
compared to M-CSF macrophages; paired t-test).  
Refer to appendix A; (8.1.8) CT values and (8.1.9) for full blot image.  
 

















































































Figure 3.4.14 PDGF-BB and TGFb1 increases human M-CSF polarised macrophage vimentin 
mRNA and protein expression.  
(a) Vimentin mRNA levels in PDGF-BB and TGFb1 treated M-CSF macrophages relative to untreated 
M-CSF directed control macrophages, (mean±SEM; n=6; *P < 0.05 denotes significant difference 
compared to M-CSF macrophages; paired t-test).  
(b) Quantification and representative western blots for vimentin protein expression in PDGF-BB and 
TGFb1 treated M-CSF macrophages relative to untreated M-CSF directed control macrophages. Stain 
free gel is shown as loading control. Data are expressed as fold change against untreated M-CSF-
directed control macrophages, (mean±SEM; n=6; *P < 0.05 denotes significant difference compared 
to M-CSF macrophages; paired t-test).  
Refer to appendix A; (8.1.10) CT values and (8.1.11) for full blot image. 
 









































































3.4.3.2 PDGF-BB and TGFb1 co-stimulation decreases protein expression of 
specific VSMC-associated markers in GM-CSF matured human 
macrophages 








Figure 3.4.15 The effect of PDGF-BB and TGFb1 co-stimulation on caldesmon mRNA and 
protein expression in GM-CSF polarised macrophages. 
(a) Caldesmon mRNA levels in PDGF-BB and TGFb1 treated GM-CSF macrophages relative to 
untreated GM-CSF directed control macrophages, (mean±SEM; n=6; paired t-test).  
(b) Quantification and representative western blots for caldesmon protein expression in PDGF-BB and 
TGFb1 treated GM-CSF macrophages relative to untreated GM-CSF directed control macrophages. 
Stain free gel is shown as loading control. Data are expressed as fold change against untreated GM-
CSF-directed control macrophages, (mean±SEM; n=6; **P < 0.01 denotes significant difference 
compared to GM-CSF macrophages; paired t-test).  
















































































Figure 3.4.16 The effects of PDGF-BB and TGFb1 co-stimulation on calmodulin mRNA and 
protein expression in GM-CSF polarised macrophages. 
(a) Calmodulin mRNA levels in PDGF-BB and TGFb1 treated GM-CSF macrophages relative to 
untreated GM-CSF directed control macrophages, (mean±SEM; n=6; paired t-test).  
(b) Quantification and representative western blots for calmodulin protein expression in PDGF-BB 
and TGFb1 treated GM-CSF macrophages relative to untreated GM-CSF directed control 
macrophages. Stain free gel is shown as loading control. Data are expressed as fold change against 
untreated GM-CSF-directed control macrophages, (mean±SEM; n=6; **P < 0.01 denotes significant 
difference compared to GM-CSF macrophages; paired t-test).  


















































































Figure 3.4.17 The effects of PDGF-BB and TGFb1 co-stimulation on vimentin mRNA and 
protein expression in GM-CSF polarised macrophages. 
(a) Vimentin mRNA levels in PDGF-BB and TGFb1 treated GM-CSF macrophages relative to untreated 
GM-CSF directed control macrophages, (mean±SEM; n=6; paired t-test).  
(b) Quantification and representative western blots for vimentin protein expression in PDGF-BB and 
TGFb1 treated GM-CSF macrophages relative to untreated GM-CSF directed control macrophages. 
Stain free gel is shown as loading control. Data are expressed as fold change against untreated GM-
CSF-directed control macrophages, (mean±SEM; n=6; **P < 0.01 denotes significant difference 
compared to GM-CSF macrophages; paired t-test).  
Refer to appendix A; (8.1.10) CT values and (8.1.11) for full blot image. 
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3.4.4 Differing human macrophage phenotypes display distinct changes in 
their expression of VSMC-associated markers 
The expression of markers considered specific for VSMCs were also evaluated in multiple differing 
macrophage phenotypes in vitro. Seven-day M-CSF matured human macrophages (sometimes 
referred to as M0) were activated with different inducers for three days to generate different 
macrophage phenotypes before stimulation with PDGF-BB and TGFb1. The inducers used are 
described in detail under section 3.3.3, and include IFNg and LPS for M1 macrophage polarisation 
(Martinez et al., 2006), IL-4 for M2a macrophage polarisation (Stein et al., 1992), IL-10 for M2c 
macrophage polarisation (Lang et al., 2002), PF4 (CXCL4) for M4 macrophage polarisation (Gleissner 
et al., 2010), oxPAPC for Mox macrophage polarisation (Kadl et al., 2010), and oxLDL for foam cell 
macrophage formation (Kruth et al., 2002). See summary Figure 3.4.35 detailing the results in this 
section. 
Collectively, the expression of VSMC-associated marker genes/proteins showed variable responses 
amongst the differing macrophage phenotypes, when compared to control M-CSF directed 
macrophages (please see summary Figure 3.4.35). M1 polarisation with IFNg and LPS co-stimulation 
significantly down-regulated protein expression of caldesmon (41% change; P<0.01; n=6; Figure 
3.4.18 b), calmodulin (37% change; P<0.05; n=6; Figure 3.4.19 b), smoothelin, (45% change; P<0.05; 
n=6; Figure 3.4.20 b), and vimentin (41% change; P<0.05; n=6; Figure 3.4.21 b). Conversely, 
increased mRNA expression of calmodulin (3.0-fold change; P<0.05; n=6; Figure 3.4.19 a) and 
vimentin (1.6-fold change; P<0.05; n=6; Figure 3.4.21 a) was detected, with no change in caldesmon 
or smoothelin mRNA expression identified (Figure 3.4.18 and Figure 3.4.20). No effect of IFNg and 
LPS co-stimulation on Myh11 mRNA and protein levels were observed (data not shown).  
With regard to IL-4 stimulated macrophages to induce M2a polarisation, the mRNA and protein 
expression of Myh11, smoothelin, and vimentin were unchanged when compared to unstimulated 




levels of caldesmon were decreased (35% and 39% change; P<0.05; n=6; Figure 3.4.22 b), while 
calmodulin protein expression was increased (1.8-fold change; P<0.05; n=6; Figure 3.4.23 b). 
Similarly, no effect of M2c macrophage polarisation with IL-10 was detected for caldesmon, Myh11 
and vimentin mRNA and protein expression (see summary Figure 3.4.35). Although, a reduction in 
the protein expression of calmodulin (55% change; P<0.01; n=6; Figure 3.4.24 b) and smoothelin was 
detected (35% change; P<0.05; n=6; Figure 3.4.25 b), but with no effect at the mRNA level observed. 
Comparably, M4 macrophage polarisation through stimulation with PF4 had no effect on mRNA and 
protein expression of caldesmon, calmodulin, Myh11 or smoothelin (see summary Figure 3.4.35), 
relative to unstimulated control M-CSF macrophages, with only an increase in vimentin protein 
expression observed (1.7-fold change; P<0.05; n=6; Figure 3.4.26 b). 
The stimulation of human macrophages with oxPAPC to induce Mox polarisation significantly 
increased protein expression of Myh11 (1.7-fold change; P<0.05; n=6; Figure 3.4.27) and vimentin 
(1.8-fold change; P<0.05; n=6; Figure 3.4.28) although no corresponding differences in mRNA levels 
were seen (Figure 3.4.27 - Figure 3.4.28). Conversely, smoothelin mRNA and protein expression were 
decreased (36% change and 52% change; P<0.05; n=6; Figure 3.4.29), when compared to control M-
CSF macrophages. The induction of macrophage foam cell formation through the addition of oxLDL 
to human macrophages affected all VSMC-related markers, with significant elevations in the protein 
expression of caldesmon (1.6-fold change; P<0.05; n=6; Figure 3.4.30 b), calmodulin (1.8-fold 
change; P<0.05; n=6; Figure 3.4.31 b), Myh11 (1.8-fold change; P<0.05; n=6; Figure 3.4.32 b) and 
vimentin (3.5-fold change; P<0.05; n=6; Figure 3.4.33 b) detected in comparison to control 
unstimulated M-CSF macrophages. However, no changes were seen at the mRNA level for any of the 
markers (see summary Figure 3.4.35). In opposition oxLDL-induced foam cell formation was 
associated with a decreased mRNA and protein expression of smoothelin (34.7% and 52.8%; P<0.05; 

















Figure 3.4.18 The effects of PDGF-BB and TGFb1 co-stimulation on caldesmon mRNA and 
protein expression in M-CSF/IFNg/LPS polarised macrophages. 
(a) Caldesmon mRNA levels in M-CSF/IFNg/LPS macrophages relative to M-CSF directed 
macrophages, (mean±SEM; n=6; paired t-test).  
(b) Quantification and representative western blots for caldesmon protein expression in M-
CSF/IFNg/LPS macrophages relative to M-CSF directed macrophages. Stain free gel is shown as 
loading control. Data are expressed as fold change against untreated M-CSF-directed macrophages, 
(mean±SEM; n=6; **P < 0.01 denotes significant difference compared to M-CSF macrophages; paired 
t-test).  







































































Figure 3.4.19 The effects of PDGF-BB and TGFb1 co-stimulation on calmodulin mRNA and 
protein expression in M-CSF/IFNg/LPS polarised macrophages. 
(a) Calmodulin mRNA levels in M-CSF/IFNg/LPS macrophages relative to M-CSF directed 
macrophages, (mean±SEM; n=6; *P < 0.05 denotes significant difference compared to M-CSF 
macrophages; paired t-test).  
(b) Quantification and representative western blots for calmodulin protein expression in M-
CSF/IFNg/LPS macrophages relative to M-CSF directed macrophages. Stain free gel is shown as 
loading control. Data are expressed as fold change against untreated M-CSF-directed macrophages, 
(mean±SEM; n=6; *P < 0.05 denotes significant difference compared to M-CSF macrophages; paired 
t-test).  












































































Figure 3.4.20 The effects of PDGF-BB and TGFb1 co-stimulation on smoothelin mRNA and 
protein expression in M-CSF/IFNg/LPS polarised macrophages. 
(a) Smoothelin mRNA levels in M-CSF/IFNg/LPS macrophages relative to M-CSF directed 
macrophages, (mean±SEM; n=6; paired t-test). 
(b) Quantification and representative western blots for smoothelin protein expression in M-
CSF/IFNg/LPS macrophages relative to M-CSF directed macrophages. Stain free gel is shown as 
loading control. Data are expressed as fold change against untreated M-CSF-directed macrophages, 
(mean±SEM; n=6; *P < 0.05 denotes significant difference compared to M-CSF macrophages; paired 
t-test).  


































































Figure 3.4.21 The effects of PDGF-BB and TGFb1 co-stimulation on vimentin mRNA and 
protein expression in M-CSF/IFNg/LPS polarised macrophages. 
(a) Vimentin mRNA levels in M-CSF/IFNg/LPS macrophages relative to M-CSF directed macrophages, 
(mean±SEM; n=6; *P < 0.05 denotes significant difference compared to M-CSF macrophages; paired 
t-test).  
(b) Quantification and representative western blots for vimentin protein expression in M-
CSF/IFNg/LPS macrophages relative to M-CSF directed macrophages. Stain free gel is shown as 
loading control. Data are expressed as fold change against untreated M-CSF-directed macrophages, 
(mean±SEM; n=6; **P < 0.01 denotes significant difference compared to M-CSF macrophages; paired 
t-test).  






































































Figure 3.4.22 The effects of PDGF-BB and TGFb1 co-stimulation on caldesmon mRNA and 
protein expression in M-CSF/IL4 polarised macrophages. 
(a) Caldesmon mRNA levels in M-CSF/IL4 macrophages relative to M-CSF directed macrophages, 
(mean±SEM; n=6; *P < 0.05 denotes significant difference compared to M-CSF macrophages; paired 
t-test).  
(b) Quantification and representative western blots for cladesmon protein expression in M-CSF/IL4 
macrophages relative to M-CSF directed macrophages. Stain free gel is shown as loading control. 
Data are expressed as fold change against untreated M-CSF-directed macrophages, (mean±SEM; 
n=6; **P < 0.01 denotes significant difference compared to M-CSF macrophages; paired t-test).  




































































Figure 3.4.23 The effects of PDGF-BB and TGFb1 co-stimulation on calmodulin mRNA and 
protein expression in M-CSF/IL4 polarised macrophages. 
(a) Calmodulin mRNA levels in M-CSF/IL4 macrophages relative to M-CSF directed macrophages, 
(mean±SEM; n=6; paired t-test).  
(b) Quantification and representative western blots for calmodulin protein expression in M-CSF/IL4 
macrophages relative to M-CSF directed macrophages. Stain free gel is shown as loading control. 
Data are expressed as fold change against untreated M-CSF-directed macrophages, (mean±SEM; 
n=6; *P < 0.05 denotes significant difference compared to M-CSF macrophages; paired t-test).  








































































Figure 3.4.24 The effects of PDGF-BB and TGFb1 co-stimulation on calmodulin mRNA and 
protein expression in M-CSF/IL10 polarised macrophages. 
(a) Calmodulin mRNA levels in M-CSF/IL10 macrophages relative to M-CSF directed macrophages, 
(mean±SEM; n=6; paired t-test).  
(b) Quantification and representative western blots for calmodulin protein expression in M-CSF/IL10 
macrophages relative to M-CSF directed macrophages. Stain free gel is shown as loading control. 
Data are expressed as fold change against untreated M-CSF-directed macrophages, (mean±SEM; 
n=6; **P < 0.01 denotes significant difference compared to M-CSF macrophages; paired t-test).  





































































Figure 3.4.25 The effects of PDGF-BB and TGFb1 co-stimulation on smoothelin mRNA and 
protein expression in M-CSF/IL10 polarised macrophages. 
(a) Smoothelin mRNA levels in M-CSF/IL10 macrophages relative to M-CSF directed macrophages, 
(mean±SEM; n=6; paired t-test).  
(b) Quantification and representative western blots for smoothelin protein expression in M-CSF/IL10 
macrophages relative to M-CSF directed macrophages. Stain free gel is shown as loading control. 
Data are expressed as fold change against untreated M-CSF-directed macrophages, (mean±SEM; 
n=6; *P < 0.05 denotes significant difference compared to M-CSF macrophages; paired t-test).  



































































Figure 3.4.26 The effects of PDGF-BB and TGFb1 co-stimulation on vimentin mRNA and 
protein expression in M-CSF/PF4 polarised macrophages. 
(a) Vimentin mRNA levels in M-CSF/PF4 macrophages relative to M-CSF directed macrophages, 
(mean±SEM; n=6; paired t-test).  
(b) Quantification and representative western blots for vimentin protein expression in M-CSF/PF4 
macrophages relative to M-CSF directed macrophages. Stain free gel is shown as loading control. 
Data are expressed as fold change against untreated M-CSF-directed macrophages, (mean±SEM; 
n=6; *P < 0.05 denotes significant difference compared to M-CSF macrophages; paired t-test).  











































































Figure 3.4.27 The effects of PDGF-BB and TGFb1 co-stimulation on Myh11 mRNA and protein 
expression in M-CSF/oxPAPC polarised macrophages. 
(a) Myh11 mRNA levels in M-CSF/oxPAPC macrophages relative to M-CSF directed macrophages, 
(mean±SEM; n=6; paired t-test).  
(b) Quantification and representative western blots for Myh11 protein expression in M-CSF/oxPAPC 
macrophages relative to M-CSF directed macrophages. Stain free gel is shown as loading control. 
Data are expressed as fold change against untreated M-CSF-directed macrophages, (mean±SEM; 
n=6; *P < 0.05 denotes significant difference compared to M-CSF macrophages; paired t-test).  
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Figure 3.4.28 The effects of PDGF-BB and TGFb1 co-stimulation on vimentin mRNA and 
protein expression in M-CSF/oxPAPC polarised macrophages. 
(a) Vimentin mRNA levels in M-CSF/oxPAPC macrophages relative to M-CSF directed macrophages, 
(mean±SEM; n=6; paired t-test).  
(b) Quantification and representative western blots for vimentin protein expression in M-CSF/oxPAPC 
macrophages relative to M-CSF directed macrophages. Stain free gel is shown as loading control. 
Data are expressed as fold change against untreated M-CSF-directed macrophages, (mean±SEM; 
n=6; *P < 0.05 denotes significant difference compared to M-CSF macrophages; paired t-test).  






































































Figure 3.4.29 The effects of PDGF-BB and TGFb1 co-stimulation on smoothelin mRNA and 
protein expression in M-CSF/oxPAPC polarised macrophages. 
(a) Smoothelin mRNA levels in M-CSF/oxPAPC macrophages relative to M-CSF directed macrophages, 
(mean±SEM; n=6; *P < 0.05 denotes significant difference compared to M-CSF macrophages; paired 
t-test). 
(b) Quantification and representative western blots for smoothelin protein expression in M-
CSF/oxPAPC macrophages relative to M-CSF directed macrophages. Stain free gel is shown as loading 
control. Data are expressed as fold change against untreated M-CSF-directed macrophages, 
(mean±SEM; n=6; **P < 0.01 denotes significant difference compared to M-CSF macrophages; paired 
t-test).  









































































Figure 3.4.30 The effects of PDGF-BB and TGFb1 co-stimulation on caldesmon mRNA and 
protein expression in M-CSF/oxLDL polarised macrophages. 
(a) Caldesmon mRNA levels in M-CSF/oxLDL macrophages relative to M-CSF directed macrophages, 
(mean±SEM; n=6; paired t-test). 
(b) Quantification and representative western blots for caldesmon protein expression in M-CSF/oxLDL 
macrophages relative to M-CSF directed macrophages. Stain free gel is shown as loading control. 
Data are expressed as fold change against untreated M-CSF-directed macrophages, (mean±SEM; 
n=6; *P < 0.05 denotes significant difference compared to M-CSF macrophages; paired t-test).  
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Figure 3.4.31 The effects of PDGF-BB and TGFb1 co-stimulation on calmodulin mRNA and 
protein expression in M-CSF/oxLDL polarised macrophages. 
(a) Calmodulin mRNA levels in M-CSF/oxLDL macrophages relative to M-CSF directed macrophages, 
(mean±SEM; n=6; paired t-test). 
(b) Quantification and representative western blots for calmodulin protein expression in M-
CSF/oxLDL macrophages relative to M-CSF directed macrophages. Stain free gel is shown as loading 
control. Data are expressed as fold change against untreated M-CSF-directed macrophages, 
(mean±SEM; n=6; *P < 0.05 denotes significant difference compared to M-CSF macrophages; paired 
t-test).  




































































Figure 3.4.32 The effects of PDGF-BB and TGFb1 co-stimulation on Myh11 mRNA and protein 
expression in M-CSF/oxLDL polarised macrophages. 
(a) Myh11 mRNA levels in M-CSF/oxLDL macrophages relative to M-CSF directed macrophages, 
(mean±SEM; n=6; paired t-test). 
(b) Quantification and representative western blots for Myh11 protein expression in M-CSF/oxLDL 
macrophages relative to M-CSF directed macrophages. Stain free gel is shown as loading control. 
Data are expressed as fold change against untreated M-CSF-directed macrophages, (mean±SEM; 
n=6; *P < 0.05 denotes significant difference compared to M-CSF macrophages; paired t-test).  






































































Figure 3.4.33 The effects of PDGF-BB and TGFb1 co-stimulation on vimentin mRNA and 
protein expression in M-CSF/oxLDL polarised macrophages. 
(a) Vimentin mRNA levels in M-CSF/oxLDL macrophages relative to M-CSF directed macrophages, 
(mean±SEM; n=6; paired t-test). 
(b) Quantification and representative western blots for vimentin protein expression in M-CSF/oxLDL 
macrophages relative to M-CSF directed macrophages. Stain free gel is shown as loading control. 
Data are expressed as fold change against untreated M-CSF-directed macrophages, (mean±SEM; 
n=6; *P < 0.05 denotes significant difference compared to M-CSF macrophages; paired t-test).  



































































Figure 3.4.34 The effects of PDGF-BB and TGFb1 co-stimulation on smoothelin mRNA and 
protein expression in M-CSF/oxLDL polarised macrophages. 
(a) Smoothelin mRNA levels in M-CSF/oxLDL macrophages relative to M-CSF directed macrophages, 
(mean±SEM; n=6; **P < 0.01 denotes significant difference compared to M-CSF macrophages; paired 
t-test). 
(b) Quantification and representative western blots for smoothelin protein expression in M-
CSF/oxLDL macrophages relative to M-CSF directed macrophages. Stain free gel is shown as loading 
control. Data are expressed as fold change against untreated M-CSF-directed macrophages, 
(mean±SEM; n=6; *P < 0.05 denotes significant difference compared to M-CSF macrophages; paired 
t-test).  































































Caldesmon Calmodulin Myh11 Smoothelin Vimentin  
mRNA protein  mRNA protein  mRNA protein  mRNA protein  mRNA protein  
IFNg + LPS 1.1 0.6 2.9 0.6 1.0 1.1 1.0 0.6 1.6 0.6 
IL-4 0.6 0.6 1.2 1.8 1.0 1.2 1.1 1.1 1.1 1.1 
IL-10 1.0 1.0 1.1 0.4 1.2 1.1 1.1 0.6 1.1 1.2 
PF4 1.2 1.1 1.1 1.1 1.0 1.1 1.1 1.1 1.1 1.7 
oxPAPC 1.1 1.0 1.2 1.1 1.1 1.7 0.6 0.5 1.0 1.8 
oxLDL 1.3 1.6 1.2 1.8 1.2 1.8 0.3 0.5 1.1 3.5 
 
Figure 3.4.35 Summary result for polarised M-CSF macrophages with PDGF-BB + TGFb1 co-stimulation 
Fold change in mRNA and protein expression of VSMC-associated markers compared to PDGF-BB/TGFb1 treated M-CSF matured human macrophages 





3.4.5 The expression of VSMC-related markers in M-CSF and GM-CSF 
matured macrophages relative to human coronary artery VSMCs  
Although all VSMC-associated markers were present within human macrophages, and expression 
patterns varied between M-CSF or GM-CSF-matured cells with and without stimulation with PDGF-
BB/TGFb1, it was deemed important to relate expression levels to those observed in primary VSMCs, 
as an indicator of macrophages truly shifting towards a VSMC-like phenotype. Accordingly, the 
expression of VSMC-related markers was compared between human macrophage baseline cultures 
(M-Mac and GM-Mac) and human primary coronary artery VSMC cultures. Although M-CSF matured 
macrophages expressed all the markers evaluated, protein levels for all were significantly lower than 
those detected by Western blotting in coronary artery VSMCs; caldesmon (40% change; P<0.01; n=6; 
Figure 3.4.36 b), calmodulin (69% change; P<0.05; n=6; Figure 3.4.37 b), Myh11 (38% change; 
P<0.01; n=6; Figure 3.4.38 b), smoothelin (65% change; P<0.0001; n=6; Figure 3.4.39 b) and vimentin 
(67% change; P<0.001; n=6; Figure 3.4.40 b). Reciprocal changes at the mRNA level were also 
observed, with the exception of Myh11 where no difference was seen (see summary Figure 3.4.41). 
A distinctly different pattern was observed in GM-CSF matured macrophages, which displayed 
comparable protein levels for calmodulin, Myh11 and smoothelin as those detected in human 
coronary artery VSMCS (see summary Figure 3.4.41). Moreover, caldesmon protein expression was 
significantly increased within GM-CSF matured macrophages (1.9-fold change; P<0.05; n=6; Figure 
3.4.36 b) in relation to VSMCs, although mRNA levels were seen to decrease (99.95% change; 
P<0.0001; n=6; Figure 3.4.36 a). Mirroring the pattern in M-CSF matured macrophages, vimentin 
mRNA and protein expression was significantly decreased in GM-CSF differentiated macrophages 
compared to VSMCs (18% and 49% change; P<0.05; n=6; Figure 3.4.40). It should be noted that for 
caldesmon, a high molecular weight isoform (120 kDa) was detected in primary VSMC cultures which 
was not apparent in either macrophage population (please see appendix A (8.1.3) for full western 











Figure 3.4.36 Caldesmon mRNA and protein expression in M-CSF or GM-CSF polarised 
macrophages relative to human coronary artery VSMC. 
(a) Caldesmon mRNA levels in M-CSF and GM-CSF macrophages relative to human coronary artery 
VSMC, (mean±SEM; n=6; ****P < 0.0001 denotes significant difference compared to VSMC, ANOVA 
Tukey-Kramer multiple comparison test).  
(b) Quantification and representative western blots for caldesmon protein expression in M-CSF and 
GM-CSF macrophages relative to human coronary artery VSMC. Stain free gel is shown as loading 
control. Data are expressed as fold change against human coronary artery VSMC, (mean±SEM; n=6; 
**P<0.01 denotes significant difference compared to VSMC, ANOVA Tukey-Kramer multiple 
comparison test).  























































Figure 3.4.37 Calmodulin mRNA and protein expression in M-CSF or GM-CSF polarised 
macrophages relative to human coronary artery VSMCs. 
(a) Calmodulin mRNA levels in M-CSF and GM-CSF macrophages relative to human coronary artery 
VSMC, (mean±SEM; n=6; ***P < 0.001 denotes significant difference compared to VSMC, ANOVA 
Tukey-Kramer multiple comparison test). 
(b) Quantification and representative western blots for calmodulin protein expression in M-CSF and 
GM-CSF macrophages relative to human coronary artery VSMC. Stain free gel is shown as loading 
control. Data are expressed as fold change against human coronary artery VSMC, (mean±SEM; n=6; 
**P<0.01 denotes significant difference compared to VSMC, ANOVA Tukey-Kramer multiple 
comparison test).  
Refer appendix A; (8.1.4) CT values and (8.1.5) full blot image. 
  




















































Figure 3.4.38 Myh11 mRNA and protein expression in M-CSF or GM-CSF polarised 
macrophages relative to human coronary artery VSMCs. 
(a) Myh11 mRNA levels in M-CSF and GM-CSF macrophages relative to human coronary artery VSMC, 
(mean±SEM; n=6; ANOVA Tukey-Kramer multiple comparison test). 
(b) Quantification and representative western blots for Myh11 protein expression in M-CSF and GM-
CSF macrophages relative to human coronary artery VSMC. Stain free gel is shown as loading control. 
Data are expressed as fold change against human coronary artery VSMC, (mean±SEM; n=6; 
**P<0.01 denotes significant difference compared to VSMC, ANOVA Tukey-Kramer multiple 
comparison test).  



















































Figure 3.4.39 Smoothelin mRNA and protein expression in M-CSF or GM-CSF polarised 
macrophages relative to human coronary artery VSMCs. 
(a) Smoothelin mRNA levels in MCSF and GM-CSF macrophages relative to human coronary artery 
VSMC, (mean±SEM; n=6; ****P < 0.0001 denotes significant difference compared to VSMC, ANOVA 
Tukey-Kramer multiple comparison test).  
(b) Quantification and representative western blots for smoothelin protein expression in M-CSF and 
GM-CSF macrophages relative to human coronary artery VSMC. Stain free gel is shown as loading 
control. Data are expressed as fold change against human coronary artery VSMC, (mean±SEM; n=6; 
****P<0.0001 denotes significant difference compared to VSMC, ANOVA Tukey-Kramer multiple 
comparison test).  























































Figure 3.4.40 Vimentin mRNA and protein expression in M-CSF or GM-CSF polarised 
macrophages relative to human coronary artery VSMCs. 
(a) Vimentin mRNA levels in MCSF and GM-CSF macrophages relative to human coronary artery 
VSMC, (mean±SEM; n=6; ***P < 0.001 and *P<0.05 denotes significant difference compared to 
VSMC, ANOVA Tukey-Kramer multiple comparison test).  
(b) Quantification and representative western blots for vimentin protein expression in M-CSF and 
GM-CSF macrophages relative to human coronary artery VSMC. Stain free gel is shown as loading 
control. Data are expressed as fold change against human coronary artery VSMC, (mean±SEM; n=6; 
***P < 0.001 and **P<0.01 denotes significant difference compared to VSMC, ANOVA Tukey-Kramer 
multiple comparison test).  
























































Figure 3.4.41 Summary result for VSMC and macrophage  
Fold change in mRNA and protein expression of VSMC-associated markers in baseline M-CSF or GM-CSF polarised macrophages compared to human 
coronary artery VSMCs. Green boxes indicate significantly reduced expression, whereas red boxes indicate significantly increased levels. 
†M-CSF caldesmon mRNA = 0.00052-fold change; smoothelin mRNA = 0.02063-fold change.	
‡GM-CSF caldesmon mRNA = 0.00042-fold change. 
 
Cell type 
Caldesmon Calmodulin Myh11 Smoothelin Vimentin  
mRNA protein  mRNA protein  mRNA protein  mRNA protein  mRNA protein  
VSMC 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 
M-CSF 0.0† 0.6 0.3 0.3 1.2 0.6 0.0† 0.3 0.3 0.3 




3.4.6 In vitro macrophages retain macrophage marker expression after co-
stimulation with PDGF-BB and TGFβ1 
The above evidence demonstrates that human macrophages matured with either M-CSF or GM-CSF, 
express an array of VSMC-associated markers which can be further modulated through co-
stimulation with the VSMC-related growth factors PDGF-BB and TGFβ1. Considering the expression 
of VSMC-associated markers suggest a subsequent shift towards a VSMC-like phenotype, 
macrophages may deviate from their macrophage lineage. Accordingly, the expression of a 
macrophage marker, Mac-2 (Galectin-3), was evaluated in macrophage cultures by 
immunofluorescence staining to assess if expression was affected upon culture and stimulation with 
PDGF-BB and TGFb1 (Figure 3.4.42). As can be observed within Figure 3.4.43, greater than 90% of M-
CSF and GM-CSF matured macrophages displayed positive immunolabelling for Mac-2 (galectin-3). 
Subsequent co-incubation with PDGF-BB and TGFb1 did not affect macrophage Mac-2 expression in 








Figure 3.4.42 Fluorescent immunocytochemistry for Mac-2 (galectin-3) protein expression in 
human macrophage subsets with and without PDGF-BB and TGFβ1 co-stimulation. 
Representative images of in vitro human monocyte-derived macrophages matured with either M-CSF 
or GM-CSF for seven, followed with or without co-stimulation with PDGF-BB and TGFβ1 for three 
days, then subjected to immunocytochemistry for Mac-2 (green) and counterstained with DAPI (blue; 
nuclei). Scale bar in panel D represents 100 µM and is applicable to all panels. 
 
 
(a) M-CSF (b) M-CSF+PDGF-BB/TGFb1 








Figure 3.4.43 Effect of M-CSF or GM-CSF macrophage maturation and subsequent co-
incubation with PDGF-BB and TGFβ1 on Mac-2 expression. 
Quantification of in vitro human monocyte-derived macrophages matured with either M-CSF or GM-
CSF for seven days, followed with or without co-stimulation with PDGF-BB and TGFβ1 for three days, 
and then subjected to immunocytochemistry for Mac-2 (green) and counterstained with DAPI (blue; 
nuclei). Data are expressed as fold change in percentage of Mac-2 positive cells against control M-


























Macrophages have been described as terminally differentiated mononuclear phagocytes which exist 
as heterogeneous populations (Takahashi et al., 1989). Terminally differentiated macrophages are 
considered to principally participate in immune regulation responses and can display characteristics 
of end stage killer cells through their ability to produce NO. Macrophages can then die from 
autocrine NO production and further propagate inflammatory responses through the need for their 
replacement by newly recruited cells, mainly derived from bone marrow (Italiani and Boraschi, 
2014). However, the understanding on the heterogenous concept of macrophages has recently 
changed. It is now well accepted that macrophages can exhibit plasticity depending on the stimulus 
they encounter, enabling them to adapt to changing microenvironments through exposure to pro-
inflammatory or anti-inflammatory  cytokines and growth factors (Stout and Suttles, 2004). 
Macrophages can be converted into a state whereby they resume cell division (during early 
development i.e., embryogenesis and haematopoiesis) and also revert back to a non-proliferative 
form (Ruhnke et al., 2005a). Therefore, macrophages can potentially serve as a source for the 
generation of non-haematopoietic cells by modulating their behaviour through creating a specific 
microenvironment which they are capable of reacting to.  
Cell-type transformation, macrophage conversion to a VSMC-like cell for instance, will involve 
changes in the organisation of the cell microstructure, such as the organisation of the cytoskeleton, 
morphology, motility, adhesion-dependent cell growth, contact inhibition and change in cellular 
adhesiveness. These processes may involve disruption of actin filaments and changes in focal 
adhesions, following cell transformation induced by various stimuli (Pawlak and Helfman, 2001).  
Within this chapter, two distinct in vitro macrophage phenotypes have been assessed, which show 
different cellular morphology under the influence of M-CSF or GM-CSF signalling cues (described in 
detail in section 3.4.1), which is in agreement with previous reports (Waldo et al., 2008). Similarly, 




were observed to undergo cytoskeletal adaptation, with the changes described in detail above 
(under the section 3.4.1), which are in line with published findings demonstrating specific 
cytoskeletal organisational changes such as changes in cell shape and size (McWhorter et al., 2013). 
Indeed, macrophage polarisation to an alternatively activated phenotype (M2) is associated with cell 
elongation, whereas classically activated macrophages (M1) display reduced cell length (McWhorter 
et al., 2013). Generally, the shape of alternatively activated macrophages (either with IL-4, IL-10, PF4 
or oxPAPC) have been described to acquire a mixture of rounded and stretched cell morphology 
(Young et al., 1990) similar to conventional inactivated macrophages (control M-CSF polarised 
macrophages, sometimes referred to as M0 macrophages) (Gleissner et al., 2010). In addition, PF4-
polarised macrophages are associated with marked pseudopodia formation (Scheuerer et al., 2000). 
Interestingly, PDGF-BB and TGFb1 co-stimulation did not alter cellular morphology of in vitro 
macrophages, through phase contrast observation. 
Reportedly, in vitro cultured VSMCs assume a synthetic phenotype (Wanjare et al., 2013) with a 
more epithelioid morphology as opposed to the spindle/elongated shape attributed to the 
contractile phenotype (Hao et al., 2003).  Early passage in vitro primary VSMCs are characterised by 
their high density of myofilaments and expression of contractile genes/proteins such as α-SM-actin 
alongside low proliferative capacity. However, after several days in tissue culture conditions they 
attain a synthetic phenotype with a high proliferative capacity and reduced expression of α-SM-
actin, which is a typical VSMC phenotype commonly found during vascular development and 
regeneration (Metz et al., 2012). It has been postulated that during culture, VSMCs may enter a 
senescence stage and lose their proliferative capacity, especially arterial derived VSMCs. Indeed, this 
was observed during this study, with late passage VSMC cultures displaying reduced confluency 
when compared to early passage cultures. In addition, late passage primary VSMCs may transform 
into a state where they lose their replicative capability, even though already transformed into a 




The main findings within this chapter demonstrate that in vitro macrophages express genes and 
proteins commonly associated and used as markers of VSMCs. This is in line with previous findings 
where (embryonic) Myh11, a-SM-actin and calponin were shown to be expressed by rat peritoneal 
macrophages in vitro (Ninomiya et al., 2006). In our study, however, calponin was not expressed by 
macrophage cultures, but other genes/proteins commonly associated with VSMCs were expressed 
by in vitro macrophages, including a-SM-actin, caldesmon, calmodulin, Myh11, smoothelin, and 
vimentin. There is some support for these novel observations from recent single-cell transcriptomic 
analyses of mouse atherosclerotic aortas, where intraplaque macrophage populations display 
significant enrichment for vimentin and calmodulin-1 (Cochain et al., 2018), alongside α-SM-actin 
and transgelin (Kim et al., 2018). Moreover, inflammatory activation of human and mouse 
macrophages was shown to induce expression of α-SM-actin in vitro and was confirmed in vivo using 
a mouse MI-model (Haider et al., 2019). Similarly, exposure of macrophages to foreign bodies and 
their subsequent engulfment was associated with elevated α-SM-actin expression (Mesure et al., 
2010). 
The above suggests that inflammatory stimulation appears to drive macrophages towards a smooth 
muscle cell-like phenotype. Interestingly and in relation to the findings within this chapter, GM-CSF 
is associated with inducing a pro-inflammatory macrophage phenotype, whereas M-CSF is described 
as an anti-inflammatory inducer (Di Gregoli et al., 2017; Johnson et al., 2014; Johnson et al., 2008). 
Indeed, based upon the expression changes in the VSMC-related markers, GM-CSF directed 
macrophages demonstrated a greater transition towards a VSMC-like phenotype through higher 
expression of a suite of VSMC-related genes and proteins compared to M-CSF directed 
macrophages. Thus, under baseline tissue culture conditions, GM-CSF directed macrophages can be 
considered to already display divergent polarisation towards a VSMC-like phenotype.  
Contrastingly, the addition of PDGF-BB and TGFb1, growth factors which support phenotypic 




macrophages with VSMC-like characteristics but downregulates the expression of the same suite of 
VSMC-associated markers in GM-CSF directed macrophage. The upregulation of VSMC-markers in 
M-CSF polarised macrophages is possibly due to an anti-inflammatory environment created by 
addition of PDGF-BB and TGFb1. As described previously, cytokines and growth factors found within 
the inflammatory milieu, such as TGFb1, can promote expression of numerous VSMC-related 
markers in cultured macrophages, and TGFb1 can exert ant-inflammatory actions in addition to 
promoting fibrosis (Ninomiya et al., 2006).  
What is additionally interesting is the observation that the changes in marker expression are largely 
restricted to the protein level, suggesting post-translational regulatory mechanisms independently 
or through a network, modulate VSMC-related protein levels. MicroRNA regulation of protein 
expression represents such a mechanism, which while beyond the scope of the present study, 
warrants further examination. Indeed, previous findings have demonstrated divergent expression 
profiles of microRNAs between M-CSF and GM-CSF polarised macrophages and subsequent effects 
on macrophage function and behaviour (Di Gregoli et al., 2014; Di Gregoli et al., 2017). On the other 
hand, a possible explanation for the downregulation of VSMC-associated markers in GM-CSF 
macrophages by PDGF-BB and TGFb1 could be through a negative feedback regulatory mechanism, 
where gene and protein expression in immune cells such as monocytes and macrophages are tightly 
controlled at both transcriptional and post-transcriptional levels  (Schott et al., 2014). Indeed, recent 
work from my supervisor’s lab demonstrated that the pro-inflammatory behaviour of GM-CSF-
polarised macrophages is negatively regulated by TGFβ signalling (Di Gregoli et al., 2020). This area 
in relation to VSMC-like-transformation would be interesting to explore in future studies.  
Similarly, variations in the expression of VSMC-connected markers were observed between the 
other macrophage subsets assessed. Relative to M-CSF-polarised macrophages co-stimulated with 
PDGF-BB and TGFb1, pro-inflammatory macrophages induced with IFNg and LPS (M1 subset) appear 




macrophages (which can be considered anti-inflammatory) showed minimal changes in VSMC 
marker expression.  
Previous studies have implied that macrophage lipid accumulation may be associated with a pro-
fibrotic response (Thomas et al., 2015a), similar to that observed when synthetic VSMCs 
predominate during wound healing and vascular injury (Thomas et al., 2015b). In line with this 
proposition, oxLDL-induced macrophage foam cell formation was the only macrophage phenotype 
that showed consistent upregulation of VSMC-related markers at the protein level (refer to 3.4.4), 
suggesting lipid accumulation within macrophages induces their transformation towards a VSMC-like 
phenotype which can participate in pro-fibrotic responses. Foam cell macrophages are considered 
the hallmark of atherosclerotic plaque development, alongside VSMC-driven formation of the 
protective fibrous cap (George and Lyon, 2010). As described above, foam cells are commonly 
thought to originate from lipid accumulation within monocyte-derived macrophages (Johnson and 
Newby, 2009). However, recent findings have challenged this dogma and propose that VSMCs may 
significantly contribute to intraplaque foam cell numbers (Huff and Pickering, 2015; Rong et al., 
2003). However, the data within this chapter demonstrating foam cell macrophages express VSMC-
associated proteins (which are commonly used to identify VSMCs within plaque tissues), implies that 
VSMC-derived foam cells within plaques may actually be of macrophage origin. Although beyond the 
scope of this thesis, this interesting proposition requires further investigation and may provide a 
new understanding of the mechanisms underlying early atherosclerotic plaque formation, such as 
the transition from adaptive to pathological intimal thickenings.  
There is suggestive evidence to support the plasticity and transformation capacity of 
monocyte/macrophages, especially towards a VSMC-like phenotype. CD34 is considered a marker 
for hematopoietic stem/progenitor cells but has also recently been shown to be expressed by 
monocytes (D'Aveni et al., 2015), inferring that isolation of circulating stem/progenitor cells based 




blood CD34+-enriched cell population transplanted into the left ventricle of mice with surgically-
induced MI suggested CD34+ cells trans-differentiated towards cardiomyocytes, endothelial cells 
and VSMCs (Yeh et al., 2003). However, this finding (Yeh et al., 2003) emphasised the necessity of 
contact between CD34+ cells and resident cells through cell fusion or cell-to-cell contact to permit 
tissue regeneration post-injury (MI). In another report, in vitro trans-differentiation of macrophages 
towards a VSMC-like phenotype was proposed due to the observed increased expression of the 
VSMC-associated markers α-SM-actin, calponin and Myh11 after stimulation of rat peritoneal 
exudate macrophages with TGFb1 (Ninomiya et al., 2006). Interestingly, a concomitant decreased 
expression of the commonly used macrophage marker CD11b was reported, potentially underlying 
the aforementioned mis-identification of intraplaque foam cells as of VSMC-origin.  
A further indication that macrophages acquire the ability to shift their phenotype towards other cell-
like types is hinted through their ability to regain proliferative capacity when matured from 
monocytes with M-CSF and interleukin-3 (IL-3) (Ruhnke  et al., 2005b), as resumption of proliferation 
is a characteristic of pluripotent progenitor cells (Busch et al., 2015; Grinenko et al., 2018). Indeed, 
Ruhnke and colleagues demonstrated that M-CSF and IL-3 matured monocyte-derived macrophages 
exposed to specific biochemical cues, could be programmed into another cell lineages, including 
hepatocyte-like cells (with FGF4) and pancreatic islet-like cells (with insulin and C-peptide), which 
was associated with down-regulation of transcriptional repressor genes regulating cell-cycle and 
DNA synthesis (Ruhnke et al., 2005b). Interestingly, cell cycle regulators such as cyclin dependant 
kinases (CDK) and their inhibitors has been implicated not only in immune cell expansion 
(Laphanuwat and Jirawatnotai, 2019), but also activation of innate immune responses through type I 
interferon production (Cingöz and Goff, 2018). 
Collectively, these studies alongside the findings within this chapter imply that the polarisation of 
specific macrophage subsets modulates their ability to convert towards a programmable cell, 




However, the reversion of macrophages to a programmable phenotype is probably transient and not 
fully towards a haematopoietic pluripotent stem cell type, as some monocyte/macrophage markers 
are retained (Ruhnke et al., 2005b), whereas established haemopoietic stem cell markers are poorly 
expressed, suggesting such programmable macrophage subsets are similar in nature to common 
monocytic/granulocytic progenitor cells (Friedman, 2002). Such reprogramming of a cell lineage 
without inducing full reversion to haematopoietic stem cells is known as trans-differentiation (Graf 
and Enver, 2009). Lineage conversion/switching of terminally differentiated cells or mature somatic 
cells, such as macrophages, through trans-differentiation involves forcing the cell to change lineage 
without reversion to a primitive multi- or pluri-potent state (induced pluripotency), followed by re-
differentiation into another tissue lineage (Graf and Enver, 2009). Cell fusion is another mechanism 
of cell programming which permits a committed cell lineage to change without the necessity to 
revert back to pluripotency (Verfaillie, 2002). It is plausible to reason that monocyte/macrophages 
harbour the ability to trans-differentiate to other cell types to aid recovery after injury, and 
therefore provide temporary protection, before replacement by resident cells. Indeed, marked 
recruitment of monocyte/macrophages is observed acutely after injury and persists during the 
healing process, potentially providing a reservoir of cells capable of masquerading as resident cells 
to bestow protection before healing is concluded. An example could be at sites of vascular injury, 
where recruited monocyte/macrophages trans-differentiate towards an endothelial cell-like 
phenotype to provide temporary barrier function before re-growth of resident endothelial cells. 
Indeed, blood outgrowth endothelial cells (which are a derivative of endothelial progenitor cells 
(Yoder et al., 2007)) are proposed to play a similar role (Dauwe et al., 2016), and interestingly are 
derived from PBMCs using the same protocol as for monocyte isolation, raising the possibility that 
blood outgrowth endothelial cells may indeed be monocytes. Although conjecture, these 





3.6 Conclusion  
The findings within this chapter demonstrate that in vitro human monocyte-derived macrophages 
express genes and proteins which are commonly associated with VSMCs, supporting the proposition 
that primary macrophages harbour the potential to trans-differentiate towards a VSMC-like 
phenotype. Additionally, macrophage polarisation towards pro-inflammatory, anti-inflammatory, 
and lipid-laden phenotypes differentially modulates expression of VSMC-associated markers, with 
GM-CSF-directed maturation and foam cell formation favouring trans-differentiation towards a 
VSMC-like phenotype. Nevertheless, in vitro macrophages maintain their original cellular lineage as 
evidenced by maintained expression of macrophage markers, suggesting trans-differentiation is a 
temporary response. As such, macrophages can be considered a distinct population of 
haematopoietic cells that are capable of interim trans-differentiation towards another cell lineage 





4 In vitro macrophages display divergent polarisation 
towards endothelial cell-like phenotypes by pro-
angiogenic growth factor 
 
4.1 Introduction  
4.1.1 Endothelial cell phenotypes 
The vascular endothelium is comprised of a confluent monolayer of endothelial cells and serves as a 
protective anatomical barrier between circulating blood and underlying tissues. Microscopically, 
endothelial cells are characterised by a flattened shape with a single central nucleus. Besides its role 
as a protective barrier, the endothelium is also regarded as a metabolically dynamic organ that 
maintains vascular homeostasis through the release of regulatory bioactive substances, for instance 
nitric oxide (NO), endothelin and thrombomodulin. These bioactive substances are released by 
endothelial cells in response to various stimuli, such as through physical forces (or shear stress) 
applied by blood flow, blood-viscosity, as well as cell-cell interactions (Deanfield et al., 2007; Gori et 
al., 2007). Bioactive substances released by endothelial cells may act on the endothelial cells 
themselves (autocrine) and also to surrounding vascular cells (paracrine) such as VSMCs, connective 
tissue cells within the vessel wall (i.e. fibroblasts), and circulating cells within the lumen (i.e. platelets 
and monocytes) (Gori et al., 2007). Briefly, the general function of endothelial derived bioactive 
substances is to ensure uninterrupted blood flows over the endothelial-luminal surface by creating a 
non-sticky surface to circulating blood (hence preventing the formation of blood clot), as well as 
controlling the tone of the vessel wall for non-resistance and effective blood flow.   
Endothelial cells display heterogeneity based upon their function and location, for example, tight 
junctions are numerous in arterial-endothelial cells compared to venous-endothelial cells 
(Simionescu et al., 1976). Moreover, the long and narrow features of endothelial cells within arteries 
accommodate its high pressure and pulsatile characteristics whereas venous endothelial cells are 




further classified into quiescent or activated phenotypes. Generally, in healthy vessels, endothelial 
cells are in a state of quiescence to serve their physiological role as a protective barrier regulating 
molecular transport across the endothelial layer (Zecchin et al., 2017). Quiescent endothelial cells 
are non-adhesive, and display anti-coagulant and vasodilatory properties to accommodate smooth 
blood flow over the luminal surface of the vessels, while at the same time in a state capable of 
responding to  changing environmental cues (homeostasis) (Aird, 2008). On the other hand, 
activated endothelial cells (sometimes termed pro-inflammatory) are at the other end of the 
spectrum and characterised by acquiring adhesive (to circulating leukocytes and platelet), pro-
coagulant, and enhanced permeability properties, while also promoting vasoconstriction (Aird, 
2008). As inferred above, the generation of an activated endothelial cell phenotype can involve 
adaptive responses to physiological changes (to maintain homeostasis), or through non-adaptive 
responses due to exaggerated stimuli (pathological changes). On a different note, endothelial 
dysfunction during atherogenesis is regarded as a maladaptive response of activated endothelial 
cells, and is described as an abnormally hyper-adhesive endothelial cell phenotype due to increased 
expression of adhesion molecules (such as E-selectin and VCAM-1) which enhance monocyte 
adherence to the vascular wall, and is therefore classified as in a pro-inflammatory state (Aird, 
2008).  
Intriguingly, endothelial cells respond to the pattern of blood flow upon its surface. For example, in a 
straight part of an artery where blood flows is in a steady laminar state, the endothelial cells align in 
an elongated morphology in line with the direction of flow, whereas endothelial cells in areas of 
arterial branching and curvatures, where the blood flow becomes multi-directional and disturbed, 
the shape of endothelial cells is rounded (Nigro et al., 2011). In vitro experiments showed that static 
confluent endothelial cells also exhibit a rounded or polygonal morphology compared to exposure to 
laminar flow. As described above (in section 1.1), the straight segment of an artery is associated with 




whereas in the arterial branches where the flow is disturbed, endothelial cell dysfunction is 
prevalent and related to the development of atherosclerosis.  
4.1.2 Modulators of endothelial cell behaviour and function 
Vascular endothelial growth factor A (VEGF-A) and fibroblast growth factor 2 (FGF2) are among the 
widely described growth factors that support the differentiation of endothelial cells and play a 
significant role in angiogenesis (Cross and Claesson-Welsh, 2001). Reportedly, human adipose-
derived stem cells exhibit endothelial cell-like characteristics when cultured with VEGF-A and FGF2, 
determined through their expression of several key markers deemed to identify endothelial cells 
such as Platelet Endothelial Cell Adhesion Molecule-1 (PECAM-1), vWF, VE-cadherin and eNOS (Khan 
et al., 2017). In a similar study, recombinant VEGF-A addition to swine bone marrow-derived 
mesenchymal stem cells induced their expression of multiple endothelial cell markers, particularly 
PECAM-1, VE-cadherin and vWF (Ikhapoh et al., 2015). Additionally, the population of positive cells 
(for endothelial cell markers) significantly increased upon co-stimulation with angiotensin II and the 
cells organised into vessel networks when assessed within an in vitro angiogenesis assay (Ikhapoh et 
al., 2015). In another study, VEGF-A promoted proliferation and differentiation of human amniotic 
fluid derived-mesenchymal stem cells into endothelial cells (Tancharoen et al., 2017). In addition, 
human bone marrow-derived mesenchymal stem cells differentiated into cells positive for vWF with 
tube like formation within a Matrigel angiogenesis assay when stimulated with VEGF-A (Oswald et 
al., 2004).   
Other key regulators of endothelial cell growth include hepatocyte growth factor (HGF), insulin-like 
growth factors (IGF), and angiopoietin-like 5 (ANGPTL5). A study using human aorta derived-
mesenchymal stem cells showed upregulation in the expression of endothelial cell markers such as 
vWF, CD31, and KDR (or also known as VEGFR2) by flow cytometry analysis and the cells organised 
into tube-like structures when stimulated with hepatocyte growth factor (HGF) (Valente et al., 2016). 




CD133+ cells (Zhang et al., 2008). On a different note, IGF-1 is associated with the migration of 
endothelial cells, enhances tube formation, and promotes their survival through preventing 
apoptosis (Bach, 2015). In addition, with regards to angiogenesis, IGF-1  may prevent vessel 
regression from newly developed vessels (Jacobo and Kazlauskas, 2015).   
4.1.3 Gene and protein expression markers commonly associated with an 
endothelial cell  
The cell membrane of endothelial cells display a unique molecular organisation called junctional 
complexes which play a vital role in maintaining the integrity of vessels. These structures upon the 
endothelial cell membrane form bridging connections with partners on neighbouring endothelial 
cells within the inter-endothelial cleft. These connections are anchored to the endothelial cell 
cytoskeleton and therefore forms a solid binding mechanism between adjacent endothelial cells, and 
are commonly described as adhesion molecules. In addition to its important role in maintaining the 
integrity of the endothelium, these adhesion molecules can also be a useful tool to identify 
endothelial cells in a laboratory setting. Among the commonly use adhesion molecules as 
endothelial cell specific markers include VE-cadherin and PECAM-1, and their expression by 
disparate macrophage phenotypes are explored within this chapter.  
Vascular endothelial cadherin (VE-cadherin) is the main adhesion molecule that modulates 
endothelial cell permeability (Vestweber, 2008). It is comprised of calcium dependent adhesion 
molecules (cadherin) within the extracellular domain which serves to mediate adhesion with a 
complimentary motif upon neighbouring endothelial cells. VE-cadherin is a central molecule that 
regulates barrier function and endothelial permeability, in part through binding to VEGFR2 to block 
VEGF-VEGFR2 complex endocytosis and inhibiting subsequent VEGF signalling (Takahashi et al., 
2001). Activation of the VEGFR2 signalling pathway is associated with angiogenesis (Bates, 2010), 
whereby VE-cadherin molecules disengage to permit cell proliferation and migration to take place 




to form tube structures succeeding cell proliferation and migration (Wallez et al., 2006). PECAM-1 
(also known as cluster of differentiation 31; CD31) mediates endothelial cell interaction with 
circulating immune cells such as platelets and leukocytes (Dejana, 2004), but reportedly, may also 
mediate endothelial cell-cell junctions to maintain vascular integrity (Lertkiatmongkol et al., 2016).  
4.2 Aim of this chapter 
The aim of this chapter was to evaluate the expression of genes and proteins commonly associated 
with endothelial cells, in distinct human in vitro macrophage subsets, namely M-CSF directed, and 
GM-CSF directed macrophages in day-7, -11 and -14 polarisation in vitro.  
Subsequently, the dose dependent effects of VEGF-A, FGF2, IGF-1, HGF, and ANGPTL5 on endothelial 
cell-associated mRNA expression was determined in 7-day in vitro human macrophages. Next, EC-
related mRNA and protein expression were analysed following 4-day stimulation with EC-related 
growth factors. Lastly, a comparison of the expression patterns between primary macrophages and 
primary endothelial cells in vitro was conducted.  
4.3 Materials and Methods 
4.3.1 Macrophage culture  
Human monocyte-derived macrophages were isolated and generated as outlined in the methods 
sections 2.1 and 2.2. M-CSF and GM-CSF directed macrophages were maintained in culture for 7-, 
11- and 14-days according to the experimental protocol described in the methods section 2.3. In 
addition, magnetic-bead cell sorting and purification for pan monocytes were also performed to 
obtain pure CD14+ and CD16+ monocyte populations according to the later-mentioned protocol.  
Materials: 0.5% bovine serum albumin (BSA) in PBS, Pan Monocyte Isolation Kit (MACS Miltenyi 
Biotec; cat number : 130-096-537) [contains FcR Blocking Reagent (human Ig), Pan Monocyte Biotin-




on human monocytes), Anti-Biotin MicroBeads (MicroBeads conjugated to monoclonal anti-biotin 
antibodies)], autoMACS rinsing solution and MS Columns and MACS magnetic separators.  
Magnetic-bead cell sorting was performed according to the manufacturers protocol. The procedure 
was performed using pre-chilled solutions while keeping the cells cool throughout the procedure. 
Cell number was determined prior to cell sorting for a working total number of 1 x 10⁷ total cells. 
After a final HBSS wash (as in section 2.1.2), the cell pellet was resuspended in 40 µl of buffer before 
the addition of 10 µl of FcR blocking reagent and 10 µl of biotin-antibody cocktail. The preparation 
was mixed well and incubated for 5 minutes at 2-8oC. Next, 30 µl buffer was added followed by 20 µl 
of anti-biotin microbeads. After mixing well, the preparation was incubated for 10 minutes at 2-8oC.  
Magnetic separation was performed after the final incubation using MS columns inserted within the 
magnetic field of a MACS separator. The columns were activated by rinsing with 500 µl buffer before 
the cell suspensions were added to the columns. The flow-through (which contains pan-monocytes) 
were collected and the column washed with buffer for three times. This isolation technique yields 
enrichment of pure monocytes which consist of classical (CD14++CD16-), non-classical (CD14+CD16++) 
and intermediate (CD14++CD16+) monocyte populations. 
4.3.2 Stimulation of human macrophages with endothelial cell-associated 
growth factors 
Following seven days differentiation and maturation in culture, M-CSF polarised and GM-CSF 
directed macrophages were stimulated for 24 hours with either VEGF-A, FGF2, IGF-1, HGF or 
ANGPTL5 to assess their capacity to differentiate towards an endothelial cell (EC)-like phenotype. In 
the first instance, concentrations of 1 ng/ml, 10 ng/ml and 100 ng/ml  were assessed for dose-
dependent effects (Table 4.3.1) to determine the optimal dose for the subsequent experiments  
Stimulation with growth factors was undertaken for four days, with the media and growth factors 




Table 4.3.1 Endothelial cell-associated growth factors used for macrophage stimulation  
(VEGF-A = vascular endothelial growth factor A, FGF2 = fibroblast growth factor 2, IGF-1 = Insulin-like 
growth factor 1, HGF = Hepatocyte growth factor and ANPTL5 = Angiopoietin-like 5; Hm = human)  




Brand/Company Catalogue No. 
 
Hm VEGFA (165) IS 100 µg/ml 1, 10 and 100 MACS/Miltenyi Biotec 130-109-383  
Hm FGF2 100 µg/ml 1, 10 and 100 R&D System/Bio-techne 130-093-838  
Hm IGF-1 50 µg/ml 1, 10 and 100 MACS/Miltenyi Biotec 130-093-885  
Hm HGF 10 µg/ml 1, 10 and 100 Gibco®/Life Technologies PHG0254  
Hm ANGPTL5 5 µg/ml 1, 10 and 100 MACS/Miltenyi Biotec 130-086-125  
 
4.3.3 Culture of human umbilical vein endothelial cells 
Human umbilical vein endothelial cells (HUVECs) were used as a positive control for this study. 
HUVECs were maintained under culture conditions within Dulbecco’s modified Eagle's Medium 
(DMEM) (Sigma-Aldrich; PAA, E15-005) supplemented with endothelial cell growth media (Promo 
cell; C-22010), Penicillin/Streptomycin (100 U/ml Penicillin; 100 µg/ml streptomycin) (Invitrogen), 
10% Fetal Bovine/ Calf Serum (Gibco), 200 mM L-Glutamine and 10 mg/ml Gentamicin (PAA). All 
supplements were added using a syringe filter to prevent infection, mixed well, and stored at 4°C. 
HUVECs were cultured for three days (with a media and growth factor change after day two) prior to 






4.4.1 GM-CSF-directed macrophage maturation is associated with increased 
expression of EC-associated markers in comparison to M-CSF matured 
macrophages 
The mRNA and protein expression of the endothelial cell (EC) related markers PECAM-1 and VE-
cadherin were analysed in M-CSF and GM-CSF directed macrophages after 7-day, 11-day, and 14-day 
polarisation.  
M-CSF directed macrophage polarisation was associated with a significant upregulation in PECAM1 
mRNA levels at day 14 (3.6-fold change; P<0.05; n=6; Figure 4.4.1 a) compared to day-7 and -11, with 
no difference observed between day-7 and day-11 M-CSF polarised macrophages. Conversely, GM-
CSF polarised macrophages showed downregulation of PECAM1 mRNA levels at day-11 (23.2%; 
P<0.05; n=6; Figure 4.4.1 a) compared to their day-7 and day-14 counterparts (Figure 4.4.1 a). 
Comparisons between the two subsets revealed 7-day GM-CSF polarised macrophages expressed 
significantly higher PECAM1 mRNA levels relative to 7-day M-CSF directed macrophages (3.5-fold 
change; P<0.05; n=6; Figure 4.4.1 a), however, no changes at day-11 and day-14 between the two 
macrophage phenotypes were detected (Figure 4.4.1 a).  
Western blot analysis demonstrated that GM-CSF directed macrophages displayed markedly higher 
PECAM-1 protein expression compared to M-CSF polarised macrophages at all three  time points; 
day-7 (3.5-fold change; P<0.05; n=6; Figure 4.4.1 b), day-11 (5.6-fold change; P<0.05; n=6; Figure 
4.4.1 b), and day-14 (4.0 fold change; P<0.05; n=6; Figure 4.4.1 b). However, PECAM-1 protein 
expression remained constant across all time points within each macrophage phenotype (Figure 
4.4.1 b).  
Immunocytochemistry on 7-day differentiated macrophages showed a higher percentage of GM-CSF 
macrophages were positive for PECAM-1 expression (43.1% PECAM-1 positive) compared to M-CSF 













































Figure 4.4.1 PECAM-1 mRNA and protein expression in macrophage baseline cultures.  
(a) PECAM1 mRNA levels in M-CSF and GM-CSF macrophages expressed as fold change relative to 7-
day M-CSF directed control macrophages, (mean±SEM; n=6; * P < 0.05 denotes significant difference 
compared to day-7 and -11 M-CSF directed macrophages; # P < 0.05 denotes significant difference 
compared to day-7 and -14 GM-CSF directed macrophages; one-way ANOVA Tukey’s multiple 
comparison test).  
(b) Quantification and (c) representative western blots for PECAM-1 protein expression relative to the 
fold change of 7-day M-CSF directed control macrophages, (mean±SEM; n=6; * P < 0.05 denotes 
significant difference compared to day-7, -11, and -14 M-CSF directed macrophages; one-way 
ANOVA Tukey’s multiple comparison test). Stain free gel is shown as a loading control. (M-7, M-11, 
and M-14 = M-CSF directed macrophages at day-7, -11, and -14 respectively; GM-7, GM-11, and GM-
14 = GM-CSF directed macrophages at day-7, -11, and -14 respectively).  
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Figure 4.4.2 GM-CSF maturation increases human macrophage PECAM-1 protein expression 
compared to M-CSF matured macrophages.   
Representative images and quantification of immunofluorescent labelling for PECAM-1 expression in 
seven-day M-CSF or GM-CSF differentiated human macrophages. Green colour indicates PECAM-1 
immunopositivity, and blue indicates nuclei (DAPI counterstain). Scale bar represents 100 µM and is 
applicable to all panels. Data are expressed as percentage of PECAM-1 immuno-positive cells 





















VE-cadherin (CDH5) mRNA expression was significantly upregulated in M-CSF macrophage with 
increasing time in culture, with elevated expression at day-11 (21.0-fold change; P<0.01; n=6 Figure 
4.4.3 a) and day-14 (35.4-fold change; P<0.01; n=6 Figure 4.4.3 a), when compared to 7-day-M-CSF 
matured macrophages. As such, CDH5 mRNA levels in 14-day M-CSF matured macrophages were 
significantly increased compared to their day-11 counterparts (1.7-fold-change; P<0.05; n=6 Figure 
4.4.3 a).  
In contrast to the pattern observed within the M-CSF macrophage phenotype, GM-CSF matured 
macrophages exhibited comparable CDH5 mRNA levels at day-7 and day-11, but were significantly 
upregulated at day-14 (2.0-fold-change; P<0.05; n=6 Figure 4.4.3 a). Mirroring the expression of 
PECAM-1, 7-day matured GM-CSF macrophages expressed significantly higher CDH5 mRNA levels  
(15.4-fold change; P<0.01; n=6 Figure 4.4.3 a) than their 7-day M-CSF macrophage comparators. 
however, similar levels were observed at day-11 and day-14 between the two macrophage 
phenotypes (Figure 4.4.3 a).  
Similar to PECAM-1 protein expression, GM-CSF matured macrophages exhibited higher VE-cadherin 
protein expression compared to M-CSF macrophages at all time points; day-7 (3.0-fold change; P 
<0.01; n=6; Figure 4.4.3 b), day-11 (2.3-fold change; P <0.05; n=6; Figure 4.4.3 b), and day-14 (2.3-
fold change; P <0.05; n=6; Figure 4.4.3 b). However, no differences in VE-cadherin protein expression 
were detected across time points within each macrophage phenotype (Figure 4.4.3 b).  
Immunocytochemistry on 7-day differentiated macrophages showed a higher percentage of GM-CSF 
macrophages were positive for VE-cadherin expression (49.2% VE-cadherin positive) compared to M-
CSF macrophage (35.7% VE-cadherin positive, P<0.01; n=6; Figure 4.4.4). 













































Figure 4.4.3 VE-cadherin mRNA and protein expression in macrophage baseline cultures 
(a) CDH5 mRNA levels in M-CSF and GM-CSF macrophages expressed as fold change relative to 7-day 
M-CSF directed control macrophages, (mean±SEM; n=6; ** P <0.01 denotes significant difference 
compared to day-7 M-CSF directed macrophages; # P < 0.05 denotes significant difference compared 
to day-11 M-CSF directed macrophages; $ P < 0.05 denotes significant difference compared to day-7 
and -11 GM-CSF directed macrophages; one-way ANOVA Tukey’s multiple comparison test).  
(b) Quantification and (c) representative western blots for VE-cadherin protein expression relative to 
the fold change of 7-day M-CSF directed control macrophages, (mean±SEM; n=6; ** P < 0.01 denotes 
significant difference compared to day-7, -11, and -14 M-CSF directed macrophages; one-way 
ANOVA Tukey’s multiple comparison test). Stain free gel is shown as a loading control. (M-7, M-11, 
and M-14 = M-CSF directed macrophages at day-7, -11, and -14 respectively; GM-7, GM-11, and GM-
14 = GM-CSF directed macrophages at day-7, -11, and -14 respectively).  
Refer to appendix B; (9.1.3) for CT values and (9.1.4) for full blot image. 
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Figure 4.4.4 GM-CSF maturation increases human macrophage VE-cadherin protein 
expression compared to M-CSF matured macrophages   
Representative images and quantification of immunofluorescent labelling for VE-cadherin expression 
in seven-day M-CSF or GM-CSF differentiated human macrophages. Red colour indicates VE-cadherin 
immunopositivity, and blue indicates nuclei (DAPI counterstain). Scale bars represent 200 µM. Data 
are expressed as percentage of VE-cadherin immuno-positive macrophages (mean±SEM; n=6; **P < 


























4.4.2 The effect of endothelial cell-associated growth factors on macrophage 
subset expression of endothelial cell-related genes 
The mRNA expression of PECAM1 and CDH5 (VE-cadherin) were analysed 24 hours after stimulation 
with endothelial-cell related growth factors, namely VEGF-A, FGF2, IGF-1, HGF and ANGPTL5 at 1 
ng/ml, 10 ng/ml and 100 ng/ml concentrations, in seven-day differentiated M-CSF and GM-CSF 
macrophage subsets. The aim of this sub-study was to determine the optimal dose of the associated 
growth factors to be used for subsequent experiments.  
Both VEGF-A and FGF2 stimulation increased M-CSF macrophage PECAM1 and CDH5 mRNA 
expression in a dose-dependent manner (Figure 4.4.5 a, and Figure 4.4.6 a; see a summary of results 
in Figure 4.4.7). Specifically, 1 ng/ml, 10 ng/ml, and 100ng/ml of VEGF-A upregulated PECAM-1 
mRNA levels in M-CSF macrophages (1.9-fold change; P<0.05, 2.7-fold change; P<0.01 and 3.7-fold 
change; P<0.05, respectively; n=6; Figure 4.4.5 a). Between doses, PECAM-1 mRNA levels were 
significantly higher in 10 ng/ml (1.5-fold change; P<0.05; n=6; Figure 4.4.5 a) and 100 ng/ml (1.9-fold 
change; P<0.05; n=6; Figure 4.4.5 a). VEGF-A treated M-CSF macrophages compared to cells 
stimulated with 1 ng/ml VEGF-A, with no significant difference between the 10 ng/ml and 100 ng/ml 
doses of VEGF-A (Figure 4.4.5 a). 
Similarly, 1 ng/ml, 10 ng/ml and 100 ng/ml concentrations of FGF2 consistently up-regulated 
PECAM-1 mRNA expression in M-CSF macrophages (2.2-fold change, P<0.01; 2.8-fold change; P<0.01 
and 3.8-fold change; P<0.05, respectively; n=6; Figure 4.4.5 a), although no differences were 
detected between the different FGF2 concentrations.  
With regard to CDH5 (VE-cadherin) mRNA expression, concentrations of 1 ng/ml, 10 ng/ml and 100 
ng/ml of VEGF-A comparably upregulated VE-cadherin mRNA expression in M-CSF polarised 
macrophages (2.6-fold change; P<0.05, 2.5-fold change; P<0.05 and 2.9-fold change; P<0.01, 
respectively; n=6; Figure 4.4.6 a). Similarly, 1 ng/ml, 10 ng/ml and 100 ng/ml concentrations of FGF2 




P<0.05 and 3.6-fold change; P<0.01, respectively; n=6; Figure 4.4.6 a), although the  greatest 
increase in CDH5 mRNA expression was detected with 100 ng/ml FGF2 (1.5-fold change; P<0.05; 
n=6; Figure 4.4.6 a) when compared to the 1 ng/ml concentration. 
The other growth factors tested, IGF-1, HGF and ANGPTL5, did not statistically affect either PECAM1 
or CDH5 mRNA expression in M-CSF macrophage macrophages when compared to unstimulated 
control cells (Figure 4.4.5 a, and Figure 4.4.6 a). 
As opposed to M-CSF polarised macrophages, the mRNA expression of PECAM1 and CDH5 was not 
affected in GM-CSF directed macrophages by the addition of any of the endothelial cell-related 
growth factors (Figure 4.4.5 b and Figure 4.4.6 b).  
Based upon the above findings alongside evidence from previous studies (Table 4.4.1), the 
concentration for all growth factors to exert optimal effects in vitro was deemed to be as 50 ng/ml, 
and was therefore used in all subsequent associated experiments.  
Table 4.4.1 References for endothelial cell-related growth factors concentrations used in 
vitro  
(VEGF-A = vascular endothelial growth factor A, FGF2 = fibroblast growth factor 2, IGF-1 = Insulin-like 
growth factor 1, HGF = Hepatocyte growth factor and ANPTL5 = Angiopoietin-like 5)  
Factors Concentration (ng/ml) References 
Human VEGF-A (165) 2, 25, 50  (Ikhapoh et al., 2015) 
Human FGF2  10  (Khan et al. 2017) 
HGF 2.5, 5, 10, and 70  (Valente et al. 2016) 
Human IGF-1 100  (Huat et al., 2014; Supeno et al., 2013) 
ANGPTL5 100  (Zhang et al., 2008) 
  















Figure 4.4.5 PECAM-1 mRNA expression in human macrophages stimulated with endothelial 
cell related growth factors for 24 hours. 
PECAM-1 mRNA expression in seven-day differentiated (a) M-CSF macrophages and (b) GM-CSF 
macrophages after 24 hours stimulation with 1 ng/ml, 10 ng/ml and 100 ng/ml of VEGF-A, FGF2, IGF-
1, HGF or ANGPTL5 expressed as fold change relative to unstimulated control M-CSF directed and 
GM-CSF-polarised macrophages, respectively, (*P < 0.05 and ** P <0.01 denotes significant 
difference compared to control M-CSF macrophages, # P <0.05 denotes significant difference 
compared to VEGF-A 10 ng/ml and 100 ng/ml; one-way ANOVA post-hoc Tukey’s multiple 
comparison test; mean ±SEM; n=6). 
Refer to appendix B (9.1.5) for CT values.  
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Figure 4.4.6 VE-cadherin mRNA expression in human macrophages stimulated with 
endothelial cell related growth factors for 24 hours. 
VE-cadherin mRNA expression in seven-day differentiated (a) M-CSF macrophages and (b) GM-CSF 
macrophages after 24 hours stimulation with 1 ng/ml, 10 ng/ml and 100 ng/ml of VEGF-A, FGF2, IGF-
1, HGF or ANGPTL5 expressed as fold change relative to unstimulated control M-CSF directed and 
GM-CSF-polarised macrophages, respectively, (*P < 0.05 and ** P <0.01 denotes significant 
difference compared to control M-CSF macrophages, # P < 0.05 denotes significant difference 
compared to 100 ng/ml FGF2; one-way ANOVA post-hoc Tukey’s multiple comparison test; mean 
±SEM; n=6).  
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  PECAM-1 mRNA VE-cadherin mRNA 
M-CSF 
Baseline 1.0 1.0 
VEGF-A 1 ng/ml 1.9 2.6 
VEGF-A 10 ng/ml 2.7 2.5 
VEGF-A 100 ng/ml 3.7 2.9 
FGF2 1 ng/ml 2.2 2.4 
FGF2 10 ng/ml 2.8 3.0 
FGF2 100 ng/ml 3.8 3.6 
GM-CSF 
Baseline 1.0 1.0 
VEGF-A 1 ng/ml 1.2 0.9 
VEGF-A 10 ng/ml 1.1 1.1 
VEGF-A 100 ng/ml 1.2 1.2 
FGF2 1 ng/ml 1.5 1.5 
FGF2 10 ng/ml 1.2 1.3 
FGF2 100 ng/ml 1.3 1.2 
Figure 4.4.7 Summary of results for the effect of 24 hour stimulation with VEGF-A or FGF2 on 
the mRNA expression of PECAM1 and CDH5 (VE-cadherin) in 7-day differentiated 
macrophages 
Fold change in mRNA expression of endothelial cell-associated markers (PECAM1 and CDH5) in 
seven-day M-CSF or GM-CSF differentiated macrophages after 24 hours stimulation with three 






4.4.3 Upregulation of PECAM-1 and VE-cadherin upon 4-days stimulation 
with VEGF-A and FGF2 in M-CSF macrophage 
Next, the effect of four day stimulation with 50 ng/ml of VEGF-A, FGF2, HGF, IGF-1, or ANGPTL5 on 
PECAM1 and CDH5 (VE-cadherin) mRNA and protein expression were determined in seven-day M-
CSF and GM-CSF differentiated macrophages. Consistent with the previous findings after four day 
stimulation, VEGF-A and FGF2 upregulated PECAM-1 mRNA and protein expression in M-CSF 
macrophages, but was unaffected by stimulation with IGF-1, HGF and ANGPTL5 (Figure 4.4.8 a). 
Individually, PECAM1 mRNA expression was significantly upregulated by 1.7-fold in both VEGF-A 
(P<0.01; n=6; Figure 4.4.8 a) and FGF2 (P<0.05; n=6; Figure 4.4.8 a) in M-CSF macrophage, when 
compared to unstimulated control cells. At the protein level, Western blotting revealed PECAM-1 
expression was increased in M-CSF macrophages 4.1-fold and 7.0-fold-with VEGF-A and FGF2, 
respectively (P<0.05; n=6; Figure 4.4.8 b and c).  
Similarly, immunocytochemistry demonstrated that VEGF-A or FGF2 stimulation resulted in a greater 
percentage of macrophages positive for PECAM-1 (49.6% and 42.2%, respectively) compared to 


















Figure 4.4.8 PECAM-1 mRNA and protein expression in M-CSF macrophages stimulated with 
endothelial cell related growth factors for four-days.  
(a) PECAM1 mRNA levels in mature M-CSF macrophages following four-day stimulation with 50 
ng/ml VEGF-A, FGF2, IGF-1, HGF and ANGPTL5 in seven-day M-CSF differentiated human 
macrophages, expressed as fold change relative to unstimulated 11-day M-CSF control macrophages, 
(mean±SEM; n=6; * P < 0.05 and ** P <0.01 denotes significant difference compared to unstimulated 
11-day-M-CSF directed macrophages; one-way ANOVA Tukey’s multiple comparison test).  
(b) Quantification and (c) representative western blots for PECAM-1 protein expression, expressed as 
fold change relative to unstimulated 11-day M-CSF directed control macrophages, (mean±SEM; n=6; 
* P < 0.05 and ** P <0.01 denotes significant difference compared to unstimulated 11-day-M-CSF 
directed macrophages; one-way ANOVA Tukey’s multiple comparison test). Stain free gel is shown as 
a loading control. 
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Figure 4.4.9 Immunofluorescence localisation of PECAM-1 in M-CSF macrophages stimulated 
with endothelial cell-related growth factors for four-day. 
Representative images of immunofluorescent labelling for PECAM-1 expression following four-day 
stimulation with 50 ng/ml VEGF-A, FGF2, IGF-1, HGF and ANGPTL5 in seven-day M-CSF differentiated 
human macrophages. Green colour indicates PECAM-1 immunopositivity, and blue indicates nuclei 
(DAPI counterstain). Scale bar in lower right panel represents 100 µM and applicable to all panels. 
















Figure 4.4.10 Quantification of immunofluorescence cell positivity of PECAM-1 in M-CSF 
macrophages stimulated with endothelial-cell related growth factors for four-days. 
Quantification of immunofluorescent labelling for PECAM-1 expression following four-day 
stimulation with 50 ng/ml VEGF-A, FGF2, IGF-1, HGF or ANGPTL5 in seven-day M-CSF differentiated 
human macrophages. Data are expressed as percentage of PECAM-1 immuno-positive macrophages, 
(mean ±SEM; n=6; *P < 0.05 denotes significant difference compared to unstimulated M-CSF 
macrophages; one-way ANOVA Tukey’s multiple comparison test). Refer to Figure 4.4.9 for 

































In regard to VE-cadherin expression, stimulation of M-CSF matured macrophages with individual 
endothelial cell-related growth factors for four-days significantly upregulated VE-cadherin protein 
expression (4.2, 7.3, 3.9, 3.9 and 3.8-fold increase for VEGF-A, FGF2, IGF-1, HGF and ANGPTL5 
respectively; P <0.05 except for FGF2 P <0.01; n=6; Figure 4.4.11 b and c), as assessed through 
Western blotting. Mirroring these findings, immunocytochemistry for VE-cadherin demonstrated all 
endothelial cell-related growth factors increased the percentage of M-CSF matured macrophages 
expressing VE-cadherin (ranging between 40.4% to 47.4%; P<0.05, n=6; Figure 4.4.12 and Figure 
4.4.13), when compared to unstimulated control M-CSF macrophages (32.6% positive; Figure 4.4.12 
and Figure 4.4.13).  
However, CDH5 mRNA levels were not affected by any of the factors with the exception of FGF2 
which in opposition to the protein levels, downregulated CDH5 (VE-cadherin) mRNA expression 
(45%; P<0.01; n=6; Figure 4.4.11 a).  
On the other hand, qPCR, Western blotting and immunocytochemical analyses revealed that the 
mRNA and protein expression of PECAM-1 and VE-cadherin were unaffected in GM-CSF matured 
macrophages, upon subsequent four-day stimulation with any of the endothelial cell-related growth 



















Figure 4.4.11 VE-cadherin mRNA and protein expression in M-CSF macrophages stimulated 
with endothelial cell-related growth factors for four-days.  
(a) CDH5 (VE-cadherin) mRNA expression in mature M-CSF macrophages following four-day 
stimulation with 50 ng/ml VEGF-A, FGF2, IGF-1, HGF and ANGPTL5 in seven-day M-CSF differentiated 
human macrophages, expressed as fold change relative to unstimulated 11-day M-CSF control 
macrophages, (mean±SEM; n=6; ** P <0.01 denotes significant difference compared to unstimulated 
11-day-M-CSF directed macrophages; one-way ANOVA Tukey’s multiple comparison test).  
(b) Quantification and (c) representative western blots for VE-cadherin protein expression, expressed 
as fold change relative to unstimulated 11-day M-CSF directed control macrophages, (mean±SEM; 
n=6; * P < 0.05 and ** P <0.01 denotes significant difference compared to unstimulated 11-day-M-
CSF directed macrophages; one-way ANOVA Tukey’s multiple comparison test). Stain free gel is 
shown as a loading control. 
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Figure 4.4.12 Immunofluorescence localisation of VE-cadherin in M-CSF macrophages 
stimulated with endothelial cell-related growth factors for four-days. 
Representative images of immunofluorescent labelling for VE-cadherin expression following four-day 
stimulation with 50 ng/ml VEGF-A, FGF2, IGF-1, HGF and ANGPTL5 in seven-day M-CSF differentiated 
human macrophages. Red colour indicates VE-cadherin immunopositivity, and blue indicates nuclei 




























Figure 4.4.13 Quantification of immunofluorescence cell positivity of VE-cadherin in M-CSF 
macrophages stimulated with endothelial cell-related growth factors for four-days. 
Quantification of immunofluorescent labelling for VE-cadherin expression following four-day 
stimulation with 50 ng/ml VEGF-A, FGF2, IGF-1, HGF and ANGPTL5 in seven-day M-CSF differentiated 
human macrophages. Data are expressed as percentage of VE-cadherin immuno-positive, (mean 
±SEM; n=6). * P < 0.05 denotes significant difference compared to M-CSF macrophages; one-way 
ANOVA Tukey’s multiple comparison test). Refer Figure 4.4.12 for representative images.  
 
  











































Figure 4.4.14 PECAM-1 mRNA and protein expression in GM-CSF macrophages stimulated 
with endothelial cell-related growth factors for four-days.  
(a) PECAM1 mRNA expression in mature GM-CSF macrophages following four-day stimulation with 
50 ng/ml VEGF-A, FGF2, IGF-1, HGF and ANGPTL5 in seven-day GM-CSF differentiated human 
macrophages, expressed as fold change relative to unstimulated 11-day GM-CSF control 
macrophages, (mean±SEM; n=6).  
(b) Quantification and (c) representative western blots for PECAM-1 protein expression, expressed as 
fold change relative to unstimulated 11-day GM-CSF directed control macrophages, (mean±SEM; 
n=6). Stain free gel is shown as a loading control. 
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Figure 4.4.15 Immunofluorescence localisation of PECAM-1 in GM-CSF macrophages 
stimulated with endothelial cell-related growth factors for four-days. 
Representative images of immunofluorescent labelling for PECAM-1 expression following four-day 
stimulation with 50 ng/ml VEGF-A, FGF2, IGF-1, HGF and ANGPTL5 in seven-day GM-CSF 
differentiated human macrophages. Green colour indicates PECAM-1 immunopositivity, and blue 
indicates nuclei (DAPI counterstain). Scale bars represent 100 µM. Refer to Figure 4.4.16 for 












Figure 4.4.16 Quantification of immunofluorescence cell positivity of PECAM-1 in GM-CSF 
macrophages stimulated with endothelial cell-related growth factors for four-days. 
Quantification of immunofluorescent labelling for PECAM-1 expression following four-day 
stimulation with 50 ng/ml VEGF-A, FGF2, IGF-1, HGF and ANGPTL5 in seven-day GM-CSF 
differentiated human macrophages. Data are expressed as percentage of PECAM-1 immuno-positive 
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Figure 4.4.17 CDH5 (VE-cadherin) mRNA and protein expression in GM-CSF macrophages 
stimulated with endothelial cell-related growth factors for four-days.  
(a) CDH5 (VE-cadherin) mRNA expression in mature GM-CSF macrophages following four-day 
stimulation with 50 ng/ml VEGF-A, FGF2, IGF-1, HGF and ANGPTL5 in seven-day GM-CSF 
differentiated human macrophages, expressed as fold change relative to unstimulated 11-day GM-
CSF control macrophages, (mean±SEM; n=6).  
(b) Quantification and (c) representative western blots for VE-cadherin protein expression, expressed 
as fold change relative to unstimulated 11-day GM-CSF directed control macrophages, (mean±SEM; 
n=6). Stain free gel is shown as a loading control. 
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Figure 4.4.18 Immunofluorescence localisation of VE-cadherin in GM-CSF macrophages 
stimulated with endothelial cell-related growth factors for four-days. 
Representative images of immunofluorescent labelling for VE-cadherin expression following four-day 
stimulation with 50 ng/ml VEGF-A, FGF2, IGF-1, HGF and ANGPTL5 in seven-day GM-CSF differentiated 
human macrophages. Red colour indicates VE-cadherin immunopositivity, and blue indicates nuclei 

























Figure 4.4.19 Quantification of immunofluorescence cell positivity of VE-cadherin in GM-CSF 
macrophages stimulated with endothelial cell-related growth factors for four-days. 
Quantification of immunofluorescent labelling for VE-cadherin expression following four-day 
stimulation with 50 ng/ml VEGF-A, FGF2, IGF-1, HGF and ANGPTL5 in seven-day GM-CSF 
differentiated human macrophages. Data are expressed as percentage of VE-cadherin immuno-
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M-CSF 1.0 1.0 33.5% 1.0 1.0 32.6% 
VEGF-A 1.7 4.1 49.6% 0.9 4.2 46.7% 
FGF2 1.7 7.0 42.2% 0.5 7.3 47.4% 
IGF-1 1.3 1.5 38.3% 0.8 3.9 43.8% 
HGF 1.3 1.3 35.2% 0.8 3.9 41.4% 
ANGPTL5 0.9 1.2 40.0% 0.8 3.8 40.4% 
GM-CSF 1.0 1.0 43.3% 1.0 1.0 48.0% 
VEGF-A 1.1 1.2 37.0% 0.9 1.0 44.6% 
FGF2 1.1 1.1 42.2% 1.0 1.0 46.4% 
IGF-1 1.1 1.1 39.3% 1.1 0.9 42.2% 
HGF 1.2 1.1 36.8% 0.9 1.0 42.1% 
ANGPTL5 0.9 0.9 40.1% 1.1 1.2 40.0% 
Figure 4.4.20 Summary of results for the effects of 4-day stimulation with endothelial cell-
related growth factors on the mRNA and protein expression of PECAM-1 and CDH5 (VE-
cadherin) in 7-day differentiated macrophages. 
Fold change in mRNA and protein expression of endothelial cell-associated markers in seven-day M-
CSF or GM-CSF differentiated macrophages following 4-day stimulation with individual endothelial 
cell-related growth factors, relative to respective M-CSF or GM-CSF unstimulated macrophages 
(baseline). Percentage of PECAM-1 and VE-cadherin immuno-positive macrophages are also included. 






4.4.4 The expression of endothelial cell-related markers in M-CSF and GM-
CSF matured macrophages relative to human umbilical vascular 
endothelial cell levels 
The expression of PECAM-1 and CDH5 (VE-cadherin) in human macrophage subsets were compared 
to levels within human primary endothelial cells (human umbilical vein endothelial cells, HUVEC). 
Although baseline macrophage cultures expressed detectable levels of PECAM-1 and VE-cadherin, 
the mRNA levels were significantly lower compared to HUVECs (Figure 4.4.21 a, and Figure 4.4.22 a). 
Specifically, PECAM-1 mRNA expression in HUVECs was 130-fold greater compared to both 
macrophage subsets, irrespective of time in culture (P<0.0001, n=6, Figure 4.4.21 a). VE-cadherin 
mRNA expression in HUVECs was even more dramatically increased (55000-fold higher) compared to 
both macrophage subsets at all time points (P<0.0001, n=6, Figure 4.4.22 a). 
At the protein level, HUVEC expression of PECAM-1 and VE-cadherin were 15.0-fold and 17.7-fold 
higher compared to both macrophage subsets at all time points (P<0.0001, n=6, Figure 4.4.21 b, and 

































Figure 4.4.21 PECAM-1 mRNA and protein expression in human macrophage subsets and 
human umbilical vein endothelial cells.  
(a) PECAM-1 mRNA expression in M-CSF and GM-CSF macrophage subsets and HUVECs after 8-, 11-, 
and 14-days in culture, expressed as fold change relative to 8-day M-CSF macrophages. (****P < 
0.0001 denotes significant difference compared to macrophages under all conditions; ANOVA Tukey’s 
multiple comparison test).  
(b) Quantification and (c) representative western blots for PECAM-1 protein expression, expressed as 
fold change relative to 8-day M-CSF macrophages, (****P < 0.0001 denotes significant difference 
compared to macrophages under all conditions; ANOVA Tukey’s multiple comparison test). Stain free 
gel is shown as a loading control (HUVEC = human umbilical vein endothelial cell, MWM = molecular 
weight marker).  
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Figure 4.4.22 CDH5 (VE-cadherin) mRNA and protein expression in human macrophages and 
human umbilical vein endothelial cells.  
(a) CDH5 (VE-cadherin) mRNA levels in M-CSF and GM-CSF macrophage subsets and HUVECs after 8-, 
11-, and 14-days in culture, expressed as fold change relative to 8-day M-CSF macrophages, (****P < 
0.0001 denotes significant difference compared to macrophages under all conditions; ANOVA Tukey’s 
multiple comparison test).  
(b) Quantification (c) representative western blots for VE-cadherin protein expression, expressed as 
fold change relative to 8-day M-CSF macrophages, (****P < 0.0001 denotes significant difference 
compared to macrophages under all conditions; ANOVA Tukey’s multiple comparison test). Stain free 
gel is shown as loading control (HUVEC = human umbilical vein endothelial cell, MWM = molecular 
weight marker).  
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Day-7 1.0 1.0 31.4% 1.0 1.0 35.7% 
Day-11 1.1 1.0 NA 21.0 1.9 NA 
Day-14 3.6 1.2 NA 35.4 1.5 NA 
GM-CSF 
Day-7 3.5 3.5 43.1% 15.4 3.0 49.2% 
Day-11 0.8 5.6 NA 18.0 4.2 NA 
Day-14 3.3 4.8 NA 30.2 3.5 NA 
HUVEC   130.3 15.0 NA 5.5X104 17.7 NA 
Figure 4.4.23 Summary of results for the relative mRNA and protein expression of PECAM-1 
and VE-cadherin in baseline macrophage subsets and HUVECs. 
Fold change in mRNA and protein expression (by western blotting) of endothelial cell-associated 
markers in baseline macrophage subsets after seven-, eleven- and fourteen-day differentiation and 
seven-day HUVECs. All data expressed as fold change relative to 7-day M-CSF directed macrophages, 
with red highlighting indicating significantly increased expression and green highlighting indicating 
significantly decreased levels. Percentage of immuno-positive cells for PECAM-1 and VE-cadherin 









In this study, it is demonstrated that in vitro human PBMC-derived macrophages under culture 
conditions express detectable levels of proteins commonly used as markers for endothelial cells 
(Goncharov et al., 2017), namely PECAM-1 and VE-cadherin. Echoing the findings in the previous 
results chapter which assessed VSMC-related markers, baseline GM-CSF directed macrophages (GM-
Mac) showed higher expression of the endothelial cell-related markers compared to M-CSF directed 
macrophage (M-Mac). In addition to these two markers, vWF was also expressed by macrophage 
cultures in this study (results were not shown).  
Supporting the observations within this chapter, macrophages derived from human peripheral blood 
(CD34− CD14+) monocytes and stimulated for four weeks with VEGF-A, FGF2 or IGF-1 were shown to 
express the endothelial cell markers vWF, VE-cadherin and nitric oxide synthase (NOS) through FACS 
analysis and RT-PCR, without losing expression of hematopoietic lineage markers such as CD45 and 
CD68 (Schmeisser et al., 2001). Interestingly, it was demonstrated that these cells not only assemble 
clusters or colonies in vitro (as observed in this thesis, previous chapter 3.4.1), but they also formed 
tube-like structures upon Matrigel, a common approach to analyse angiogenesis formation  
(Schmeisser et al., 2001). It is essential to highlight that these cells were not deemed as circulating 
mesenchymal stem cells (CD34 positive cells), with previous reports demonstrating that cord-blood 
and peripheral blood derived CD34+ cells express VE-cadherin (Peichev et al., 2000). Circulating 
mesenchymal stem cells are found within the peripheral blood of healthy individuals at a low level, 
but can increase in number under certain pathological conditions such as bone sarcoma (Bian et al., 
2009) and following corneal injury (Lan et al., 2012). Additionally, circulating stem cells may also 
contribute to the formation of osteoblast-like cells, and are associated with vascular calcification in 
atherosclerosis (Leszczynska and Murphy, 2018). Besides CD34, other cell-surface markers that can 
be used to distinguish circulating stem cells from the monocyte/macrophage lineage include CD90, 




In a different study, macrophages from transgenic CX3CR1GFP/GFP mice were shown to express 
PECAM-1 (CD31) by immunofluorescence staining and harbour the capacity to form vascular 
networks within a subcutaneous angiogenesis assay (Barnett et al., 2016). Similarly deploying a 
subcutaneous angiogenesis assay, macrophages formed a network of interconnected PECAM-1 
positive cells within wild type C57BL/6J mice. In addition, supplementation with pro-angiogenic 
growth factors (such as VEGF) and pro-inflammatory cytokines (such as IFNγ and GM-CSF) induced 
macrophages to develop similar angiogenic-like networks (Barnett et al., 2016). Taken together, the 
findings above alongside those presented within this chapter support the notion that macrophages 
can express endothelial-related cell markers under certain conditions, and highlight GM-CSF as a 
potential modulator of this ability.  
Nevertheless, in this chapter it is shown that the expression of PECAM-1 and VE-cadherin by both in 
vitro macrophage subsets (M-Mac and GM-Mac) were low compared to primary endothelial cells 
(HUVEC) suggesting that the PECAM-1 and VE-cadherin-expressing macrophages are non-identical to 
endothelial cells-lineage but ostensibly of leukocyte-lineage with the ability to display endothelial 
cell-like characteristics. This further affirms monocyte/macrophage's heterogeneity and plasticity 
concepts, and that they can potentially be considered as a form of progenitor cell.   
The peripheral blood used in this study to isolate monocytes was obtained from healthy donors, 
suggesting that very low numbers of circulating mesenchymal stem cells or mature endothelial cells 
would be present, which is important as these cell types are commonly associated with 
atherosclerosis (Boos et al., 2007). Circulating endothelial cells are identified as a population of 
mature cells that have detached from the vessel wall following vessel damage, with their endothelial 
cell population identified through expression of CD146 (Goon et al., 2006). Reportedly, higher 
numbers of circulating endothelial cells (CD146 positive) are present within the whole blood of 
coronary artery disease patients (such as those displaying unstable angina or myocardial infarction) 




cell are increased within patients with severe atherosclerotic disease, thus their quantification can 
potentially be used as a bio-marker and therefore predict risk of future cardiovascular events (Boos 
et al., 2007). Therefore, the possibility that circulating endothelial cells contributed and/or were 
responsible for the marked PECAM-1 and VE-cadherin levels observed within the in vitro 
macrophages studies included within this chapter is highly unlikely, as the monocytes were isolated 
from healthy volunteers. Moreover, the culture media used in this study supports the differentiation 
and maintenance of monocyte/macrophage populations and is not recommended for endothelial 
cells, therefore, theoretically any possible circulating (mature) endothelial cells or stem/progenitor 
cells should have a reduced chance of survival under the culture conditions deployed in this study.  
Furthermore, the isolation of blood-derived monocytes was also performed through deployment of 
an indirect magnetic-bead cell-sorting technique which yields highly pure unlabelled monocytes 
(CD14+) before further adherence separation. Pertinently, CD14+ monocytes obtained from healthy 
individuals and chronic myeloid leukaemia patients potently supressed the growth of in vitro 
haematopoietic progenitor cells (i.e CD34+) (Heissig et al., 2000). In another study, it was 
demonstrated that endothelial cell colonies do not survive in the presence of 
monocyte/macrophage colonies (Lindner et al., 1997). Therefore, these two lines of evidence 
strongly suggest that it is likely the cells isolated and assessed within the studies described in this 
chapter are of a monocyte/macrophage lineage and not from any contaminating circulating 
endothelial cells or their progenitors.  
In line with the previous results chapter, in vitro GM-CSF matured/polarised human monocyte-
derived macrophages (GM-Mac) displayed higher expression levels of the assessed endothelial cell-
related markers than their M-CSF differentiated (M-Mac) counterparts. As emphasised before, GM-
CSF is associated with inducing a pro-inflammatory macrophage phenotype and taken together, the 
results in this chapter and its predecessor strongly suggest that GM-CSF induces macrophages to 




by their expression of specific genes/proteins. This implies that in vitro peripheral blood-derived 
macrophages following polarisation with colony stimulating factors, mainly GM-CSF, exhibit 
progenitor potential and have the capacity to trans-differentiate towards other vascular cell types 
such as VSMCs and ECs. This raises question whether M-Mac and GM-Mac subsets can behave like 
vascular wall-chameleon cells, differentiating into any cell type. As such, it will be interesting to 
further assess the potential of in vitro macrophages under the direction of M-CSF or GM-CSF to 
acquire properties of other resident vascular cells such as fibroblasts, which is a common cell type 
located within the connective tissue surrounding the vascular wall and perivascular adipocytes which 
play an important regulatory role during vascular inflammation (Britton and Fox, 2011; Stenmark et 
al., 2013).  
Interestingly, GM-CSF has also been shown to promote the development and function of endothelial 
progenitor cells (EPCs) (Cho et al., 2003; Qiu et al., 2014; Wang et al., 2009). In particular, GM-CSF 
was demonstrated to promote the re-endothelialisation of injured arteries within a rabbit balloon-
injury model, assessed through cellular expression of CD31 (PECAM-1) (Cho et al., 2003). This 
beneficial effect was attributed to the enhanced mobilisation and growth of EPCs at the site of 
vascular injury. However, the validative in vitro aspects of the study relied upon the use of PBMCs 
and did not assess if the EPCs (CD31+ cells) were of a monocytic lineage. Indeed, two further studies 
(Qiu et al., 2014; Wang et al., 2009) utilised mouse bone marrow-derived cells and PBMCs, 
respectively, to generate EPCs through culture in ‘endothelial cell culture media’ supplemented with 
GM-CSF. In both studies the EPCs were characterised and validated through their expression of 
CD31, ability to form colonies, and capacity to uptake modified lipoproteins (acetylated-LDL), which 
are all properties characteristic of macrophages, including CD31 expression in GM-CSF matured 
macrophages as shown in this chapter. Again, the possibility that the ‘EPCs’ were not of monocyte 
origin was not determined. Consequently, given the findings within this chapter it can be speculated 




endothelial cell-like phenotype that can play a protective barrier function role during vascular injury, 
and may have been previously mis-identified as endothelial progenitor cells. Although not assessed 
within this chapter, it would be pertinent to evaluate if indeed GM-CSF polarised macrophages 
acquire endothelial cell properties, in addition to simply elevating their expression of PECAM-1 
(CD31) and VE-cadherin. 
Surprisingly, stimulation with VEGF-A or FGF2, which both support phenotypic modulation of 
endothelial cells (Cross and Claesson-Welsh, 2001) endows M-CSF directed macrophages with 
endothelial cell-like characteristics as inferred by the up-regulation of PECAM-1 and VE-cadherin. 
However, neither growth factor altered the expression levels of the endothelial cell-related 
genes/proteins in GM-CSF directed macrophages. Indeed, it was interesting to note that the 
increased PECAM-1 and VE-cadherin expression induced in M-CSF macrophages through stimulation 
with VEGF-A or FGF2 brought the expression to comparable levels as those detected in unstimulated 
GM-CSF matured macrophages. These findings infer that GM-CSF polarised macrophages may 
behave as a well-differentiated (or stable) phenotype compared to M-CSF directed macrophages, 
and that the M-CSF-directed macrophage population can be further modulated into EC-like cells or a 
proangiogenic phenotype through stimulation with the angiogenesis-associated growth factors 
VEGF-A or FGF2. Furthermore, both VEGF-A and FGF2 are considered as pro-inflammatory cytokines 
(Andrés et al., 2009; Reinders et al., 2003), thus in the presence of these growth factors M-CSF 
macrophages may potentially shift from an anti-inflammatory subset (Di Gregoli et al., 2017; 
Johnson et al., 2014; Johnson et al., 2008), towards a more pro-inflammatory phenotype, behaving 
more closely to their GM-CSF counterparts.  
Another exciting finding within this chapter is the inverse relationship between the mRNA and 
protein expression of VE-cadherin in M-CSF directed macrophages, particularly under stimulation 
with FGF2. This novel observation suggests FGF2 induces a post-translational mechanism in M-CSF 




dependent process, and warrants further investigation.  Indeed, the post-transcriptional regulation 
of VE-cadherin forms the main body of work within the next chapter.  
4.6 Conclusion  
The findings within this chapter demonstrate that in vitro human monocyte-derived macrophages 
express genes and proteins which are commonly associated with endothelial cells, supporting the 
proposition that primary macrophages harbour the potential to trans-differentiate towards an 
endothelial cell-like phenotype. Additionally, macrophage polarisation towards pro-inflammatory 
and anti-inflammatory phenotypes modulates expression of endothelial cell-associated markers, 
with GM-CSF-directed maturation favouring trans-differentiation towards an endothelial cell-like 
phenotype. Nevertheless, the trans-differentiation of macrophages into an endothelial cell-like 
phenotype is probably not permanent, as the levels of the endothelial markers PECAM-1 an VE-
cadherin are markedly lower when compared to their expression in HUVECs, suggesting the 
macrophages maintain their original and distinct haematopoietic cell lineage and the transformation 
towards an endothelial cell-like phenotype is transient. In summary, based upon the findings within 
this chapter and the previous results chapter, we can conclude that macrophages in vitro harbour 










5.1.1 The role of macrophage in angiogenesis  
Angiogenesis is the formation of new blood vessels that occurs throughout life. It is an essential step 
in the development of an organ during embryogenesis, and subsequent body growth and 
maturation. Numerous biological process such as wound healing and menstruation also require 
angiogenesis to be in place. Angiogenesis is also implicated in the pathogenesis of various vascular 
conditions including tumorigenesis and atherosclerosis (Carmeliet, 2003). Essentially, the balance 
between pro-angiogenic mediators (such as VEGF, MMP9 and hypoxia) and anti-angiogenic factors 
(such as thrombospondin-1 and interferon β) regulates angiogenesis through controlling the 
angiogenic switch of endothelial cells (Ribatti et al., 2007). 
In addition to endothelial cells, macrophage have also been shown to play an active and central role 
in angiogenesis. Reportedly, an in vivo study using mice with deficiency in PU.1, a regulator of 
macrophage differentiation, showed reduced vascular network formation within the hindbrain 
vessels of 11.5-day post-coital mice, and the retina of post-natal mice, attributed to the failure of 
macrophages to mature (Fantin et al., 2010). One of the essential roles ascribed to macrophages 
during angiogenesis is to link endothelial tip cells, as proven by laser confocal observation in a 
zebrafish angiogenesis model (Fantin et al., 2010).  
Macrophages also secrete several cytokines/growth factors which can support angiogenesis such as 
VEGF, TNF-a and TGFb1 (Corliss et al., 2016). These factors act through paracrine stimulation to 
promote the sprouting of endothelial tip cells. In addition, during vessel pruning and remodeling, 
macrophages can secrete molecules capable of retarding angiogenesis such as thrombospondin 1 




Another important role macrophages play in angiogenesis is the modulation of extracellular matrix 
breakdown through the release of matrix metalloproteinases (i.e MMP-9). MMPs degrade 
extracellular matrix proteins in order to facilitate endothelial cell migration while also contributing to 
vascular permeability by degradation of endothelial cell basement membrane proteins (van 
Hinsbergh and Koolwijk, 2008).  
A recent study using a novel live imaging technique showed macrophages mediate vascular repair 
within the zebrafish brain by adherence to damage-induced gaps between endothelial cells with 
subsequent mechanical traction to seal the gap (Figure 5.1.1) (Liu et al., 2016). The study proposed 
that ATP release is required from the injured endothelial cells to recruit macrophages to the site of 
damage. This finding suggests that macrophages can temporarily acquire endothelial-like properties 
to provide transient barrier function while also facilitating the repair of damaged blood vessels. 
 
Figure 5.1.1 Macrophage role in brain endothelium repair 
Upon blood vessel rupture, ATP released from injured endothelial cells serves as a chemoattractant 
for macrophage migration towards the site of injury. Subsequently, macrophages directly adhere to 
breaking points employing adhesion molecules such as CDH5 (VE-cadherin) and PECAM-1 to close the 
gap (Liu et al. 2016). Next, the macrophage may exert tensional forces to bring the two endothelial 
cells together. Image adapted from original source (Liu et al. 2016) and made using elements 





5.1.2 Non-endothelial vasculature 
The formation of a vascular network from non-endothelial cells occurs during placenta development, 
whereby epithelial cells trans-differentiate into endothelial-like cells (Zhou et al., 1997a). This is 
evidenced through the upregulation of adhesion molecules such as VE-cadherin, PECAM-1 and a4-
integrin by in vitro human cytotrophoblasts (foetal placental cells) (Zhou et al., 1997a). This finding is 
supported by the analysis of tissue-sections from pre-eclampsia affected human placentas, which 
demonstrated that foetal placental cells are deficient for aV-family-integrins, VCAM-1 and VE-
cadherin, suggesting that during pre-eclampsia there is a defect in normal placenta vasculature, 
which is now known as endovascular invasion, a commonly described pathology in pre-eclampsia 
placenta (Zhou et al., 1997b).  
Another term commonly used for a non-endothelial vessel is vascular mimicry. It is described as the 
formation of functional vascular channels by cancer cells (Fernández-Cortés et al., 2019). One of the 
earliest documented accounts of vascular mimicry was through the histological analysis of solid 
melanoma tumours, which showed tube structures filled with erythrocytes (Maniotis et al., 1999). 
Subsequent immunohistochemical analysis of the cells of the melanoma vasculature showed lack of 
markers such as CD31, CD34, and VEGFR2 (KDR/Flk-1), which implies the presence of non-
endothelial derived vessels (Maniotis et al., 1999). This finding was further supported by in vitro 
observations which demonstrated that aggressive forms of melanoma developed tube structures 
with perfusion characteristics on matrigel/type I collagen assay that were not endothelial cell-
derived (Maniotis et al., 1999). Similarly, the vasculature within glioblastoma tumours are comprised 
of a mixture of neoplastic cells and endothelial cells (Ricci-Vitiani et al., 2010). Furthermore, a 
significant reduction in tumour growth was associated with reduced vessel network when 
glioblastomas were treated with intra-peritoneal ganciclovir, which is known to target neoplastic 
cells rather than endothelial cells (Ricci-Vitiani et al., 2010). In addition, vascular mimicry has been 




cancer (Shirakawa et al., 2002), colon cancer (Baeten et al., 2009), ovarian cancer (Qi et al., 2014) 
and lung cancer (Yao et al., 2014).  
Intriguingly, a recent report showed vascular mimicry derived from macrophages as indicated by 
positive CD163 immunohistochemical staining of the vasculature of solid tumours of melanoma, 
schwannoma, cerebellar haemangioma, meningioma and glioblastoma (Barnett et al., 2016). This 
finding was supported by in vivo angiogenesis studies, whereby F4/80 and CX3CR1GFP macrophages 
formed networks of interconnected cells with cord and filopodial extensions. Interestingly, these 
proposed macrophage-derived cells also expressed the endothelial cell marker CD31 (Barnett et al., 
2016). The authors also revealed that hypoxia inducible factor (HIF-1a) played an important role in 
the formation of vascular mimicry, as HIF-1a knockout mice presented reduced network formation 
and tumour growth (Barnett et al., 2016).  
5.1.3 MicroRNA and angiogenesis 
MicroRNAs (miR) are small non-coding single stranded RNA molecules comprised of between 19-25 
nucleotides (O'Brien et al., 2018). Unlike messenger RNA (mRNA), microRNA are not translated into 
proteins, but regulate translation of target mRNA into protein through a post-transcriptional 
mechanism, therefore the more abundant a microRNA, the lower the protein level of its targeted 
mRNA. Although contradictory with the majority of the published literature, it has been claimed that 
microRNA may potentially activate and upregulate protein translation (Vasudevan, 2012), for 
example miR-466l expressed in mouse embryonic cells is associated with upregulation of IL-10 (Ma 
et al., 2010), although there is limited evidence in human cells demonstrating microRNA expression 
is associated with the upregulation of protein translation.  
Within the nucleus, microRNA are transcribed from their respective DNA sequence (genome) as a 
primary transcript (pri-microRNA) by the RNA polymerase II enzyme, the same enzyme which 
transcribes mRNA from DNA sequences. Pri-microRNA consists of around 60-70 nucleotides in the 




belongs to the ribonuclease III family called Drosha, which results in the generation of a shorter 
nucleotide called a precursor microRNA (pre-microRNA) hairpin.  
The Drosha enzyme requires the nuclear protein known as DiGeorge Syndrome Critical Region 8 
(DGCR8) as a co-factor, in order to recognise and bind pri-microRNA. Both Drosha and DGCR8 form a 
multi-processor complex whereby in the absence of DGCR8, pri-microRNA may not be cleaved into 
pre-microRNA (Gregory et al., 2004). Nuclear pre-microRNA are then transported into the cytoplasm 
by nuclear transport factor exportin 5 before being processed by cytoplasmic a RNAse III enzyme 
called Dicer to generate a microRNA duplex which is  comprised of two substrings called the 5’ 
strand and 3’ strand. Eventually, only one strand will be incorporated into the silencing complex of 
mature microRNA (called the guide strand) which can be either of the  5’ or 3’ strands (Karathanasis 
et al., 2015). The unloaded strand is called the passenger strand (abbreviated as microRNA*), and 
may undergo degradation. The description of microRNA processing described above is a canonical 
pathway for microRNA biogenesis, although reportedly, some microRNA biogenesis may skip either 
the Drosha or Dicer cleavage steps (O'Brien et al., 2018). The microRNA-silencing complex consists of 
the microRNA guide strand and a protein called argonaute (AGO). AGO is increasingly recognised as 
an important factor for the proper function of microRNA as a protein silencing mechanism. 
The silencing of protein translation is achieved by base-pairing of the microRNA with the target 3’ or 
5’ untranslated region (UTR) of messenger mRNA (mRNA) to result in mRNA destabilisation and 
degradation (when complete alignment occurs – such as in plants) or by inhibition of protein 
translation when partial alignment takes place, as is the case in mammalian cells. Reportedly, 
besides 3’ and/or 5’ UTR mRNA, microRNA may also form silencing complexes with coding 
sequences or gene promoters (O'Brien et al., 2018). The interaction of microRNA and their target 
mRNA depends on several factors, including microRNA availability within the cytoplasm, the 
abundance of the microRNA and the target mRNA, and the interaction affinity (O'Brien et al., 2018). 




proteins to regulate protein expression in other cells. For instance, an in vitro study demonstrated 
that tumour-associated macrophages release exosomes enriched in microRNA-223 which can enter 
and regulate the invasiveness of breast cancer cells through targeting of myocyte enhancer factor 
(MEF2C) (Yang et al., 2011), thus released microRNA can also be regarded as a form of paracrine 
intercellular messenger (Chen et al., 2012).  
Recent updates have now documented more than 1900 precursors and more than 2500 mature 
microRNA sequences from the human genome (Kozomara et al., 2019). Each single microRNA may 
have a dual role for example, it modulates cell proliferation in one cell type but inhibit cell growth in 
others (Shen et al., 2019). Nevertheless, the biological function of most microRNAs remains to be 
discovered. Another unique feature of microRNAs is the diversity of their targets, which affects an 
enormous number of genes, in other words it is not limited to a single target, with most individual 
microRNAs having >500 predicted mRNA targets (Shen et al., 2019). 
There is a growing body of evidence which supports the role of microRNAs in physiology as well as 
diseases (O'Connell et al., 2010). This includes the regulation of immune cells including the early 
development of haematopoietic cells, myeloid cell development, as well as  regulation of adaptive 
immune cell (T and B cells) development (O'Connell et al., 2010). Of interest, the expression of a 
cluster of microRNAs (miR-17-5p, miR-20a and miR-106a), which can all target and therefore repress 
Runt-related transcription factor 1 (RUNX1) expression, are all decreased during the differentiation 
and maturation of monocytes from their haematopoietic progenitors. Mechanistically, the RUNX1 
transcription factor withdrives the expression of the  M-CSF receptor to promote the differentiation 
and maturation of monocytes (O'Connell et al., 2010). Studies have identified microRNAs which are 
elevated in macrophages during inflammation, miR-155 (O'Connell et al., 2007) and miR-9 (Bazzoni 
et al., 2009). In contrast, some microRNA, for instance, miR-146a, can repress inflammation through 
the targeting of mRNA which participate in the NFĸB pro-inflammatory pathway, such as IL-1R-




MicroRNAs have also been documented to play a contributory role in angiogenesis, whereby 
deletion of the Dicer enzyme (resulting in global microRNA reduction) lead to defective angiogenesis 
both in vitro (Shilo et al., 2008; Suárez et al., 2007) and in vivo (Suárez et al., 2008). Specific 
microRNAs proposed to regulate angiogenesis include miR-126, miR-221/222, miR-23/27, and the 
miR-17-92 cluster (Caporali and Emanueli, 2011; Wang and Olson, 2009). For example, miR-126 
knockdown mice are embryogenically lethal due to generalised oedema and vascular abnormalities 
from failed angiogenesis (Wang et al., 2008). Target mRNA of miR-126 include Sprouty-related EVH 
domain-containing protein (Spred-1) (Wang et al., 2008), phosphoinositol-3 kinase (PI3K) regulatory 
subunit 2 (Fish et al., 2008) and VCAM-1 (Harris et al., 2008). Accordingly, Spred-1 and PI3K 
regulatory subunit 2 repression are associated with anti-angiogenic signalling through regulation of 
the VEGF pathway (Fish et al., 2008). In addition, miR-126 shares close gene location with epidermal 
growth factor-like domain 7 (Egfl7), which is responsible for bridging endothelial cells during 
angiogenesis (Nikolic et al., 2010), thus, both miR-126 and Efgl7 may work in concert to promote 
angiogenesis, although Efgl7 is not a target gene for miR-126, but may be up-regulated 
simultaneously.  
The miR-221/222 cluster are further microRNAs associated with angiogenesis , as they exert anti-
proliferative, anti-migratory and pro-apoptotic effects in endothelial cells to serve as angiogenesis 
inhibitors (Celic et al., 2017). In addition, miR-221/222 are implicated in VSMC proliferation and 
neointimal hyperplasia (Liu et al., 2009), through opposing effects to that in endothelial cells. The 
proposed target mRNAs for the miR221/222 cluster are stem cell factor/c-kit (Poliseno et al., 2006) 
and signal transducer and activator of transcription 5A (STAT5A) (Dentelli et al., 2010).  
MicroRNA-210 is one of the most widely investigated microRNAs. Besides its association with 
hypoxia and VEGF induced angiogenesis (Wang and Olson, 2009), it is also implicated in various 
biological process such as erythropoiesis (Kosaka et al., 2008), neurogenesis (Zeng et al., 2014), 




miR-210 is associated with the progression of various tumours including lung cancer (Puisségur et 
al., 2011), renal cell carcinoma (Samaan et al., 2015), colorectal carcinoma (Tagscherer et al., 2016) 
and liver cancer (Ji et al., 2018). Thus miR-210 has many proposed effector target mRNAs such as 
NFκB (Yu et al., 2009), activin A receptor type 1B (Mizuno et al., 2009), electron transport chain 
(Puisségur et al., 2011), and CXC chemokine receptor 4 (Feng et al., 2018). Reportedly, the miR-17-
92 cluster is associated with human adenocarcinoma angiogenesis through targeting 
thrombospondin-1 and connective tissue growth factor (CTGF, also known as CCN2), both are anti-
angiogenesis factors (Dews et al., 2006).  
In addition, multiple microRNA are proposed to be involved in macrophage polarisation, for example 
miR-155, miR-127 and miR-125b. Reportedly, miR-155 targets the IL-13/STAT6A pathway to prevent 
M2 phenotype polarisation, while blocking miR-155 is associated with reduced M1 polarisation (Cai 
et al., 2012). In addition, an in vivo study showed miR-155 knockdown was associated with reduced 
M1 and increased M2 macrophage infiltration within the remodelling heart with elevation of IL-1 
and IL-14 alongside reduced IFNg expression (Zhang et al., 2016). M1 polarisation is associated with 
increased expression of miR-127, and is suppressed by IL-4, TGFβ and IL-10 (Ying et al., 2015). In 
addition, an in vivo study showed that forced expression of miR-127 resulted in upregulation of pro-
inflammatory cytokines upon LPS stimulation in alveolar macrophages (Ying et al., 2015). On a 
different note, microRNAs which are associated with M2 polarised macrophages include miR-146a 
(Li et al., 2016), miR-511-3p (Squadrito et al., 2012), miR-223 (Zhuang et al., 2012), and let-7c (Zhang 
et al., 2015).  
5.2 Aim of this chapter 
The inverse relationship between VE-cadherin mRNA and protein expression in M-CSF directed 
macrophages observed within the previous results chapter warrants further investigation, 




whereby divergent miR-24 and miR-181b levels between M-CSF and GM-CSF directed macrophages 
was observed (Di Gregoli et al., 2014; Di Gregoli et al., 2017).  
Based on these findings, this chapter aims to investigate the potential microRNA-mediated 
regulation of VE-cadherin protein expression in in vitro macrophages. This chapter also aims to 
investigate the role of the FGF2 receptor and its downstream signalling pathway, signal transducer 
and activator of transcription-3 (STAT3), on microRNA-mediated VE-cadherin expression, and finally 





5.3 Materials and Methods 
5.3.1 Macrophage culture and stimulation with FGF2 growth factor 
Human monocyte-derived macrophages were isolated and generated as outlined in methods section 
2.1. M-CSF directed macrophages (M-Mac) were maintained in culture for seven-days followed by 
stimulation with 50 ng/ml human recombinant FGF2 for four-days. In addition, magnetic-bead cell 
sorting and purification for purified pan-monocyte populations were also performed to obtain pure 
CD14+ and CD16+ monocytes according to the protocol described in section 4.3.1. 
5.3.2 Quantitative-PCR for microRNAs 
Through utilising the microRNA online database (www.targetscan.org), three mature microRNAs 
were identified that are predicted to target human VE-cadherin, which are microRNA-27a, 
microRNA-101 and microRNA-125. Accordingly, the expression of both the 3p and 5p strands for 
each microRNA were analysed in the seven-day differentiated macrophages, with and without 
subsequent four-day stimulation with FGF2. At the end of the experiments, microRNA from samples 
were collected according to the method as described in section 2.4. Quantitative-PCR (Q-PCR) 
reaction as described in section 2.8 was performed using the Qiagen primer assay (Table 5.3.1). 
Detection of each microRNA was performed with 10X universal primer (Qiagen Cat. No. 218300) 
according to the reaction in Table 5.3.2, 10X miScript primer assay was prepared by adding 550 ml 
TE, pH 9.0 and vortexed prior to aliquoting in DNAse free tubes.  
Table 5.3.1 Primer assay used for QPCR  
Qiagen miScript primers contain a mix of lyophilized primer for a specific microRNA. Each assay 
is derived from mature human microRNA sequences in the miRbase database 
(https://microrna.sanger.ac.uk). 
Assay name Gene symbol Cat. No. Sequence 
Hs_miR-27a-3p MIR27A MS00003241 UUCACAGUGGCUAAGUUCCGC 
Hs_miR-27a-5p MIR27A MS00009240 AGGGCUUAGCUGCUUGUGAGCA 
Hs_miR-101-3p MIR101-1 MS00008379 CAGUUAUCACAGUGCUGAUGCU 
Hs_miR-101-5p MIR101-1 MS00008372 UACAGUACUGUGAUAACUGAA 
Hs_miR-125b-3p MIR125B1 MS00008561 UCCCUGAGACCCUAACUUGUGA 





Table 5.3.2 Master reaction mixture LightCycler® 480 SYBR Green I Master for microRNA Q-
PCR 
Reagent/components Volume (µl) 
Water, PCR grade  3 
10X miScript Primer Assay 0.5 
10X miScript universal primer  0.5 
SYBR Green I Master 5 
Total volume/reaction 9 
 
The Q-PCR reaction was performed in a similar method as described in section 2.8, by which 1µl of 
the sample (cDNA at the same concentration) were added to the reaction mix (Table 5.3.2) for a 
total volume of 10µl QPCR reaction. Similar reaction protocol as described in the section 2.8 was 
applied, however the annealing temperature was set at 55oC according to the manufacturer 
instructions.  
5.3.3 Transfection experiment  
Following analysis of microRNAs in section 5.3.2, microRNA-27a-3p was found to show a regulatory 
association with VE-cadherin expression. In order to evaluate the effects of microRNA-27a-3p on VE-
cadherin expression in human macrophage cultures, transfection experiments through incubation 
with either a microRNA-mimic or -inhibitor (Table 5.3.3) were performed in the seven-day 
differentiated human macrophages. A chimeric peptide derived from rabies virus glycoprotein nona-
D-arginine, RVG-9dR, was used as a vehicle to deliver the microRNA-mimic or -inhibitor into the cell 
using serum free (reduced) antibiotics media (Opti-MEM, Thermo Fisher Cat. No. 31985062) over a 
four-hour incubation period at 37oC. Firstly, the RVG-9dR complex with either the microRNA-mimic 
or -inhibitor were incubated at room temperature for 10 min to allow the formation of transfection 
complexes before addition to the cells. A previous report demonstrated the efficacy of using RVG-
9dR as a tool to increase RNA complex uptake by macrophages and ensuing induction of gene 
silencing in macrophages and microglia (Kim et al., 2010). Negative controls were also deployed 




media was replaced with 10% FCS/RPMI (full) media with subsequent four-day stimulation with 
FGF2.  
Table 5.3.3 Reagents used in transfection experiment 
(RVG-9dR = Chimeric Rabies Virus Glycoprotein Fragment) 




Syn-hsa-miR-27a-3p miScript miRNA Mimic Qiagen/ MSY0000084  20 µM 5 nM 
Anti-hsa-miR-27a-3p miScript miRNA Inhibitor Qiagen/ MIN0000084 20 µM 5 nM 
RVG-9dR GenScript/ SC1208 1 mM 1 µM 
All Stars Negative Control siRNA Qiagen/ SI03650318 20 µM 5 nM 
 
5.3.4 Neutralising FGFR1-antibody experiment 
To assess the association of FGF-receptor 1 (FGFR1)-mediated signalling to VE-cadherin expression 
by FGF2 in M-CSF-matured macrophages (M-Mac), a neutralising antibody (NAb) experiment using a 
monoclonal immunoglobulin G (IgG) antibody raised against human FGFR1 was performed. The 
antibody was a human FGF R1 (IIIb) monoclonal mouse IgG1 antibody (Cat. number: MAB765; R&D 
systems), and was used at a concentration of 1 µg/ml. The antibody was added to 7-day 
differentiated M-Macs alongside recombinant FGF2 for 4 days. Mouse IgG1 at the same IgG 
concentration was used as a control. 
5.3.5 STAT3 inhibitor experiment  
In order to evaluate the regulatory role of the STAT3 transcription factor to FGF2-induced VE-
cadherin protein expression in M-CSF directed macrophages, niclosamide, a known STAT3 inhibitor 
and widely used as an antihelminth drug (Chen et al., 2018), was assessed in M-CSF directed 
macrophages. A dose dependent effect was evaluated with 1, 5 and 10 µM concentrations of 
niclosamide. Reportedly, niclosamide showed a dose-dependent inhibition of STAT3 phosphorylation 
in a human prostate cancer cell line (Ren et al., 2010). In brief, seven-day differentiated M-CSF 




concentrations of 1, 5 and 10 µM. Niclosamide (50mg) (cat. number 4079/50; Bio-techne Ltd) was 
diluted in dimethyl sulfoxide (DMSO), accordingly, a DMSO (vehicle) control was also used.  
5.3.6 Matrigel angiogenesis assay 
To investigate the angiogenic potential of macrophage subsets, the formation of tube/network-like 
structures was assessed using a Matrigel angiogenesis assay. In brief, M-CSF and GM-CSF matured 
macrophages were seeded at 1x104 on Matrigel (Growth factor-reduced Matrigel; Scientific Lab 
Supplies, cat. no.354230; stored at −20 °C) within the wells of a 48-well plastic tissue culture plate. 
The effects of recombinant human FGF2 (50ng/ml) was assessed, and live cell images captured at 
10x magnification after 24 hours seeding.  The effect of STAT3 inhibition with niclosamide on tube 
formation in M-CSF directed macrophages was also assessed. In brief, M-CSF matured macrophages 
were seeded at 1x104 on Matrigel within the wells of a 48-well plastic tissue culture plate with and 
without niclosamide or with the relevant concentration of DMSO as a control. Live cell images were 
captured at 4x magnification after 24 hours seeding. In all experiments, images from four random 







5.4 Results  
In the previous results chapter (Figure 4.4.11), an inverse relationship between VE-cadherin mRNA 
and protein expression was detected in M-CSF macrophages, suggesting the role of a post-
translational mechanism such as microRNA regulation of VE-cadherin protein levels. Stimulation 
with FGF2 markedly suppressed VE-cadherin mRNA levels while protein expression was significantly 
upregulated in M-CSF matured macrophages (Figure 4.4.11; Chapter 4). Furthermore, the 
observation that VE-cadherin mRNA expression remained unchanged by stimulation with other 
endothelial cell-related growth factors but concomitantly upregulated of VE-cadherin protein 
expression, further supports the post-translation regulation of VE-cadherin in macrophages (Figure 
4.4.11; Chapter 4). Interestingly, such a divergent regulation of VE-cadherin mRNA and protein levels 
was not observed in GM-CSF matured macrophages. Based upon this finding, the expression of three 
microRNAs predicted to target VE-cadherin (miR-27a, miR-101, and miR-125) were analysed. 
5.4.1 FGF2 stimulation downregulates microRNA-27a-3p expression in M-CSF 
directed macrophages 
Assessment of the candidate microRNAs in human PBMC-derived macrophages matured with M-CSF 
or GM-CSF, showed detectable expression levels of miR-27a and miR-101, whereas miR-125 was not 
expressed in macrophages under any of the conditions (below the level of detection). Although miR-
101-3p and miR-101-5p levels were readily detected, no significant differences in their expression 
were observed between macrophage phenotypes or after stimulation with individual EC-related 
growth factors (refer to appendix C, 10.1.1 and 10.1.2 for CT values). On the other hand, the 
expression of miR-27a-3p and miR-27a-5p were downregulated in GM-CSF directed macrophages 
(84%; P<0.0001; n=6; Figure 5.4.1 and 55%; P<0.01; n=6; Figure 5.4.2, respectively) compared to M-
CSF directed macrophages. None of the endothelial cell-related growth factors affected miR-27a-3p 
or -5p levels in either subset with the exception of FGF2 stimulation, which significantly reduced 
miR-27a-3p expression in M-CSF matured macrophages (42%; P<0.05; n=6; Figure 5.4.1), without 










Figure 5.4.1 Expression of miR-27a-3p in human macrophage subsets. 
QPCR analysis for miR-27a-3p levels in M-CSF and GM-CSF matured macrophages with subsequent 
four-day stimulation with 50 ng/ml VEGF-A, FGF2, IGF-1, HGF, or ANGPTL5, expressed as fold change 
compared to unstimulated M-CSF matured macrophages. (* P < 0.05 and **** P < 0.0001 denotes 
significant difference compared to unstimulated M-CSF macrophages; one-way ANOVA Tukey’s 
multiple comparison test; n=6). Refer appendix C (10.1.3) for CT-values. (M = M-CSF macrophage, GM 







Figure 5.4.2 Expression of miR-27a-5p in human macrophage subsets 
QPCR analysis for miR-27a-5p levels in M-CSF and GM-CSF matured macrophages with subsequent 
four-day stimulation with 50 ng/ml VEGF-A, FGF2, IGF-1, HGF, or ANGPTL5, expressed as fold change 
compared to unstimulated M-CSF matured macrophages (** P < 0.01 denotes significant difference 
compared to unstimulated M-CSF macrophages; one-way ANOVA Tukey’s multiple comparison test; 







































































































































Control  1.0 1.0 1.0 1.0 2.3 0.1 
FGF2 0.4 7.3 0.6 1.0 1.0 1.0 
Figure 5.4.3 Summary of results for the relative VE-cadherin mRNA and protein expression 
alongside miR-27a-3p levels in M-CSF and GM-CSF matured macrophage subsets with and 
without FGF2 stimulation 
Fold change in mRNA and protein expression (by Western blotting) of VE-cadherin and miR-27a-3p 
levels in seven-day matured M-CSF and GM-CSF human macrophages with and without subsequent 
four-day stimulation with FGF2. All data expressed as fold change relative to 11-day M-CSF directed 
macrophages without FGF2 stimulation, with red highlighting indicating significantly increased 
expression and green highlighting indicating significantly decreased levels.  
For VE-cadherin mRNA and protein expression in; (i) M-CSF directed macrophages refer to Figure 
4.4.11; (ii) GM-CSF directed macrophage refer to Figure 4.4.3 (comparison with 11-day M-CSF 
macrophages) and (iii) FGF2 effects on GM-CSF directed macrophages (refer to Figure 4.4.17). (M-
Mac = M-CSF directed macrophage, GM-Mac = GM-CSF directed macrophage). 
 
The results within the previous chapter showed higher protein expression of VE-cadherin in GM-CSF 
directed macrophages (2.3-fold-change; P <0.05; n=6; Figure 4.4.3 b) but equivalent mRNA levels in 
comparison to M-CSF directed macrophages (Figure 4.4.3 a). This pattern of elevated VE-cadherin 
protein expression in GM-CSF macrophages is associated with their reduced levels of miR-27a-3p 
(84%; P <0.0001; n=6; Figure 5.4.1). Interestingly, the addition of FGF2 to M-CSF directed 
macrophages upregulated VE-cadherin protein expression (7.3-fold-change; P<0.01; n=6; Figure 
4.4.11) to match that observed in GM-CSF macrophages, without a complimentary increase in  
mRNA levels (Figure 4.4.11). The elevated VE-cadherin protein expression afforded through FGF2 
stimulation was associated with reduced expression of miR-27a-3p in M-CSF directed macrophages 
(42%; P<0.05; Figure 5.4.1). However, the expression of VE-cadherin mRNA and protein expression 
as well as miR-27a-3p levels were unchanged by FGF2 addition to GM-CSF directed macrophages 
(refer to Figure 4.4.17 and Figure 5.4.1).  
Taken together the effects of FGF2 on VE-cadherin mRNA and protein expression, and microRNA-




levels by FGF2 in M-CSF macrophage strongly related to the converse changes in miR-27a-3p levels, 
implying a regulatory role for this microRNA in regulating M-CSF macrophage VE-cadherin 






5.4.2 Regulation of VE-cadherin protein expression by miR-27a-3p in M-CSF 
directed macrophages 
In order to determine whether VE-cadherin protein expression regulation involves miR-27a-3p, M-
CSF matured macrophages were transfected with either a miR-27a-3p mimic or inhibitor. A condition 
similar to overexpression of microRNA-27a-3p was created through addition of the mimic, whereas 
the inhibitor resulted in the disintegration of microRNA-27a-3p, thus similar to knockdown or 
downregulation of microRNA-27a-3p. Subsequently, the VE-cadherin protein expression was 
analysed in the presence of FGF2 (50ng/ml). This experiment was designed to validate the 
association of microRNA-27a-3p with VE-cadherin protein expression by FGF2 stimulation.  
The results are shown in Figure 5.4.4 - Figure 5.4.8. Firstly, the All Stars Negative Control siRNA 
which was used to control for RVG-9dR-mediated transfection, showed comparable VE-cadherin 
protein expression in unstimulated (baseline) M-CSF matured macrophages. Similarly, VE-cadherin 
levels were equally up-regulated through FGF2 stimulation in control transfected (2.8-fold change; 
P<0.05; n-6; Figure 5.4.4) and non-transfected M-CSF macrophages (2.5-fold change; P<0.05; n-6; 
Figure 5.4.4). It was therefore concluded that RVG-9dR-mediatied transfection did not affect VE-
cadherin regulation in M-CSF macrophage, validating this approach for the subsequent experiments 
involving miR-27a-3p modulation. Assessment of Western blotting revealed that the addition of a 
miR-27a-3p-mimic significantly downregulated (32%; P<0.05; n=6; Figure 5.4.5 a) VE-cadherin 
protein expression in M-CSF matured macrophages, while a miR-27a-3p-inhibitor markedly up-
regulated VE-cadherin protein levels (2.6-fold change; P<0.05; n=6; Figure 5.4.5 b) , when compared 
to negative control macrophages. Additionally, FGF2-induced upregulation of VE-cadherin in M-CSF 
matured macrophages was significantly blunted through co-incubation with a miR-27a-3p-mimic 
(49%; P<0.05; n=6; Figure 5.4.5 c).  
VE-cadherin protein expression was also evaluated by immunocytochemistry and showed similar 




directed macrophages and negative control-transfected cells showed a comparable increase in the 
percentage of VE-cadherin positive macrophages, either unstimulated (69.9% and 71.7%, 
respectively; P<0.05; n=6; Figure 5.4.7a and b), or in response to FGF2 stimulation (79.3% and 85.0%, 
respectively; P<0.05; n=6; Figure 5.4.7a and b). As expected from the Western blotting results, the 
percentage of VE-cadherin positive macrophages was significantly increased with addition of a miR-
27a-3p-inhibitor (84.3%) compared to the negative control cells (71.7%; P<0.05; n=6; Figure 5.4.7d). 
However, the miR-27a-3p-mimic increased VE-cadherin positive M-CSF macrophages (79.8%) 
compared to negative control (71.7%; P<0.01; n=6; Figure 5.4.7c) opposing the results obtained by 
western blot analysis. Nonetheless, under FGF2 stimulation, the percentage of VE-cadherin positive 
macrophages (63.4%) was markedly reduced in the presence of the miR-27a-3p-mimic, compared to 

















Figure 5.4.4 Validation of RVG-9dr-mediated transfection. 
(a) Quantification and (b) representative Western blotting of VE-cadherin protein expression in 
seven-day (baseline) M-CSF matured macrophages with and without FGF2 stimulation (50ng/ml), 
and with or without RVG-9dr-mediated transfection with a negative control scrambled RNA (negative 
control). Data are expressed as fold change against each control, (*P < 0.05 denotes significant 
difference compared to respective controls; paired t-test; n=6) (Stain free gel is shown as a loading 
control).  
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Figure 5.4.5 VE-cadherin protein expression in M-CSF directed macrophages with or without a miR-27a-3p-mimic or inhibitor.  
Quantification (a-c) and representative Western blots (d) of VE-cadherin protein expression in M-CSF matured macrophages with or without FGF2 
stimulation (50ng/ml) and RVG-9dr-mediated transfection with a miR-27a-3p mimic, a miR-27a-3p inhibitor, or negative control scrambled RNA. Data are 
expressed as fold change against each control, (*P < 0.05 denotes significant difference compared to relative negative control (for a and b), and with 
negative control + FGF2 (for c); paired t-test; n=6) Stain free gel is shown as a loading control.  
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Figure 5.4.6 Immunofluorescence labelling for VE-cadherin in M-CSF directed macrophages 
with or without a miR-27a-3p-mimic or inhibitor.  
Representative images of immunofluorescent labelling for VE-cadherin expression in M-CSF 
differentiated human macrophages treated with either a miR-27a-3p mimic or inhibitor and 
with or without subsequent stimulation with FGF2 (50ng/ml). Red colour indicates VE-cadherin 
immuno-positive macrophages, and blue indicates nuclei (DAPI counterstain). Scale bars 
represent 200 µM.  
For quantification refer to Figure 5.4.7.
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Figure 5.4.7 Quantification of immunofluorescence cell positivity of VE-cadherin in M-CSF macrophages with or without a miR-27a-3p-mimic or 
inhibitor.  
Quantification of immunofluorescent labelling for VE-cadherin protein levels in M-CSF matured macrophages at (a) baseline (± FGF2), (b) negative control 
(±FGF2), (c) miR-27a-3p-mimic treated, (d) miR-27a-3p-inhibitor treated, or (e) FGF2 ± miR-27a-3p-mimic treated. Data are expressed as percentage of VE-
cadherin immuno-positive cells (*P< 0.05 and **P<0.01 denotes significant difference compared to relative control group; paired t-test; mean ± SEM; n=6). 
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These findings support the hypothesis that miR-27a-3p regulates VE-cadherin protein levels within 
M-CSF matured macrophages (M-Mac). Modulation of miR-27a-3p in GM-CSF differentiated 
macrophages showed no changes (results not shown), in line with no discrepancies between the 
mRNA and protein expression of in VE-cadherin in GM-CSF matured macrophages. To ensure the 
observed changes in VE-cadherin protein levels afforded from miR-27a-3p modulation were not due 
to reciprocal alterations at the mRNA level, QPCR analysis was evaluated and showed that RVG-9dR-
mediated transfection of either the miR-27a-3p-mimic or -inhibitor did not adversely affect VE-
cadherin (CDH5) mRNA levels (Figure 5.4.8). Indeed, in agreement with the findings in chapter 4, 
CDH5 mRNA levels were down-regulated by FGF2 stimulation (52%; P<0.01; n=6; Figure 5.4.8a), an 
effect unperturbed by RVG-9dr-mediated transfection (44%; P<0.01; n=6; Figure 5.4.8b).  
These findings consistently suggest that when VE-cadherin protein elevation is observed, it is 
mirrored by an inverse reduction at the mRNA level, potentially through increased translation as 
microRNA expression is diminished. In support, the mRNA expression of CDH5 (VE-cadherin) in M-
CSF matured macrophages was not decreased through addition of a miR-27a-3p-mimic (Figure 
5.4.8c). However, in the presence of a miR-27a-3p-inhibitor which increases VE-cadherin protein 
levels, CDH5 mRNA expression was reduced (47%; P<0.01; n=6; Figure 5.4.8d), indicating restored 
translation of mRNA into VE-cadherin protein, as shown earlier (Figure 5.4.5b and Figure 5.4.7d). 
This inverse pattern of mRNA and protein expression of VE-cadherin afforded with a miR-27a-3p 
inhibitor, mirrors the changes observed with FGF2 stimulation, which was shown to reduce miR-27a-
3p levels (Figure 5.4.1). Consequently, the addition of a miR-27a-3p mimic to FGF-stimulated M-CSF 
macrophages significantly upregulated CDH5 (VE-cadherin) levels (1.7-fold change; P<0.05; n=6; 
Figure 5.4.8e), again suggestive of mRNA accumulation as a result of reduced protein translation 














Figure 5.4.8 CDH5 (VE-cadherin) mRNA expression in M-CSF directed macrophage with or without a miR-27a-3p-mimic and -inhibitor. 
Quantification of QPCR for CDH5 (VE-cadherin) mRNA levels in M-CSF matured macrophages at (a) baseline (± FGF2), (b) negative control (±FGF2), (c) miR-
27a-3p-mimic treated, (d) miR-27a-3p-inhibitor treated, or (e) FGF2 ± miR-27a-3p-mimic treated. Data are expressed as fold change against the relative 
control group (*P< 0.05 and **P<0.01 denotes significant difference compared to relative control group; paired t-test; mean ± SEM; n=6).  
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Next, the effect of RVG-9dr-mediated delivery of the miR-27a-3p -mimic and -inhibitor on miR-27a-
3p expression was assessed. FGF2 stimulation decreased miR-27a-3p levels in the presence of RVG-
9dr-mediated delivery of a scrambled RNA (38%; P<0.05; n=6; Figure 5.4.9a), reproducing the similar 
decrease observed in baseline M-CSF directed macrophages (refer to Figure 5.4.1). No changes in 
miR-27a-3p expression were detected with the addition of the mimic (Figure 5.4.9b) compared to 
negative control cells, consistent with no change in CDH5 (VE-cadherin) mRNA levels (Figure 5.4.8c) 
and low protein levels (Figure 5.4.5a) Therefore, it could be postulated that the  basal endogenous 
levels of miR-27a-3p are so abundant that addition of the mimic does not translate to an increase in 
total miR-27a-3p levels.  
On the other hand, the addition of a miR-27a-3p inhibitor to M-CSF matured macrophages was 
associated with a significant reduction in miR-27a-3p levels (29%; P<0.05; n=6; Figure 5.4.9c), 
consistent with elevated VE-cadherin protein expression (Figure 5.4.5b and Figure 5.4.7d) and 
reduced CDH5 (VE-cadherin) mRNA levels (Figure 5.4.8d). Conversely, microRNA-27a-3p expression 
was significantly upregulated in FGF2-stimulated M-CSF macrophages treated with the miR-27a-3p 
mimic (1.8-fold change; P<0.01; n=6; Figure 5.4.9e), in line with higher CDH5 (VE-cadherin) mRNA 
levels (Figure 5.4.8 e) and reduced protein expression (Figure 5.4.5c and Figure 5.4.7e).  















Figure 5.4.9 Effect of miR-27a-3p mimic or inhibitor treatment on M-CSF matured 
macrophage miR-27a-3p levels.  
Quantification of QPCR for miR-27a-3p levels in M-CSF matured macrophages treated with (a) 
scrambled negative control RNA (negative control) ± FGF2; (b) negative control ± miR-27a-3p mimic; 
(c) negative control ± miR-27a-3p-inhibitor; or (d) negative control + FGF2 ± miR-27a-3p-mimic 
treated. Data are expressed as fold change against the relative control group (*P< 0.05 denotes.  
Refer appendix C (10.1.7) for CT-values.






















































(a) microRNA-27a-3p  









































 mRNA WB IF mRNA WB IF mRNA WB IF mRNA WB IF 
M-CSF 1.0 1.0 69.9% 1.0 1.0 1.0 71.7% 1.0 0.9 0.7 79.8% 1.1 0.5 2.6 84.3% 0.7 
+FGF2 0.5 2.5 79.3% 0.6 0.6 2.8 85.0% 0.6 1.7 0.5 63.4% 1.8     
Figure 5.4.10 Summary of results assessing the effect of a miR-27a-3p mimic or inhibitor on mRNA and protein expression of VE-cadherin 
alongside miR-27a-3p levels in M-CSF directed macrophages with and without FGF2 stimulation.  
Fold change in expression of VE-cadherin mRNA, protein and microRNA-27a-3p, and percentage of immuno-positive VE-cadherin macrophages without 
treatment (baseline), or treatment with a scrambled RNA negative control, a microRNA-27a-3p -mimic, or a miR-27a-3p inhibitor. All cells were either 
stimulated with or without FGF2. For baseline and negative control groups, data are expressed as fold change compared to M-CSF non-FGF2 stimulated. For 
microRNA-27a-3p-mimic and -inhibitor treated groups, data are expressed as fold change compared to non-FGF2-stimulated negative control. For 
microRNA-27a-3p-mimic group with FGF2 stimulation, data are expressed as fold change compared to FGF2 stimulated macrophages treated with negative 






5.4.3 FGF2 signalling through FGFR1 regulates M-CSF matured macrophage 
VE-cadherin expression FGF2/FGFR1 regulates VE-cadherin expression 
 
Next, the FGF2 signalling pathway was interrogated to determine the manner in which FGF2 induced 
VE-cadherin expression through downregulation of microRNA-27a-3p. Firstly, the expression of the 
FGF-receptor 1 (FGFR1) was evaluated in human M-CSF matured macrophages, with or without FGF2 
stimulation, and in the presence or absence of a miR-27a-3p mimic or inhibitor. QPCR analysis 
revealed the mRNA expression of FGFR1 was not affected by FGF2 stimulation, and/or with addition 
of a miR-27a-mimic or -inhibitor (Figure 5.4.11).  
 
Figure 5.4.11 FGFR1 mRNA expression in M-CSF matured macrophages.  
Quantification of QPCR for FGF-receptor-1 (FGFR1) mRNA levels in M-CSF matured macrophages 
treated with a scrambled negative control RNA ± FGF2, a miR-27a-3p mimic ± FGF2, or a miR-27a-
3p-inhibitor ± FGF2. Data are expressed as fold change compared to the scrambled RNA negative 
control group (mean ± SEM; n=6).  
Refer to appendix C (10.1.8) for CT-values.  
 
To investigate whether FGF2-induced upregulation of VE-cadherin requires the FGF-receptor 1 
(FGFR1), a FGFR1 neutralising antibody was deployed, and the results are shown in Figure 5.4.12. By 
blocking FGFR1 with a specific neutralising antibody, the FGF2-induced downregulation of CDH-5 
(VE-cadherin) mRNA expression was inhibited, resulting in similar levels as that observed in 



























increased VE-cadherin protein levels afforded through FGF2 stimulation were blunted by the FGFR1 
neutralising antibody, reducing expression comparable to that detected in control M-CSF 
macrophages without FGF2-stimulation (Figure 5.4.12b). These findings support the hypothesis that 
FGF signals through FGFR1 to modulate VE-cadherin protein levels in a microRNA-dependent 
manner. Strengthening the proposition that miR-27a-3p plays such a role down-stream of FGF2, 
miR-27a-3p levels were restored to those detected in unstimulated control M-CSF macrophages 
upon co-incubation with the FGFR1 neutralising antibody in the presence of FGF2 (Figure 5.4.13), 
consolidating the previous findings indicating that microRNA-27a-3p regulates M-CSF macrophage 




































Figure 5.4.12 Addition of a FGFR1 neutralising antibody prevents FGF2-induced regulation of 
VE-cadherin mRNA and protein expression in M-CSF matured macrophages. 
Quantification of QPCR analysis (a), alongside quantification and representative Western blots (b and 
c) for mRNA and protein expression of VE-cadherin in M-CSF matured macrophages treated with an 
anti-FGFR1 neutralising antibody with and without FGF2 (50ng/ml), alongside unstimulated and 
relevant IgG controls. Data are expressed as fold change compared to unstimulated control M-CSF 
macrophages, (** P < 0.01 denotes significant difference from all other groups; one-way ANOVA 
Tukey’s multiple comparison test; mean±SEM; n=6).  
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Figure 5.4.13 Addition of a FGFR1 neutralising antibody prevents FGF2-induced regulation of 
miR-27a-3p expression in M-CSF matured macrophages.  
Quantification of QPCR for miR-27a-3p levels in M-CSF matured macrophages treated with an anti-
FGFR1 neutralising antibody with and without FGF2 (50ng/ml), alongside unstimulated and relevant 
IgG controls. Data are expressed as fold change compared to unstimulated control M-CSF 
macrophages, (* P < 0.05 denotes significant difference from all other groups; one-way ANOVA 
Tukey’s multiple comparison test; mean±SEM; n=6). 
Refer to appendix C; (10.1.11) for CT values. 
 
Next, it was assessed if blocking the function of FGFR1 altered its expression, indirectly underlying 
the subsequent regulation of miR-27a-3p levels. However, both the mRNA and protein expression of 
FGFR1 were unaffected in M-CSF macrophages through addition of either a FGFR1 neutralising 
antibody (anti-FGFR1) or with FGF2 stimulation (Figure 5.4.14). The above results are also 




































Figure 5.4.14 FGFR1 mRNA and protein expression were unaffected by addition of a FGFR1 
neutralising antibody in M-CSF matured macrophages.  
Quantification of QPCR analysis (a), alongside quantification and representative Western blots (b and 
c) for mRNA and protein expression of FGFR1 in M-CSF matured macrophages treated with an anti-
FGFR1 neutralising antibody with and without FGF2 (50ng/ml), alongside unstimulated and relevant 
IgG controls. Data are expressed as fold change compared to unstimulated control M-CSF 
macrophages, (mean±SEM; n=6). 
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5.4.4 The STAT3 transcription factor regulates VE-cadherin expression in M-
CSF matured macrophages  
FGF2 ligation of FGFR1 is known to induce downstream signalling through activation 
(phosphorylation) of the STAT3 transcription factor and may therefore represent a mechanism 
through which FGF2 controls M-CSF macrophage levels of miR-27a-3p, and subsequent VE-cadherin 
protein expression. Firstly, M-CSF macrophages stimulated with FGF2 demonstrated a significant 
increase in STAT3 phosphorylation (1.6-fold change; P<0.05; n=6; Figure 5.4.15), which was 
prevented in the presence of a FGFR1 neutralising antibody (Figure 5.4.15). This finding illustrates 
















Figure 5.4.15 FGF2 stimulation increases STAT3 phosphorylation in M-CSF matured 
macrophages and is dependent on FGFR1.  
(a) Quantification and (b) representative western blots for STAT3 phosphorylation (pSTAT3) and total 
STAT3 expression in M-CSF matured macrophages treated with an anti-FGFR1 neutralising antibody 
with and without FGF2 (50ng/ml) stimulation, alongside unstimulated and relevant IgG controls. 
Data are expressed as fold change compared to unstimulated control M-CSF macrophages, (* P < 
0.05 denotes significant difference from all other groups; one-way ANOVA Tukey’s multiple 
comparison test; mean±SEM; n=6) Stain free gel is shown as a loading control.  
Refer to appendix C; (10.1.14) for full blot.  
 
To validate a role for STAT3 activation (phosphorylation) in the regulation of FGF2-induced VE-
cadherin expression in M-CSF matured macrophages, niclosamide was deployed as a STAT3 
inhibitor. Indeed, FGF-2 stimulated upregulation of VE-cadherin protein expression was significantly 
reduced by co-incubation with niclosamide in a dose-related fashion (Figure 5.4.16). Specifically, VE-
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10 µM niclosamide, respectively, compared to DMSO control (P<0.01; n=6; Figure 5.4.16). Consistent 
with the observed reduction in VE-cadherin levels reliant on STAT3 activation, niclosamide 
treatment also markedly reduced STAT3 phosphorylation levels and STAT3 expression by 41% 
(P<0.05), 66% (P<0.05) and 76% (P<0.01), with 1 µM, 5 µM and 10 µM niclosamide, respectively 
when compared to DMSO controls, while total STAT3 levels were unaffected (n=6; Figure 5.4.16).  
In addition, fluorescence immunocytochemistry for VE-cadherin and STAT3 phosphorylation showed 
similar results as those observed by Western blotting analysis (Figure 5.4.17). Addition of 1 µM, 5 
µM, or 10 µM niclosamide to FGF2-stimulated M-CSF matured macrophages resulted in a 15% 
(P<0.05), 20% (P<0.05) and 34% (P<0.01) reduction in the percentage of VE-cadherin positive cells, 
respectively, (n=6; Figure 5.4.18a). Supportingly, the percentage of macrophages displaying STAT3 
phosphorylation was significantly lower with addition of 1 µM (14%; P<0.05), 5 µM (19%; P<0.05), or 
10 µM (32%; P<0.01) niclosamide, compared to DMSO controls (n=6; Figure 5.4.18b).  
In accordance with the above observations, FGF2 stimulated M-CSF macrophage CDH5 (VE-cadherin) 
mRNA expression was upregulated in the presence of 1 µM (1.4-fold change; P<0.05), 5 µM (1.5-fold 
change; P<0.01), or 10 µM (1.7-fold change; P<0.05) niclosamide compared to control cells (n=6; 
Figure 5.4.19a). The decreased protein expression alongside elevated mRNA levels of VE-cadherin is 
consistent with miR-27a-3p regulation, the expression of which was expectedly increased in the 
presence of 1 µM (1.3-fold change; P<0.01), 5 µM (1.4-fold change; P<0.01), or 10 µM (1.5-fold 
change; P<0.05) niclosamide, relative to control macrophages,  (n=6; Figure 5.4.19b). The findings 
within this section are summarised within Figure 5.4.21, and collectively demonstrate that FGF2 
stimulation of M-CSF matured macrophages increases VE-cadherin protein expression, which is in 


































Figure 5.4.16 Niclosamide (STAT3 inhibitor) decreases VE-cadherin protein expression and 
STAT3 phosphorylation in FGF2 stimulated M-CSF macrophages. 
(a) Quantification and (b) representative Western blot images of VE-cadherin, STAT3 phosphorylation 
(pSTAT3), and total STAT3 expression in M-CSF matured macrophages stimulated with FGF2 
(50ng/ml) and treated with niclosamide (STAT3 inhibitor) or DMSO as a vehicle control. Data are 
expressed as fold change compared to unstimulated control M-CSF macrophages, (*P <0.05 and **P 
<0.01 denotes significant differences compared to DMSO control; #P <0.05 denotes significant 
differences compared to 10 "M niclosamide; one-way ANOVA Tukey’s multiple comparison test; n=6; 
mean ±SEM).  
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Figure 5.4.17 Niclosamide decreases VE-cadherin expression and STAT3 phosphorylation in 
FGF2 stimulated M-CSF macrophages.  
Representative images of immunofluorescent labelling for VE-cadherin and phosphorylated STAT3 
(pSTAT3) in FGF2-stimulated M-CSF differentiated human macrophages treated with niclosamide (1, 
5, or 10 µM). Red colour indicates VE-cadherin immuno-positive macrophages, green colour indicates 
STAT3 phosphorylation, and blue indicates nuclei (DAPI counterstain). Scale bars represent 100 µM. 
For quantification refer to Figure 5.4.18. (DMSO = vehicle control for niclosamide; Nic = niclosamide). 





















































Figure 5.4.18 Niclosamide (STAT3 inhibitor) reduces VE-cadherin protein expression and 
STAT3 phosphorylation in FGF2 stimulated M-CSF macrophages.  
Quantification of immunofluorescent labelling for (a) VE-cadherin and (b) phosphorylated STAT3 
(pSTAT3) in FGF2-stimulated M-CSF matured macrophages treated with the STAT3 inhibitor 
niclosamide (1, 5 or 10 µM). Data are expressed as percentage of (a) VE-cadherin positive and (b) 
phosphorylated STAT3 expressing macrophages, (*P< 0.05, ** P <0.01 denotes significant difference 
compared to DMSO control cells; # P <0.05 and ## P<0.01 denotes significant difference compared to 
Nic 10 "M (one-way ANOVA Tukey’s multiple comparison test; mean ± SEM; n=6). For 
immunofluorescence images refer to Figure 5.4.17. (DMSO = vehicle control for niclosamide; Nic 1, 5 






Figure 5.4.19 Niclosamide (STAT3 inhibitor) increases CDH5 (VE-cadherin) mRNA expression 
and microRNA-27a-3p levels in FGF2 stimulated M-CSF macrophages. 
Quantification of QPCR for (a) CDH5 (VE-cadherin) mRNA expression and (b) miR-27a-3p levels in 
FGF2-stimulated M-CSF matured macrophages treated with the STAT3 inhibitor niclosamide (1, 5 or 
10 µM). Data are expressed as fold change compared to unstimulated control M-CSF macrophages,(* 
P < 0.05 and ** P < 0.01 denotes significant differences compared to DMSO control macrophages 
(one-way ANOVA Tukey’s multiple comparison test; mean ± SEM; n=6). Refer to appendix C; (10.1.16) 






























(a) VE-cadherin expression  
 
  






































 VE-cadherin MicroRNA-27a-3p FGFR1 STAT3 
 mRNA protein mRNA protein 
M-CSF 1.0 1.0 1.0 1.0 1.0 1.0 
IgG 1.0 1.0 1.1 1.0 1.1 1.0 
IgG+FGF2 0.5 1.6 0.7 1.1 1.1 1.7 
Anti-FGFR1 1.0 1.0 1.2 1.0 1.0 1.1 
Anti-FGFR1+FGF2 0.9 0.7 1.3 1.1 1.0 1.0 
Figure 5.4.20 Summary of results assessing the effect of a FGFR1 neutralising antibody on M-CSF directed macrophages. 
Fold change in expression of VE-cadherin mRNA and protein, microRNA-27a-3p, FGFR1 mRNA and protein, and STAT3 phosphorylation in human M-CSF 
matured macrophages treated with an anti-FGFR1 neutralising antibody with and without FGF2 (50ng/ml), alongside unstimulated and relevant IgG 
controls. Data are expressed as fold change compared to unstimulated control M-CSF macrophages. Red highlighting indicates significantly increased 
expression and green highlighting indicates significantly decreased levels.  
 VE-cadherin STAT3 microRNA-
27a-3p  WB ICC mRNA WB ICC 
M-CSF 1.0 74.4% 1.0 1.0 79.3% 1.0 
DMSO 1.2 73.6% 1.1 1.1 78.9% 1.0 
Nic 1 0.5 62.6% 1.4 0.6 67.8% 1.3 
Nic 5 0.2 59.0% 1.5 0.3 63.7% 1.4 
Nic 10 0.2 48.4% 1.7 0.2 53.8% 1.5 
Figure 5.4.21 Summary of results assessing the effect of STAT3 inhibition on FGF2-stimulated M-CSF directed macrophages. 
Fold change in expression of VE-cadherin mRNA and protein alongside percentage of immuno-positive VE-cadherin macrophages, STAT3 phosphorylation by 
Western blotting (WB) and immunocytochemistry (ICC), and miR-27a-3p levels, in FGF2-stimulated M-CSF matured macrophages treated with the STAT3 
inhibitor niclosamide (1, 5 or 10 µM). Data are expressed as fold change compared to unstimulated control M-CSF macrophages for mRNA and WB analysis, 
or is expressed as percentage of VE-cadherin positive or phosphorylated STAT3 expressing macrophages, for the ICC. Red highlighting indicates significantly 




5.4.5 FGF2 stimulation of M-CSF matured macrophages increases in vitro 
angiogenesis 
The in vitro Matrigel angiogenesis assay involves culturing cells upon Matrigel for 24-hours, then 
assessing the formation of tube-like structures and the number of branches from the structures, 
representing the development of immature angiogenic networks. The previous data presented 
within this chapter and chapter 4 would suggest that GM-CSF matured macrophages are more pro-
angiogenic than their M-CSF directed counterparts. Indeed, while M-CSF matured macrophages 
developed some tube-like structures, significantly reduced branching formation (5-8 branches) was 
observed in comparison to GM-CSF directed macrophages (12-17 branches; P <0.001; n=6; Figure 
5.4.22). However, the stimulation of M-CSF matured macrophages with FGF2 (50ng/ml) increased 
the formation of tube-like structures, as shown through a 2.3-fold increase in the number of 
branches compared to unstimulated M-CSF macrophages (P <0.001; n=6; Figure 5.4.22), which is 







    














Figure 5.4.22 FGF2 stimulation of M-CSF matured macrophages increases in vitro 
angiogenesis. 
Representative images and quantification of tube-like formation in M-CSF and GM-CSF matured 
human macrophages with and without FGF2 stimulation (50ng/ml). Data are expressed as average 
number of branches per x10 magnification field, (****P < 0.0001, *** P<0.001 and **P<0.01 denotes 
significant differences compared to unstimulated M-CSF macrophages; one-way ANOVA Tukey’s 
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Next, the effects of the STAT3 inhibitor niclosamide on tube-like formation in FGF2 stimulated M-CSF 
macrophages was investigated. In the presence of niclosamide, tube-like formation (assessed 
through the number of branches) was almost completely abolished (91%; P<0.0001; n=6; Figure 
5.4.23), compared to control macrophages. This suggests FGF2 induction of angiogenesis is STAT3 
dependent. 
 
     














Figure 5.4.23 Niclosamide (STAT3 inhibitor) reduces in vitro angiogenesis in FGF2-stimulated 
M-CSF matured macrophages. 
Representative images and quantification of tube-like formation in FGF2 stimulated M-CSF matured 
human macrophages in FGF2-stimulated (50ng/ml) M-CSF matured macrophages treated with the 
STAT3 inhibitor niclosamide (1, 5 or 10 µM), or DMSO as a vehicle control. Data are expressed as 
average number of branches per x4 magnification field, (****P < 0.0001 denotes significant 
difference compared to DMSO control macrophages; one-way ANOVA Tukey’s multiple comparison 
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5.5 Discussion  
The findings within this study demonstrate that low levels of VE-cadherin protein expression are 
consistent with elevated expression of microRNA-27a-3p in M-CSF matured macrophages (M-Mac - 
an anti-inflammatory macrophage phenotype), effects which are reversed with FGF2 stimulation. 
These novel observations suggest that VE-cadherin protein levels are under the regulatory control of 
miR-27a-3p within M-CSF macrophages. This association was validated by utilising a miR-27a-3p-
mimic and inhibitor to modulate miR-27a-3p levels within macrophages. Increasing miR-27a-3p 
levels with the mimic attenuated FGF2-induced VE-cadherin protein expression in M-Mac, while 
retarding miR-27a-3p function with the inhibitor augmented VE-cadherin protein levels upon FGF2 
stimulation. Considering the above mechanism, it is not therefore surprising that the elevated VE-
cadherin protein expression observed in GM-CSF directed macrophages (GM-Mac - a pro-
inflammatory phenotype), was associated with low levels of microRNA-27a-3p, and was unaffected 
by FGF2 stimulation. Indeed, the VE-cadherin protein and reciprocal miR-27a-3p levels were 
comparable between FGF2 stimulated M-Mac and unstimulated GM-Mac, suggesting that FGF2 
drives M-Mac towards a GM-Mac phenotype in regard to displaying endothelial cell-like properties.  
The canonical signalling pathways for FGF2 involves its receptor (FGFR1) and tyrosine kinase down-
stream signalling molecules including STAT3, PI3K, and MAPK. The evidence provided within this 
chapter demonstrates that FGF2 modulation of miR-27a-3p levels and ensuing VE-cadherin protein 
expression in M-Mac, is in part dependent on FGFR1 and subsequent activation (phosphorylation) of 
STAT3. Translating these findings into functional effects, M-CSF matured macrophages stimulated 
with FGF2 displayed an increased propensity to form tube-like structures during an angiogenesis 
assay, suggesting the augmented VE-cadherin protein levels affords M-Macs to acquire functions 
normally attributed solely to endothelial cells and their progenitors. Moreover, inhibition of STAT3 
activation with niclosamide retarded FGF2-induced the in vitro angiogenic response of M-CSF 




of macrophage subsets. Interestingly, GM-CSF matured macrophages showed angiogenic potential 
without FGF2 stimulation, in line with their low levels of miR-27a-3p and heightened protein 
expression of VE-cadherin. This implies that FGF2 stimulation of M-CSF macrophages shifts their 
phenotype towards that closely linked to GM-CSF macrophages, particularly in regard to acquiring 
endothelial cell-like expression patterns and angiogenic properties. In addition, these observations 
further confirm the specific features of macrophage subsets in response to different 
microenvironment cues. 
MicroRNA-27a has been identified among one of the microRNAs involved in endothelial cell 
angiogenesis (Zhou et al., 2011). It is highly expressed in the endothelial cells of highly vascularised 
tissues such as lung and heart (Zhou et al., 2011), and forms a cluster with miR-23a and miR-24-2 
within MIR23AHG (the miR-23a/27a/24-2 cluster host gene), which has been proposed to regulate 
biological processes in various cancers including leukaemia, breast cancer and colorectal cancer 
(Chhabra et al., 2010). In particular, miR-27a is associated with VEGF-mediated endothelial cell 
proliferation, migration and matrigel tube-like formation, attributed to its targeting of Sprouty2 and 
SEMA6A proteins (Zhou et al., 2011). These proteins are associated with anti-angiogenic effects by 
interfering with the VEGF-induced MAPK pathway (Urbich et al., 2012; Wietecha et al., 2011). In 
another study, miR-27a levels were reported to be downregulated in response to angiogenesis 
stimulatory molecules such as VEGF (Young et al., 2013). In support of the findings within this 
chapter pertaining to pro-angiogenic macrophage subsets, heightened miR-27a expression is 
associated with reduced angiogenesis through targeting of VE-cadherin in HUVECs and mouse 
capillaries (Young et al., 2013). Additionally, elevated miR-27a levels were associated with the 
inhibition of vascular leaks induced by thrombin and ischaemia (Young et al., 2013).  
Additionally, miR-27a has been implicated in indirectly promoting macrophage polarisation towards 
a pro-inflammatory phenotype through suppressing expression of the anti-inflammatory mediator 




miR-23a and miR-24, to promote a pro-inflammatory macrophage phenotype with enhanced 
expression of pro-inflammatory cytokines such as IL-1β, IL-6, and TNFα (Ma et al., 2016). Thus, based 
on these reports, elevated miR-27a expression can be regarded as a feature of pro-inflammatory 
macrophages. However, this is in contrast to the findings within this chapter, whereby the pro-
inflammatory GM-Mac subset expressed lower levels of miRNA-27a-3p (as well as its passenger 
strand miR-27a-5p), compared to their anti-inflammatory M-Mac counterparts.  
However, the inverse correlation of miR-27a-3p and VE-cadherin protein levels and angiogenic 
potential demonstrated within this chapter are in line with another report, although in different cell 
type. Reportedly, miR-27a downregulation is associated with in vitro endothelial cell angiogenesis 
and in vivo new vessel formation (Young et al., 2013). Elevated expression of miR-27a was associated 
with reduced VE-cadherin expression and related diminished capillary tube formation (Young et al., 
2013). Moreover, addition of a miR-27a-inhibitor reduced VEGF-induced vascular permeability, with 
vascular leakage due to increased permeability serving as a common observation in angiogenesis, 
thus highlighting miR-27a-inhibition as a potential pro-angiogenic agent resulting in a lessened 
oedematous effect (Young et al., 2013). It would be interesting to investigate the regulatory effect of 
FGF2-induced miR-27a suppression on macrophage-derived tube formation with regard to perfusion 
characteristics and vascular permeability aspects. On a different note, and as described in the 
previous chapter, under FGF2 stimulation M-Mac shift towards an endothelial cell-like phenotype 
which could be regarded as a pro-inflammatory phenotype. Collectively, these original findings 
suggest that the pro-inflammatory and pro-angiogenic phenotype of FGF2-induced M-Mac is in part 
regulated by diminished miR-27a-3p expression which in turn permits VE-cadherin translation and 
an ensuing increase in protein levels.  
Another important finding in this study is the identification of a key regulatory role for STAT3 
signalling in FGF2-induced VE-cadherin protein expression by M-Mac. To induce down-stream target 




subsequent translocation into the nucleus, enhancing the expression of various genes regulating cell 
growth and apoptosis, among others (Yuan et al., 2004). STAT3 activation and upregulation of its 
target genes have been implicated in early mouse development (Takeda et al., 1997), cell growth 
(Hirano et al., 2000), and angiogenesis (Chen and Han, 2008). Consequently, STAT3 has been 
ascribed a significant role in the development of heart disease (Kurdi et al., 2018) and various 
tumours (Yu et al., 2009). In addition, STAT3 has been implicated in VEGF-induced endothelial cell 
migration and capillary tube formation (Yahata et al., 2003). In another study, FGF2-induced 
endothelial cell proliferation was shown to be mediated by co-activation of platelet activating factor 
and STAT3 (Deo et al., 2002). A recent study deploying an ex vivo model of choroidal endothelial 
sprouting demonstrated that FGF2-induced angiogenesis is associated with enhanced STAT3 
signalling (Dong et al., 2019). The findings in this chapter reveal a similar mechanism exists within 
human macrophages under in vitro conditions, whereby FGF2-induced tube formation in M-Mac was 
prevented by inhibiting STAT3 signalling. This intimates FGF2 engenders specific macrophage subsets 
(M-Mac) with the capacity to acquire an endothelial cell-like phenotype. Relatedly, it was recently 
shown that FGF2 modulates the phenotypic programming of tumour-associated macrophages to 
increase tumour growth, which was associated with increased angiogenesis (Im et al., 2020). 
Unfortunately, this study did not explore the possibility that the angiogenesis formed within the 
tumours was in part macrophage-derived, alongside development from resident endothelial cells. 
Under inflammatory conditions, STAT3 is activated by IL-6 to induce a pro-inflammatory macrophage 
phenotype (Tugal et al., 2013). This report supports the observation in this chapter showing that 
FGF2-induced VE-cadherin expression is regulated via STAT3 in M-Mac, which attains a pro-
inflammatory macrophage phenotype, based on upon VE-cadherin protein upregulation and miR-
27a-3p downregulation. However, a contradictory study suggests STAT3 promotes the generation of 




Again, these conflicting finding are not surprising given that macrophage phenotype behaviour can 
be altered by different biochemical cues and is usually transient.  
Focussing on endothelial cell function, IL-6-induced vascular permeability and subsequent loss of 
barrier function was dependent on STAT3 activation and altered ensuing expression patterns of ZO1 
and VE-cadherin, key cell junctional proteins (Alsaffar et al., 2018). A further study similarly 
demonstrated that STAT3 signalling was associated with increased vascular permeability through 
adverse regulation of VE-cadherin expression patterns and its down-stream transcription factor β-
catenin (Hox et al., 2016). These reports are in opposition to the negative relationship shown in this 
chapter, albeit in macrophages, STAT3 activation is associated with macrophage-derived tube 
formation through upregulation of VE-cadherin in FGF2-stimulated M-Mac. A possible explanation 
for the differential expression and function of STAT3 and VE-cadherin may be attributed to cell-
specific mechanisms, with M-CSF matured macrophages utilising a disparate regulation of VE-
cadherin through STAT3 activation than that which takes place in endothelial cells, particularly in 
response to FGF2. Nevertheless, other studies have shown that STAT3 activation supports 
angiogenesis through upregulation of VE-cadherin (Chen and Han, 2008; Osugi et al., 2002), which 
supports the findings in M-Mac.  
A potential limitation of the findings presented within this chapter is the expression of VE-cadherin 
and STAT3 were only assessed for their regulation at the mRNA and protein levels. The cellular 
characterisation of VE-cadherin and STAT3 were not evaluated with a cytoplasmic shift of VE-
cadherin and associated proteins and nuclear translocation of β-catenin alongside nuclear 
accumulation of phosphorylated STAT3 a commonly observed finding in activated HUVECs (Noria et 
al., 1999). Additional confocal microscopy analysis and quantification of cell localisation of VE-
cadherin, and STAT3 phosphorylation would be informative, and indeed demonstrate if the altered 
expression patterns seen in endothelial cells also occur in M-Mac. However, niclosamide addition 




Nonetheless, it remains plausible that STAT3 and VE-cadherin regulation and interaction in 
macrophages may differ compared to primary endothelial cells. 
The finding that GM-CSF polarised macrophages develop tube-like structures within the Matrigel 
angiogenesis assay and is mirrored by M-CSF matured macrophages with FGF stimulation is in 
accordance with previous observations reporting macrophages can form tube like structures on 
Matrigel (Barnett et al., 2016; Schmeisser et al., 2001). However, the novel aspect presented within 
this chapter is that the angiogenic potential differs between macrophage subsets at baseline, with 
the pro-inflammatory GM-Mac readily forming tube-like structures, whereas M-Mac require FGF2 
stimulation to display a comparable angiogenic response, in a STAT3-dependent manner.  
5.6 Conclusions  
In this chapter, a novel pro-angiogenic regulatory axis is reported involving FGF2/FGFR1/STAT3/miR-
27a-3p regulation of VE-cadherin protein levels in in vitro M-CSF matured human macrophages. As 
such, in response to vascular injury, when FGF2 production is increased, anti-inflammatory 
macrophage subsets (under M-CSF cues) may be responsible to provide an endothelial cell-like 
phenotype to provide temporary protection and facilitate healing. This beneficial role involves the 
downregulation of miR-27a-3p levels to drive VE-cadherin protein expression via STAT3-dependent 
signalling. On the other hand, baseline GM-Mac are readily pro-angiogenic which is not reliant on 
FGF2 signalling and may therefore provide a more acute response during vascular injury, such as 
providing barrier function before resident endothelial cells can recover. However, in advanced 
atherosclerotic plaques where neovascularisation is associated with plaque instability and 
subsequent adverse clinical outcomes, intra-plaque macrophages acquiring an endothelial cell-like 






6 General Discussion, conclusion, limitations and future 
directions 
6.1 General Discussion 
The intricate process of tissue repair and remodelling after injury includes angiogenesis which 
involves the adaptation of vascular cells, such as VSMCs and endothelial cells. These two cell types 
are the predominant cells which constitute the vascular wall, together with extracellular matrix 
components serving as a scaffold such as basement membrane proteins alongside collagens and 
elastin (Davis and Senger, 2005). In addition, various connective tissue cells such as fibroblasts and 
perivascular adipocytes found within the adventitial region of blood vessels, may also play an active 
role in ensuring proper function of vascular networks. For instance, fibroblast-derived factors 
support neovessel sprouting and lumen formation (Newman et al., 2011), whereas perivascular 
adipocytes may change phenotype during inflammation to support VSMC proliferation and 
migration (Horimatsu et al., 2017; Verhagen and Visseren, 2011). Together with recruited 
monocyte/macrophage populations and resident adventitial macrophages, these divergent cell types 
work in concert to establish a new vascular network (angiogenesis) to provide effective and fast 
delivery of oxygenation and nutrients to the ischaemic or injured site, while also ensuring the 
competent removal of toxic products and apoptotic bodies.  
Therefore, under physiological conditions, angiogenesis can be considered as an advantageous 
tissue response to ensure normal function is kept in check. Besides its role in perfusion physiology, 
angiogenesis can also be regarded as a deleterious mechanism in response to chronic pathological 
remodelling such as neovascularisation of atherosclerotic plaques and malignant cancerous tissue. 
The common dogma is that the angiogenesis/neovascularisation that develops within advanced 
atherosclerotic plaques, cancers, wound sites, and around areas of ischaemia (such as a myocardial 
infarct) are derived from resident VSMCs and endothelial cells. (Furuya et al., 2005; Moreno et al., 




and accumulate within the locus of injury and ischaemia, and the process of angiogenesis occurs 
before the complete resolution of inflammation (such as in chronic inflammation), it is plausible 
monocyte/macrophages directly contribute to new vessel formation. Indeed, challenging the 
concept that VSMCs and endothelial cells exclusively form angiogenic vessels, perhaps 
monocyte/macrophages harbour the ability to trans-differentiate towards a VSMC-like and/or 
endothelial cell-like phenotype, and subsequently actively participate in new vessel formation during 
inflammation-associated injury.  
Although the role attributed to monocyte/macrophages are mainly with regard to the resolution of 
inflammation through the clearance of apoptotic bodies and foreign material (Gregory and Devitt, 
2004), the concept that macrophages can adapt to different environmental cues which can 
reprogramme their phenotype, strengthen the idea of their direct role in the establishment of early 
neovessel networks through a progenitor capacity to give rise to vascular-like cells. Another 
interesting aspect to consider whether monocyte/macrophages act similar to the mechanism 
involved in developmental angiogenesis whereby circulating stem cells and existing resident 
progenitor cells within the site of injury/inflammation can differentiate into vascular cells.  
Accordingly, the work within this study was designed to investigate the potential progenitor capacity 
of macrophages to trans-differentiate towards vascular-like cells, namely VSMCs and endothelial 
cells. The growth and differentiation of human monocyte-derived macrophages is controlled by the 
biochemical signals within the surrounding microenvironment. To investigate the possibility that 
human macrophages may serve as a potential source of VSMC-like and endothelial-like cells during 
angiogenesis, it is essential to understand how in vitro biochemical signals regulate macrophage 
trans-differentiation towards a phenotype similar to VSMCs or endothelial cells. Within this thesis 
two distinct macrophage populations were produced from human blood-derived monocytes, 
utilising the colony stimulating factors M-CSF and GM-CSF to generate well-characterised anti-




characterised in both populations. Additional macrophage phenotypes were also investigated at the 
beginning, but in the later part of the thesis the focus is solely on the M-Mac and GM-Mac subsets.  
Similarly, endothelial cell-like characteristics in the M-Mac and GM-Mac phenotypes were evaluated 
in vitro. Initial studies assessed the expression patterns of the candidate markers over different time 
periods (refer to section 4.4.1), with prolonged exposure to growth factors providing similar results 
as those observed in seven-day macrophages. Accordingly, subsequent studies were conducted in 
seven-day differentiated human macrophages followed by four-day growth factor stimulation, 
accepting that seven-day macrophage maturation is common duration for in vitro macrophage 
studies (Jin and Kruth, 2016).  
A major finding of this study was the divergent effect of FGF2 stimulation on M-Mac VE-cadherin 
mRNA and protein expression. As such, focus was given to identifying the potential mechanism 
underlying the unique post-transcriptional regulation of VE-cadherin expression in macrophages. 
Collectively, the findings identified a novel signalling axis within M-CSF matured macrophages 
whereby FGF2/FGFR1-mediated signalling induces STAT3 activation (phosphorylation) and 
subsequent down-regulation of miR-27a-3p levels, which in turn permits increased VE-cadherin 
protein expression. To confirm this regulatory axis stimulated M-Macs to acquire a functional 
endothelial cell-like phenotype afforded through the increase in VE-cadherin protein expression, in 
vitro angiogenesis was assessed and indeed demonstrated increased tube-like formation by FGF2-
induced M-Macs that was dependent upon STAT3 activation. However, if STAT3 directly or indirectly 
down-regulated miR-27a-3p levels was not explored due to time constraints. Nonetheless, previous 
evidence has demonstrated that STAT3 can act as both a transcriptional activator and suppressor 
and is therefore capable of directly up- and down-regulating target gene expression (Lu et al., 2018). 
Indeed, analysis of the upstream sequence of miR-27a-3p using the JASPAR database identified 
two highly-conserved predicted STAT3 binding sites, with supporting findings in a tumour cell 




2018). Therefore, it can be speculated that FGF2-induced STAT3 activation down-regulates miR-
27a-3p in M-Macs, leading to the elevated VE-cadherin protein levels and their associated 
endothelial-like function. 
Macrophages are key effector cells of the innate immune system and play central inflammatory and 
remodelling functions during the development and progression of atherosclerosis (refer to section 
1.4 and 1.5), despite their purported beneficial role in modulating angiogenesis (refer to section 
5.1.1).  The findings within this thesis support the proposition that macrophages can play a potential 
progenitor cell role in the formation of non-resident endothelial cell vascular network formation 
(refer to section 5.1.2). Accordingly, within specific microenvironments with the correct cues/stimuli, 
macrophages can directly form nascent tube-like structures reminiscent of capillaries, for instance 
during tumorigenesis, before the establishment of a mature vasculature by resident ‘true’ 
endothelial cells, or possibly the direct trans-differentiation of macrophages. Indeed, the functional 
perfusion of macrophage-derived vascular networks has been previously demonstrated (Barnett et 
al., 2016). The premise that macrophages harbour the ability to trans-differentiate into endothelial 
cells is not a recent one. Previous research has postulated this idea based upon the observation that 
macrophages form branched cell columns when cultured upon synthetic extracellular matrix 
proteins (Anghelina et al., 2004). Further studies have suggested that macrophages can trans-
differentiate into endothelial-like cells (Kumar et al., 2013; Schmeisser et al., 2001) and VSMC-like 
cells (Kumar et al., 2010). Similar observations are reported within this thesis, but excitingly, 
demonstrate that the progenitor potential of macrophages to trans-differentiate into VSMC- and 
endothelial-like cells is dictated by their polarisation/phenotype, while also identifying the possible 
novel signalling pathways involved.  
Progenitor cells are more or less similar to stem cells whereby they are defined through their ability 
to differentiate into a specific cell type. However, in opposed to undifferentiated stem cells which 




restricted proliferative potential, and are therefore considered a differentiated cell with the 
capability to be induced into other target cell types  (Seaberg and van der Kooy, 2003). Thus, 
macrophages with phagocytotic activity as their main feature, can be described as a differentiated 
type of haematopoietic population of cells with progenitor potential.  
The expression of certain VSMC and endothelial cell-associated markers support the unique 
observation and proposition that macrophages can serve as progenitor cells. However, it is possible 
that the monocyte/macrophages used in the studies within this thesis contain a population of 
stem/progenitor cell. Yet, the protocol deployed for the isolation of monocytes is a well-established 
and characterised procedure which relies upon the subsequent use of macrophage-specific colony 
stimulating factors for their maturation. In addition, monocyte isolation using magnetic-bead 
separation yields similar findings as those that rely upon adherence isolation and are consistent with 
the practices for isolating and obtaining macrophage-pure cultures. As such, the observation that 
features of trans-differentiation persist (acquired VSMC and endothelial cell marker expression) 
under these conditions provide confidence that the cells are macrophage populations and not from 
circulating stem cells. Indeed, this proposition is further strengthened by the observation that the 
expression of a macrophage-specific marker is maintained. It could equally be proposed that VSMCs 
and/or endothelial cells were present within the collected blood and gave rise to the observed 
increases in gene and protein expression of VSMC and endothelial cell-related markers. However, 
the expression pattern of these markers in the macrophage subsets were markedly different from 
primary human VSMCs and endothelial cells, as indicated at the end of chapter 3 and 4 respectively 
(refer section 3.4.5 and 4.4.4). Therefore, these further observations lend support to the concept 
that macrophages harbour progenitor potential and plasticity, in regard to their expression of 
vascular cell-like features under certain conditions.   
A further prominent finding in this thesis is the recognition that macrophage subsets have a 




GM-CSF (GM-Mac) are considered a pro-inflammatory phenotype (Di Gregoli and Johnson, 2012), 
and upon maturation readily expressed select VSMC- and endothelial cell-related markers compared 
to their M-CSF matured counterparts (M-Mac), which are classed as an anti-inflammatory phenotype 
(Di Gregoli and Johnson, 2012). Moreover, GM-Macs freely formed capillary tube-like structures 
upon Matrigel without the need of exogenous stimuli. However, upon stimulation with FGF2, M-
Macs showed comparable VE-cadherin protein levels and capillary tube-like formation as that 
observed in unstimulated GM-Macs. Similarly, M-Macs displayed diminished expression of multiple 
VSMC-associated markers relative to pro-inflammatory GM-Macs, which could be increased to 
comparable levels through stimulation with PDGF-BB/TGFβ1. Although, whether the acquired 
expression of VSMC-related markers afforded the macrophage subsets with VSMC functions was not 
explored.  
Nonetheless, the findings reported here imply a relationship between M-Macs acquiring a more pro-
inflammatory phenotype and displaying progenitor potential when exposed to specific stimuli, 
rendering them similar to their GM-Mac equivalent. It would therefore be interesting and 
informative to examine the inflammatory expression profile of PDGF-BB/TGFβ1 and FGF2 stimulated 
M-Mac, to determine if they do indeed become more pro-inflammatory. Relatedly, the inflammatory 
cytokines released by macrophages during angiogenesis include IL-1β, IL-6 and TNF-α, which are 
important to ensure the persistent infiltration of immune cells (Fahey and Doyle, 2019; Fajardo et 
al., 1992; Heidemann et al., 2003). Reportedly, alternatively activated (anti-inflammatory) 
macrophages (IL-4 polarised macrophage) are associated with reduced TIMP-1 expression and 
associated high MMP-9 activity, which favours a pro-angiogenic environment (Zajac et al., 2013). In 
addition, systemic depletion of macrophages through deficiency of M-CSF in osteopetrotic (op/op) 
mice supresses angiogenesis (Kubota et al., 2009) whereas in vivo addition of macrophages supports 
angiogenesis in the mouse hind limb ischaemia model (Hirose et al., 2008) and embryonic zebrafish 




stages of the angiogenic response, with pro-inflammatory M1-polarised macrophages purported to 
support angiogenesis but their pro-longed accumulation to cause vessel regression, whereas various 
anti-inflammatory M2-phenotypes are associated with modulation of pericytes and endothelial cells 
during angiogenic vessel maturation (Graney et al., 2020). These findings demonstrate that 
macrophages play a pivotal role in angiogenesis, but their direct contribution to vessel formation 
through their transformation into endothelial-like cells was never considered or examined. 
This study has added new knowledge to the potential mechanisms by which macrophage -derived 
neo-vasculature may occur. Colony stimulating factors are essential cues for the differentiation and 
maturation of monocytes into macrophages, with the capacity to give rise to different macrophage 
phenotypes, with divergent innate capacity to exhibit vascular cell-like progenitor potential. The 
ensuing interaction of macrophages (under the control of M-CSF) with further stimuli including 
PDGF-BB, TGFβ1, VEGF and FGF2, can shift macrophages towards vascular-like cells. Consequently, 
the participation of macrophages to the formation of capillary tube-like structures during the early 
phase of angiogenesis is not merely a response to vascular injury and to assist the growth of new 
vessels, but they may also participate directly to the formation of angiogenic vessels through their 
conversion to endothelial-like cells. With the associated identification of a possible regulatory 
pathway, it potentially permits the discovery of novel therapeutic targets for preventing early 
pathological angiogenesis. Such strategies could include localised or systemic delivery of; a FGFR1-
blocker, a STAT3-inhibitor to restore miR-27a-3p levels, or a miR-27a-3p mimic in order to suppress 
VE-cadherin protein levels to disrupt macrophage derived neo-vasculature formation during the 
early stages of tumour growth, or to limit neovascularisation in advanced atherosclerotic plaques. 
Reassuringly, FGFR1-neutralisation and inhibition of STAT-3 are therapeutic approaches under 
assessment in clinical trials for a variety of different diseases, including several cancers. In addition, 
multiple microRNA-based therapeutics have advanced to evaluation in clinical trials (Rupaimoole 




whether such therapeutic approaches modulate the direct contribution of macrophages to 





6.2 Concluding remarks 
GM-CSF matured macrophages (GM-Mac) are pro-inflammatory and can be considered to 
intrinsically display VSMC-like and endothelial cell-like properties and function based upon their 
expression of associated markers, alongside their capacity to form capillary tube-like structures in 
vitro. Conversely, the M-CSF matured macrophages (M-Mac) are anti-inflammatory and require 
PDGF-BB/TGFβ1 co-stimulation or FGF2 signalling in order to display comparable VSMC-like and 
endothelial cell-like features, respectively. In addition, lipid-laden foam cell macrophages induces a 
VSMC-like transition. Collectively, it can be speculated that M-Mac and GM-Mac (in vitro) represent 
two ends of macrophage phenotypic spectrum and should be used as baseline references for 
experimental studies. These findings add new attributes to in vitro M-CSF and GM-CSF directed 
macrophages as described in section 1.6 above, in regard to their progenitor potential that warrant 
further in vivo investigation and validation. The salient findings from this thesis are summarised in 
the following figure: -  
  
• Macrophage colony stimulating factor 
• Anti-inflammatory 
• Less VSMC-like and EC-like characteristics 
• ↑ miR-27a-3p, ↓ VE-cadherin protein/ ↓ 
STAT3 activation  
• Less tube formation (less angiogenic) 
PDGF-BB+TGF"1 
• Shift towards ‘pro-inflammatory’ 
• ↑ VSMC-like characteristics 
Foam cell 
• Shift towards ‘pro-inflammatory’ 
• ↑ VSMC-like characteristics 
FGF2 
• Shift towards ‘pro-inflammatory’ 
• ↑ EC-like characteristics 
• ↓ miR-27a-3p, ↑ VE-cadherin protein 
• ↑ tube formation/STAT3 activation 
M-Mac 
  
• Granulocyte Macrophage-colony 
stimulating factor 
• Pro-inflammatory 
• More VSMC-like and EC-like cells 
characteristics 
• ↓ miR-27a-3p, ↑ VE-cadherin 
protein/ ↑ STAT3 activation 
• ↑ tube formation (pro-angiogenic) 
 
PDGF-BB+TGF"1 
• ↓ VSMC-like characteristics 






• Maintain EC-like characteristics 





6.3 Limitations of the study 
One of the limitations in this study is the use of monocyte-derived macrophages from random 
healthy donors without prior investigation and specification of the monocyte subset percentages 
(based on cell-surface expression of CD14 and CD16) for each individual. This was not included in 
this study, even though as described in chapter 5, we used pan-monocyte isolation (isolation of all 
CD14+ and CD16+ monocytes) for subsequent differentiation and maturation into macrophages. The 
use of different monocyte subsets (as described in Table 1.2.1), may have provided insight into the 
differential capacity of the monocytes subsets (inflammatory, patrolling, and phagocytotic subsets), 
to differentiate into M-Mac and GM-Mac, and subsequent expression of VSMC and endothelial cell-
related-markers. Additionally, CD16+ monocytes are increased in individuals with cardiovascular 
disease and are therefore considered pro-inflammatory and drive plaque instability. Although our 
donors appear healthy, certain individuals may have subclinical atherosclerosis with an associated 
increased number of circulating CD16+ monocytes, which may have altered progenitor capacity. 
However, the small variance and normal distribution of our data from n=6 donors suggest this was 
not the case. Nonetheless, it would be interesting to determine if monocytes (particularly the CD16+ 
population) from cardiovascular disease patients are more pro-inflammatory and display augmented 
progenitor potential towards VSMC and endothelial-like cells, compared to age/gender-matched 
healthy controls. 
On a different note, different in vitro culture durations may also lead to conflicting results and thus 
confound the consistency of the presented results, as briefly mentioned in chapter 5. It is plausible 
that shorter or longer culture periods may differentially affect the macrophage phenotypes, with the 
expression patterns of the assessed markers varying depending on time in culture. Indeed, 
macrophages may undergo distinct phenotype modulation such as changes in pro-inflammatory 




and IFNg (or M1)-activated macrophages show differential responses to angiogenesis at earlier time 
points compared to the later stages of angiogenesis (Graney et al., 2020).  
The expression of the VSMC and endothelial cell-associated markers by macrophages in this study 
are reliant on the robustness and validity of the primary antibodies used. Nonetheless, Western 
blotting for all proteins was validated in primary human VSMCs or HUVECs to ensure that the 
detected bands were of the correct predicted weight. On some occasions there were slight 
discrepancies which requires the findings to be interpreted carefully. For example, many antibodies 
raised against VE-cadherin for use in Western blotting detect bands at a molecular weight between 
120-130 kDa alongside a band around 75 kDa. Although bands at both molecular weights were 
observed in HUVECs, the 75 kDa band was the most intense (refer to figure in section 9.1.4), while it 
was the only band detected in human macrophage lysates under any condtions. Furthermore, the 
immunofluorescence staining in this study also used the same antibody as for western blotting, thus 
the analysis of VE-cadherin expression in this study is consistent. Possible reasons for the detection 
of different molecular weight bands detected between macrophages and HUVECs maybe due to the 
different prevalence of splice variants, degree of glycosylation, or multimers of the proteins, which 






6.4 Future directions 
The studies within this thesis have raised additional new questions which would require further 
attention and experimental work to address. In the first result chapter, divergent effects of PDGF-
BB/TGFβ1 on selected VSMC-markers was observed, whereby down-regulation of protein levels 
were detected while mRNA expression was largely unaffected in GM-Mac. This differential pattern 
suggests the contribution of a post-transcriptional regulatory mechanism, highlighting possible 
microRNA involvement and/or a negative feedback process. The higher expression of VSMC-markers 
afforded by PDGF-BB/TGFβ1 co-stimulation -in GM-Mac may involve a negative feedback 
mechanism as baseline GM-Mac already displayed high expression of VSMC-markers. This 
observation may also suggest that GM-Mac are a differentiated macrophage phenotype with innate 
VSMC-like features. In contrast, M-Mac require further modulation (PDGF-BB/TGFβ1 co-stimulation) 
in order to trans-differentiate towards a VSMC-like phenotype. Future studies could also examine if 
the observed marked expression of the VSMC-associated proteins in macrophages resulted in them 
acquiring functions normally attributed to VSMCs. For example, the contractile ability of 
macrophages could be investigated. Additional biochemical stimuli alongside mechanical force/cyclic 
strain could be applied to the macrophage subsets to further characterise their capability to function 
as VSMC-like cells.  
Another experiment worthy of further investigation is the in vivo angiogenic capacity of 
macrophages to form neo-vessels. This could be achieved either by a subcutaneous matrigel 
angiogenesis assay or choroidal angiogenesis in transgenic mice where the monocyte/macrophages 
are fluorescently labelled, such as CD68-GFP-Tg mice. In addition, wound healing angiogenesis may 
also be feasibly investigated. Such in vivo angiogenesis experiments would validate the in vitro 
findings reported within this thesis. Additionally, the perfusion function and permeability of 
macrophage derived neo-vessel formation can also be assessed, for example laser confocal 




function (Fantin et al., 2010). Additionally, it would be interesting to investigate the contribution of 
hypoxia macrophage derived neovessel formation, as hypoxia is a known main inducer of 
angiogenesis and inflammatory cell recruitment (Krock et al., 2011).  
Finally, monocyte/macrophages have been implicated as a potential source of osteoblast-like cells, 
therefore potentially capable of contributing to vascular calcification in advanced atherosclerosis 
(Burgmaier et al., 2018). Therefore, the progenitor potential of macrophages to trans-differentiate 
into bone-like cells in regard to atherosclerotic plaques could be investigated. In addition, the 
potential of macrophages to trans-differentiate into cardiomyocyte-like cells is further potential area 
for future examination, particularly given myocardial infarction induces marked accumulation of 
monocyte/macrophages ripe for potential reprogramming. Furthermore, the regeneration of 
cardiomyocytes following heart failure requires progenitor cell recruitment (Mekala et al., 2018), 
thus a similar study could be undertaken to evaluate if macrophages can serve as potential 
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8 Appendix A – (Result, Chapter 3) 
8.1 Expression of VSMC-related markers in baseline M-CSF and GM-CSF 
macrophage and the effects of PDGF-BB and TGFb1 
(for section 3.4.2 and 3.4.3) 
8.1.1 Representative image for Stain Free Gel for baseline macrophage  







8.1.2 CT values - caldesmon  
Figure 3.4.6 (a), Figure 3.4.15 (a) and Figure 3.4.36 (a) 
Caldesmon mRNA CT Min CT Max CT average 
M-CSF 32.7 35.6 33.9 
M-CSF + PDGF-BB/TGFb1 33.1 36.1 34.7 
GM-CSF 33.0 35.9 34.5 
GM-CSF + PDGF-BB/TGFb1 33.1 35.6 34.2 
VSMC 21.7 23.9 22.5 
 
8.1.3 Full blot image - caldesmon  


































8.1.4 CT values - calmodulin  
Figure 3.4.7 (a), Figure 3.4.11 (a), Figure 3.4.16 (a) and Figure 3.4.37 (a) 
Calmodulin mRNA CT Min CT Max CT average 
M-CSF 25.0 26.5 25.8 
M-CSF + PDGF-BB/TGFb1 25.7 26.7 26.1 
GM-CSF 23.5 25.0 24.3 
GM-CSF + PDGF-BB/TGFb1 23.9 25.8 24.8 
VSMC 23.7 24.7 24.2 
 
8.1.5 Full blot image - calmodulin  

































8.1.6 CT values - Myh11  
Figure 3.4.8 (a), Figure 3.4.12 (a) and Figure 3.4.38 (a)  
Myh11 mRNA CT Min CT Max CT average 
M-CSF 29.5 33.1 31.4 
M-CSF + PDGF-BB/TGFb1 29.9 34.0 31.5 
GM-CSF 29.5 32.9 31.5 
GM-CSF + PDGF-BB/TGFb1 30.0 33.2 31.3 
VSMC 34.5 37.8 36.1 
 
8.1.7 Full blot image - Myh11  
































8.1.8 CT values - smoothelin  
Figure 3.4.9 (a), Figure 3.4.13 (a) and Figure 3.4.39 (a) 
Smoothelin mRNA CT Min CT Max CT average 
M-CSF 32.4 33.2 32.8 
M-CSF + PDGF-BB/TGFb1 32.0 34.2 32.9 
GM-CSF 31.0 31.8 31.4 
GM-CSF + PDGF-BB/TGFb1 31.0 32.0 31.5 
VSMC 25.7 28.6 26.8 
 
8.1.9 Full blot image - smoothelin  




































































8.1.10 CT values - vimentin  
Figure 3.4.10 (a), Figure 3.4.14 (a), Figure 3.4.17 (a), Figure 3.4.40 (a) 
Vimentin mRNA CT Min CT Max CT average 
M-CSF 21.5 22.9 22.0 
M-CSF + PDGF-BB/TGFb1 20.6 21.5 21.2 
GM-CSF 19.3 21.6 20.4 
GM-CSF + PDGF-BB/TGFb1 19.1 21.3 20.2 
VSMC 19.2 21.3 20.0 
 
8.1.11 Full blot image - vimentin  
























































8.2 Differing human macrophage phenotypes display distinct changes in 
their expression of VSMC-associated markers 
8.2.1 Representative image for Stain Free Gel for M-CSF macrophage, 
IFNg /LPS, IL-4 and IL-10, co-stimulation with PBGF-BB and TGFb1 
Figure 36 (b) – Figure 43 (b) 
 
8.2.2 Representative image for Stain Free Gel for M-CSF, OxPAPC, PF4 and 
OxLDL 































8.2.3 CT values - caldesmon 
Figure 3.4.18 (a), Figure 3.4.22 (a), Figure 3.4.30 (a) 
Caldesmon mRNA CT Min CT Max CT average 
M-CSF 32.1 35.2 34.1 
IFNg/LPS 31.9 35.0 34.0 
IL-4 32.2 36.8 35.0 
IL-10 32.2 35.7 34.2 
PF4 31.8 36.2 34.0 
oxPAPC 31.7 35.1 34.0 
oxLDL 32.6 35.2 33.9 
 
8.2.4 Full blot image – caldesmon 
Figure 3.4.18 (b), Figure 3.4.22 (b) 






































8.2.5 CT values – calmodulin 
Figure 3.4.19 (a), Figure 3.4.23 (a), Figure 3.4.24 (a) and Figure 3.4.31 (a) 
Calmodulin mRNA CT Min CT Max CT average 
M-CSF 25.0 27.2 26.4 
IFNg/LPS 23.6 26.3 25.0 
IL-4 24.4 27.6 26.2 
IL-10 24.0 27.3 26.2 
PF4 24.9 27.4 26.4 
oxPAPC 25.0 27.0 26.2 
oxLDL 24.7 27.3 26.2 
 
8.2.6 Full blot image – calmodulin 
Figure 3.4.19 (b), Figure 3.4.23 (b), Figure 3.4.24 (b) 







































8.2.7 CT value – smoothelin 
Figure 3.4.20 (a), Figure 3.4.25 (a), Figure 3.4.29 (a), Figure 3.4.34 (a) 
*downregulation in oxPAPC and oxLDL group 
Smoothelin mRNA CT Min CT Max CT average 
M-CSF 32.6 35.2 33.6 
IFNg/LPS 32.8 35.6 33.6 
IL-4 33.2 34.3 33.6 
IL-10 32.5 34.9 33.5 
PF4 32.8 35.3 33.5 
oxPAPC 33.0 36.7 34.3 
oxLDL 33.0 38.4 35.5 
 
8.2.8 Full blot image – smoothelin  
Figure 3.4.20 (b) and Figure 3.4.25 (b) 





































8.2.9 CT value - vimentin  
Figure 3.4.21 (a), Figure 3.4.26 (a), Figure 3.4.28 (a), Figure 3.4.33 (a) 
*no changes except for IFNg/LPS 
Vimentin mRNA CT Min CT Max CT average 
M-CSF 21.3 23.0 22.2 
IFNg/LPS 20.6 22.8 21.6 
IL-4 21.5 22.9 22.2 
IL-10 21.5 23.1 22.2 
PF4 21.3 22.7 22.1 
oxPAPC 21.4 22.8 22.3 
oxLDL 21.3 23.5 22.2 
 
8.2.10 Full blot image – vimentin  
Figure 3.4.21 (b) 










































8.2.11 Full blot image - vimentin  
Figure 3.4.26 (b), Figure 3.4.28 (b), and Figure 3.4.33 (b) 
vimentin in all groups significantly upregulated compared to control (M-CSF) 
 
8.2.12 CT value – Myh11 
Figure 3.4.27 (a), Figure 3.4.32 (a) 
*all macrophage phenotypes showed no changes 
Myh11 mRNA CT Min CT Max CT average 
M-CSF 29.4 31.6 30.4 
IFNg/LPS 29.2 31.6 30.4 
IL-4 29.6 31.9 30.6 
IL-10 29.5 31.0 30.2 
PF4 29.7 31.4 30.5 
oxPAPC 29.2 31.3 30.4 


































8.2.13 Full blot image – Myh11 
Figure 3.4.27 (b), Figure 3.4.32 (b) 
oxPAPC and oxLDL group showed higher expression compared to M-CSF macrophage (control)  
 
8.2.14 Full blot image - smoothelin  
Figure 3.4.29 (b), and Figure 3.4.34 (b) 





























































8.2.15 Full blot image - caldesmon  
Figure 3.4.30 (b)  
*Only OxLDL group showed higher expression compared to M-CSF macrophage (control) 
 
8.2.16 Full blot image - calmodulin  
Figure 3.4.31 (b) 





























































9 Appendix B (Result, Chapter 4) 
9.1 Representative image for Stain Free Gel for baseline macrophage M-CSF 
& GM-CSF day-8, day-11 and day-14 
Figure 4.4.1 and Figure 71 
 
 
9.1.1 CT values - PECAM-1 
Figure 4.4.1 (a) and Figure 4.4.21 (a) 
PECAM-1 mRNA CT Min CT Max CT average 
M-CSF day-7 25.2 27.9 26.8 
M-CSF day-11 26.2 27.2 26.9 
M-CSF day-14 24.5 26.0 25.1 
GM-CSF day-7 24.0 25.9 25.1 
GM-CSF day-11 25.9 28.3 27.2 
GM-CSF day-14 24.0 25.9 25.1 

































9.1.2 Full blot image – Stain free gel and PECAM-1 
Figure 4.4.1 (b) and Figure 4.4.21 (c) 
 
9.1.3 CT values - VE-cadherin 
Figure 4.4.3 (a) and Figure 4.4.22 (a) 
VE-cadherin mRNA CT Min CT Max CT average 
M-CSF day-7 36.3 37.3 36.8 
M-CSF day-11 31.9 33.2 32.5 
M-CSF day-14 31.0 32.8 31.8 
GM-CSF day-7 32.1 33.5 32.9 
GM-CSF day-11 32.3 33.2 32.7 
GM-CSF day-14 31.4 32.5 32.0 






























9.1.4 Full blot image – VE-cadherin 



































9.1.5 CT values - PECAM-1  
Figure 4.4.5 (a) 
PECAM-1 mRNA CT Min CT Max CT average 
M-CSF 27.2 27.8 27.5 
VEGF-A 1 ng/ml 24.3 27.2 26.0 
VEGF-A 10 ng/ml 23.5 26.5 25.5 
VEGF-A 100 ng/ml 23.3 26.2 25.1 
FGF2 1 ng/ml 24.3 26.9 25.8 
FGF2 10 ng/ml 24.0 26.4 25.4 
FGF2 100 ng/ml 24.2 25.8 25.2 
IGF-1 1 ng/ml 25.4 27.5 26.5 
IGF-1 10 ng/ml 24.8 27.2 26.1 
IGF-1 100 ng/ml 26.0 27.4 26.7 
HGF 1 ng/ml 25.6 27.8 26.7 
HGF 10 ng/ml 25.3 27.7 26.5 
HGF 100 ng/ml 25.8 27.8 26.7 
ANGPTL5 1 ng/ml 25.9 27.7 26.9 
ANGPTL5 10ng/ml 26.1 27.9 26.8 
ANGPTL5 100 ng/ml 25.7 27.9 26.6 
 
Figure 4.4.5 (b) 
PECAM-1 mRNA CT  min CT  Max CT Average 
GM-CSF 24.6 26.3 25.8 
VEGF-A 1 ng/ml 23.9 26.6 25.7 
VEGF-A 10 ng/ml 25.0 27.0 25.9 
VEGF-A 100 ng/ml 24.7 26.5 25.6 
FGF2 1 ng/ml 24.2 26.9 25.4 
FGF2 10 ng/ml 24.7 26.2 25.6 
FGF2 100 ng/ml 24.6 27.1 25.6 
IGF-1 1 ng/ml 25.2 26.7 25.8 
IGF-1 10 ng/ml 24.6 26.3 25.6 
IGF-1 100 ng/ml 24.1 26.7 25.6 
HGF 1 ng/ml 25.4 26.8 25.9 
HGF 10 ng/ml 24.0 27.0 25.6 
HGF 100 ng/ml 25.5 26.4 25.9 
ANGPTL5 1 ng/ml 24.3 26.9 25.7 
ANGPTL5 10ng/ml 24.1 27.2 25.7 




9.1.6 CT values – VE-cadherin 
Figure 4.4.6 (a) 
VE-cadherin mRNA CT Min CT Max CT average 
M-CSF 36.0 40.0 38.3 
VEGF-A 1 ng/ml 34.0 38.9 34.0 
VEGF-A 10 ng/ml 35.3 38.7 35.3 
VEGF-A 100 ng/ml 35.2 38.5 35.2 
FGF2 1 ng/ml 34.3 39.4 34.3 
FGF2 10 ng/ml 33.7 38.7 33.7 
FGF2 100 ng/ml 33.6 38.2 33.6 
IGF-1 1 ng/ml 35.4 40.0 35.4 
IGF-1 10 ng/ml 35.9 40.0 35.9 
IGF-1 100 ng/ml 36.2 40.0 36.2 
HGF 1 ng/ml 34.7 39.1 34.7 
HGF 10 ng/ml 35.3 39.5 35.3 
HGF 100 ng/ml 36.2 40.0 36.2 
ANGPTL5 1 ng/ml 37.0 38.4 37.0 
ANGPTL5 10ng/ml 37.0 40.0 37.0 
ANGPTL5 100 ng/ml 37.1 39.1 37.1 
 
Figure 4.4.6 (b) 
VE-cadherin mRNA CT Min CT Max CT average 
GM-CSF 33.1 34.9 33.8 
VEGF-A 1 ng/ml 33.2 35.3 34.1 
VEGF-A 10 ng/ml 33.1 34.8 33.8 
VEGF-A 100 ng/ml 32.7 34.8 33.7 
FGF2 1 ng/ml 33.0 33.9 33.4 
FGF2 10 ng/ml 32.7 34.8 33.5 
FGF2 100 ng/ml 32.5 34.7 33.7 
IGF-1 1 ng/ml 32.1 35.1 33.5 
IGF-1 10 ng/ml 32.6 34.8 33.6 
IGF-1 100 ng/ml 33.0 34.8 33.7 
HGF 1 ng/ml 32.8 35.0 33.6 
HGF 10 ng/ml 32.5 35.0 33.9 
HGF 100 ng/ml 32.0 35.0 33.7 
ANGPTL5 1 ng/ml 32.1 34.9 33.5 
ANGPTL5 10ng/ml 32.9 35.1 33.8 




9.1.7 CT values – PECAM1 
Figure 4.4.8 a 
PECAM-1 mRNA CT Min CT Max CT average 
M-CSF 26.8 27.8 27.3 
VEGF-A 25.8 27.0 26.5 
FGF2 25.7 26.8 26.5 
IGF-1 26.1 27.6 26.9 
HGF 26.4 27.6 26.9 






9.2 Representative image for Stain Free Gel for baseline macrophage M-CSF 
stimulated with 50 ng/ml endothelial growth factor for four-day 
Figure 4.4.8 c and Figure 78 c 
 
 
9.2.1 Full blot image – PECAM-1 















9.2.2 CT values – VE-cadherin 
Figure 4.4.11 a 
VE-cadherin mRNA CT Min CT Max CT average 
M-CSF 31.7 33.1 32.5 
VEGF-A 32.0 33.2 32.6 
FGF2 33.0 34.8 33.7 
IGF-1 32.2 33.9 32.8 
HGF 31.7 33.8 32.8 
ANGPTL5 32.1 33.7 32.8 
 
9.2.3 Full blot image – VE-cadherin 
Figure 4.4.11 c 
 
 
9.2.4 CT values – PECAM1  
Figure 81 a 
PECAM-1 mRNA CT Min CT Max CT average 
GM-CSF 26.1 28.3 27.3 
VEGF-A 26.4 28.4 27.3 
FGF2 26.5 28.1 27.2 
IGF-1 26.0 28.0 27.1 
HGF 26.5 27.9 27.1 










9.3 Representative image for Stain Free Gel for baseline macrophage GM-
CSF stimulated with 50 ng/ml endothelial growth factor for four-day 
 
 
9.3.1 Full blot image – PECAM-1 
(GM-CSF after 4-day stimulation with EC-GF) 














9.3.2 CT values – VE-cadherin 
Figure 4.4.17 c 
VE-cadherin mRNA CT Min CT Max CT average 
GM-CSF 31.9 33.3 32.6 
VEGF-A 31.9 33.6 32.8 
FGF2 31.8 33.5 32.7 
IGF-1 31.8 33.4 32.6 
HGF 31.8 33.8 32.8 
ANGPTL5 31.5 33.4 32.5 
 
9.3.3 Full blot image – VE-cadherin 










10 Appendix C (Result, Chapter 5) 
10.1 CT values for microRNA 
10.1.1 CT values for microRNA-101-3p 
microRNA-101-3p CT Min CT Max CT average 
M-CSF 35.1 36.5 35.6 
M+VEGFA 34.5 35.6 35.0 
M+FGF2 34.6 36.9 35.7 
M+IGF-1 35.9 36.3 35.9 
M+HGF 34.4 36.2 35.9 
M+ANGPTL5 34.1 36.9 35.2 
GM-CSF 34.1 36.1 35.2 
GM+VEGFA 35.9 36.0 35.7 
GM+FGF2 33.2 35.5 34.3 
GM+IGF-1 33.2 35.4 34.7 
GM+HGF 34.7 36.5 35.5 
GM+ANGPTL5 34.0 35.5 35.3 
 
10.1.2 CT values for microRNA-101-5p 
microRNA-101-5p CT Min CT Max CT average 
M-CSF 37.1 38.9 38.5 
M+VEGFA 36.9 38.1 37.8 
M+FGF2 37.1 38.3 37.6 
M+IGF-1 37.0 38.3 37.4 
M+HGF 36.1 38.3 37.6 
M+ANGPTL5 36.7 38.4 37.9 
GM-CSF 37.4 38.7 38.1 
GM+VEGFA 36.6 37.9 37.2 
GM+FGF2 36.5 37.4 36.9 
GM+IGF-1 36.6 37.5 37.0 
GM+HGF 36.9 37.6 37.3 






10.1.3 CT values for microRNA-27a-3p 
Figure 5.4.1 
microRNA-27a-3p CT Min CT Max CT average 
M-CSF 36.4 38.0 37.2 
M+VEGFA 36.3 38.0 37.4 
M+FGF2 36.9 38.7 37.8 
M+IGF-1 36.0 38.0 37.2 
M+HGF 36.0 37.8 37.1 
M+ANGPTL5 36.5 38.5 37.4 
GM-CSF 40.0 40.0 40.0 
GM+VEGFA 40.0 40.0 40.0 
GM+FGF2 40.0 40.0 40.0 
GM+IGF-1 37.6 40.0 39.4 
GM+HGF 38.0 40.0 39.3 
GM+ANGPTL5 37.9 40.0 38.9 
 
10.1.4 CT values for microRNA-27a-5p 
Figure 5.4.2 
microRNA-27a-5p CT Min CT Max CT average 
M-CSF 29.9 31.1 30.4 
M+VEGFA 30.0 31.1 30.5 
M+FGF2 29.3 31.7 30.4 
M+IGF-1 29.7 31.4 30.3 
M+HGF 29.6 30.6 30.0 
M+ANGPTL5 29.7 32.1 30.5 
GM-CSF 30.9 32.0 31.6 
GM+VEGFA 30.1 32.6 31.5 
GM+FGF2 30.3 31.9 31.2 
GM+IGF-1 30.4 32.7 31.8 
GM+HGF 30.6 32.4 31.4 








10.1.5 Full blot image for transfection experiment 
Figure 5.4.4 and Figure 5.4.5 
 
10.1.6 CT values VE-cadherin mRNA (transfection experiment) 
Figure 5.4.8 
VE-cadherin mRNA CT Min CT Max CT average 
M-CSF 31.7 33.1 32.5 
M+FGF2 32.8 35.0 33.7 
NEG CTRL 30.2 33.3 31.9 
NEG CTRL +FGF2 30.4 35.0 32.9 
microRNA-27a-3p-mimic 30.1 33.2 32.1 
microRNA -27a-3p-mimic +FGF2 30.0 34.1 32.2 
microRNA -27a-3p-inhibitor 30.4 35.3 33.2 









10.1.7 CT values microRNA-27a-3p (transfection experiment) 
Figure 5.4.9 
microRNA-27a-3p CT Min CT Max CT average 
NEG CTRL 36.1 38.2 37.3 
NEG CTRL +FGF2 37.0 39.0 38.1 
microRNA-27a-3p-mimic 36.4 38.5 37.2 
microRNA -27a-3p-mimic +FGF2 36.0 38.2 37.2 
microRNA -27a-3p-inhibitor 36.5 38.5 37.9 
microRNA -27a-3p-inhibitor +FGF2 37.5 38.6 38.0 
 
10.1.8 CT values FGFR1 mRNA (transfection experiment) 
Figure 5.4.11 
FGFR1 mRNA CT Min CT Max CT average 
NEG CTRL 28.1 29.2 28.7 
NEG CTRL +FGF2 27.4 29.4 28.7 
microRNA-27a-3p-mimic 27.2 30.1 28.9 
microRNA -27a-3p-mimic +FGF2 27.6 29.7 28.8 
microRNA -27a-3p-inhibitor 28.0 30.0 29.0 
microRNA -27a-3p-inhibitor +FGF2 27.8 29.6 28.5 
 
10.1.9 CT values VE-cadherin mRNA (FGFR1 neutralising antibody 
experiment) 
Figure 5.4.12 a 
VE-cadherin mRNA CT Min CT Max CT average 
M-CSF 30.20 33.07 31.87 
IgG control 30.39 33.60 32.01 
IgG control +FGF2 31.72 33.94 32.88 
anti-FGFR1 31.18 33.16 31.99 






10.1.10 Full blot (FGFR1 neutralising antibody experiment) 
Figure 5.4.12 b 
 
10.1.11 CT values microRNA-27a-3p (FGFR1 neutralising antibody 
experiment) 
Figure 5.4.13 
microRNA-27a-3p CT Min CT Max CT average 
M-CSF 36.13 37.94 36.91 
IgG control 36.28 37.53 36.81 
IgG control +FGF2 36.74 38.27 37.46 
anti-FGFR1 36.09 37.95 36.72 
anti-FGFR1 +FGF2 35.70 37.58 36.51 
 
10.1.12  CT values FGFR1 mRNA (neutralising antibody experiment) 
Figure 5.4.14  
microRNA-27a-3p CT Min CT Max CT average 
M-CSF 36.13 37.94 36.91 
IgG control 36.28 37.53 36.81 
IgG control +FGF2 36.74 38.27 37.46 
anti-FGFR1 36.09 37.95 36.72 










































































































































10.1.13 Full blot (FGFR1 neutralising antibody experiment) 
Stain Free Gel for Figure 5.4.14  
 
 































































































































































































































































10.1.16  CT values VE-cadherin mRNA (niclosamide experiment) 
Figure 5.4.19 
VE-cadherin mRNA CT Min CT Max CT average 
M-CSF + FGF2 32.50 34.05 33.30 
DMSO 32.90 34.20 33.24 
Nic 1 31.94 33.61 32.79 
Nic 5 32.08 33.73 32.73 
Nic 10 32.03 33.51 32.60 
 
microRNA-27a-3p mRNA CT Min CT Max CT average 
M-CSF + FGF2 36.55 37.79 37.06 
DMSO 36.43 37.83 37.13 
Nic 1 36.22 37.18 36.67 
Nic 5 35.91 37.05 36.54 
Nic 10 35.90 37.06 36.50 
 
 
 
 
